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New antibiotics with novel targets or mechanisms of action are needed to counter the 
steady emergence of bacterial pathogens that are resistant to antibiotics used in the clinic. MraY, 
a promising novel target for antibiotic development, initiates the lipid cycle for the biosynthesis 
of peptidoglycan cell wall, which is essential for the survival of most, if-not-all, bacteria. MraY 
is an enzyme that catalyzes the transfer and attachment of phospho-MurNAc-pentapeptide to a 
lipid carrier, undecaprenylphosphate. Muraymycins are recently discovered lipopeptidyl 
nucleoside antibiotics that exhibit remarkable antibiotic activity against Gram-positive as well 
as Gram-negative bacteria by inhibiting MraY. We conducted a thorough examination of the 
metabolic profile of Streptomyces sp. strain NRRL 30473, a known producer of muraymycins. 
Eight muraymycins were isolated and characterized by a suite of spectroscopic methods, 
including three new members of muraymycin family named B8, B9 and C5. Muraymycins B8 
and B9, which differ from other muraymycins by having an elongated fatty acid side chain, 
showed potent antibacterial activity against Escherichia coli ∆tolC mutant and pM IC50 against 
Staphylococcus aureus MraY. Muraymycin C5, which is characterized by an N-acetyl 
modification of the disaccharide’s primary amine, greatly reduced its antibacterial activity, 
which possibly indicates this modification is used for self-resistance. 
In addition to the discovery of new muraymycins, eleven enzymes from the 
biosynthetic pathway were functionally assigned and characterized in vitro. Six enzymes 
involved in the biosynthesis of amino ribofuranosylated uronic acid moiety of muraymycin 
were characterized: Mur16, a non-heme, Fe(II)-dependent α-ketoglutarate: UMP dioxygenase; 
Mur17, an L-threonine: uridine-5′-aldehyde transaldolase; Mur20, an L-methionine:1-
aminotransferase; Mur26, a low specificity pyrimidine nucleoside phosphorylase; Mur18, a 
primary amine-requiring nucleotidylyltransferase; Mur19, a 5-amino-5-
deoxyribosyltransferase. A one-pot enzyme reaction was utilized to produce this disaccharide 
moiety and its 2′′-deoxy analogue. Two muraymycin-modifying enzymes that confer self-
resistance were functionally assigned and characterized: Mur28, a TmrB-like ATP-dependent 
muraymycin phosphotransferase, and Mur29, a muraymycin nucleotidyltransferase. Notably, 
Mur28 preferentially phosphorylates the intermediate, aminoribofuranosylated uronic acid, in 
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the muraymycin biosynthetic pathway to produce a cryptic phosphorylated-dissacharide 
intermediate. Mur23 and Mur24 were assigned as two enzymes that modify the cryptic 
phosphorylated intermediate by attachment of an aminopropyl group. Mur24 catalyzes the 
incorporation of butyric acid into the phosphorylated-disaccharide. Following the incorporation, 
Mur23 catalyzes a PLP-dependent decarboxylation. Finally, Mur15, which belongs to the cupin 
family, is functionally assigned as a non-heme, Fe(II)-dependent α-ketoglutarate dioxygenase 
that catalyzes the β-hydroxylation of a leucine moiety in muraymycin D1 to form muraymycin 
C1. Mur15 can also hydroxylate the γ-position of leucine moiety to muraymycins with fatty 
acid chain in β-position. 
































Steven G. Van Lanen 
Director of Dissertation 
David Feola 
Director of Graduate Studies 
12/14/2017 
Date 
DISCOVERY OF NOVEL MURAYMYCIN ANTIBIOTICS AND 































I am indebted to the following people for their help and support: 
To my mentor, Dr. Steven Van Lanen, thank you for leading me into the realm of biochemistry, 
showing me its tremendous beauty and logic, and helping me overcome every obstacle we met 
in the journey.  
To my husband, Xiaofei Zhang, thank you for tolerating my obsession, sharing my happiness 
and sadness, and doing the first format editing. 
To my amazing committee members (Dr. Jurgen Rohr, Dr. Sylvie Garneau-Tsodikova and Dr. 
Luke Moe), thank you for the guidance, patience, encouragement and the prompt reply for 
every email. I believe you guys will keep doing that after my graduation. I would also like to 
thank you all especially Dr. Garneau-Tsodikova for helping with my thesis modification. 
To our awesome collaborators in Christian Ducho’s lab and my super cooperative friends, Dr. 
Yinan Zhang, Dr. Xiaodong Liu and Dr. Wenlong Cai, thank you for helping me dealing with 
synthetic problems and activity assays. I would also like to thank Dr. Xiachang Wang here for 
analyzing all the NMR data showed in this thesis. 
To all wonderful members in Van Lanen lab and natural product super group, thank you for 
your priceless friendship and helpful discussion. 




TABLE OF CONTENTS 
 
ACKNOWLEDGEMENTS ...................................................................................................... iii 
LIST OF TABLES .................................................................................................................... ix 
LIST OF FIGURES ................................................................................................................... x 
LIST OF FIGURES IN SUPPORTING INFORMATION ..................................................... xiii 
LIST OF ABBREVIATIONS ................................................................................................ xviii 
Chapter 1 : Introduction and Background .................................................................................. 1 
1.1 Muraymycins Discovery .................................................................................................. 1 
1.2 Targets of Muraymycin .................................................................................................... 3 
1.3 SAR of Muraymycins ...................................................................................................... 5 
1.4 Muraymycin Related Nucleoside Antibiotics .................................................................. 7 
1.5 Biosynthetic Gene Cluster of Muraymycin ...................................................................... 8 
1.6 Contents of the Dissertation ............................................................................................. 9 
Chapter 2 : Antibacterial Muraymycins from Streptomyces sp. NRRL 30473 ........................ 10 
2.1 Introduction .................................................................................................................... 10 
2.2 Materials and Methods ................................................................................................... 12 
2.2.1 General Experimental Procedures ........................................................................... 12 
2.2.2 Fermentation, Extraction, Isolation and Purification .............................................. 13 
2.2.3 DNA Extraction, Genome Sequencing, and Analysis ............................................. 14 
2.2.4 Antimicrobial Bioactivities ...................................................................................... 15 
2.2.5 MraY Inhibition Assay ............................................................................................ 16 
2.3 Results ............................................................................................................................ 19 
2.3.1 Structure Elucidation ............................................................................................... 21 
2.3.2 Antimicrobial Bioactivity ........................................................................................ 26 
2.4 Discussion ...................................................................................................................... 29 
2.4.1 Synthesized Muraymycin B9 Analogue with Good Antibacterial Activity ............. 29 
v 
 
2.4.2 Resistant Modifications of Muraymycin ................................................................. 30 
2.5 Conclusion ..................................................................................................................... 30 
2.6 Supporting Information .................................................................................................. 32 
Chapter 3 : Enzymatic Formation of Ribofuranosylated Glycyl-uridine Scaffold of Antibiotic 
Muraymycin ............................................................................................................................. 46 
3.1 Introduction .................................................................................................................... 46 
3.2 Materials and Methods ................................................................................................... 48 
3.2.1 Cloning, Overexpression and Purification of Proteins ............................................ 48 
3.2.2 Synthesis of 2'-Methoxy-UMP, 1c........................................................................... 49 
3.2.3 Activity Assay of Mur16 ......................................................................................... 50 
3.2.4 Kinetics of Mur16 ................................................................................................... 51 
3.2.5 Activity Assay of Mur17 ......................................................................................... 51 
3.2.6 Activity Assay of Mur20 ......................................................................................... 52 
3.2.7 Activity Assay of Mur26 ......................................................................................... 52 
3.2.8 Activity Assay of Mur18 ......................................................................................... 52 
3.2.9 Activity Assay of Mur19 ......................................................................................... 53 
3.2.10 MIC assay of AQC modified 8b ............................................................................ 53 
3.2.11 One-Pot Enzymatic Reaction for the Biosynthesis of 8a ...................................... 54 
3.2.12 One-Pot Enzymatic Reaction for the Biosynthesis of 8b ...................................... 54 
3.3 Results and Discussion ................................................................................................... 54 
3.3.1 Functional Assignment of Mur16 as a Non-heme, Fe(II)-dependent α-Ketoglutarate: 
UMP Dioxygenase ........................................................................................................... 54 
3.3.2 Functional Assignment of Mur17 as an L-Threonine: Uridine-5′-aldehyde 
Transaldolase .................................................................................................................... 58 
3.3.3 Functional Assignment of Mur20 as an L-Methionine: 2-Aminotransferase. ......... 60 
3.3.4 Functional Assignment of Mur26 as a Low Specificity Uridine Nucleoside 
Phosphorylase ................................................................................................................... 62 
3.3.5 Functional Assignment of Mur18 as a Primary Amine-requiring 
vi 
 
Nucleotidylyltransferase. .................................................................................................. 63 
3.3.6 Functional Assignment of Mur19 as a GlyU: 5-Amino-5-Deoxyribosyltransferase
 .......................................................................................................................................... 65 
3.3.7 One-Pot Six-enzyme Synthesis of Ribofuranosylated Uronic Acid Moiety of 
Muraymycin ..................................................................................................................... 70 
3.4 Conclusion ..................................................................................................................... 73 
3.5 Supporting Information .................................................................................................. 74 
Chapter 4 : Self-Resistance During Muraymcyin Biosynthesis: A Complementary 
Nucleotidyltransferase and Phosphotransferase with Identical Modification Sites and Distinct 
Temporal Order ........................................................................................................................ 90 
4.1 Introduction .................................................................................................................... 90 
4.2 Materials and Methods ................................................................................................... 94 
4.2.1 Chemicals, reagents, and instrumentation ............................................................... 94 
4.2.2 Cloning Genes of mur28, mur29 and tmrB ............................................................. 95 
4.2.3 Production of muraymycin D congeners ................................................................. 97 
4.2.4 Enzyme reactions .................................................................................................... 98 
4.2.5 Single-substrate kinetics .......................................................................................... 98 
4.2.6 Antimicrobial Bioactivity ........................................................................................ 99 
4.2.7 MraY Inhibition ..................................................................................................... 100 
4.3 Results .......................................................................................................................... 101 
4.3.1 Functional insight through bioinformatic analysis ................................................ 101 
4.3.2 In vitro functional assignment and characterization of recombinant Mur29 ......... 102 
4.3.3 In vitro functional assignment and characterization of Mur28 .............................. 106 
4.3.4 Insight into the Function of Mur28-homologs BsTmrB ........................................ 112 
4.3.5 Potential role of Mur29 and Mur28 in self-resistance ........................................... 112 
4.4 Discussion .................................................................................................................... 114 
4.4.1 Why We Choose Muraymycin D Series to Test the Activity ................................. 114 
4.4.2 Distinct Temporal Order for Mur29 and Mur28 Catalysis .................................... 115 
vii 
 
4.4.3 Predicted Phosphorylation Position of Tunicamycin by TmrB ............................. 116 
4.5 Conclusion ................................................................................................................... 117 
4.6 Supporting Information ................................................................................................ 118 
Chapter 5 : A PLP and AdoMet Dependent Strategy for Aminopropyl Group Incorporation in 
Nuceloside Antibiotics Biosynthesis ...................................................................................... 147 
5.1 Introduction .................................................................................................................. 147 
5.2 Materials and Methods ................................................................................................. 149 
5.2.1 Synthesis ................................................................................................................ 149 
5.2.2 Isotopic Enrichment .............................................................................................. 150 
5.2.3 Heterologous Protein Expression .......................................................................... 151 
5.2.4 Enzyme Assays ...................................................................................................... 154 
5.3 Results and Discussion ................................................................................................. 158 
5.3.1 Bioinformatic Analysis of Mur23 and Mur24 ....................................................... 158 
5.3.2 Feeding Experiments: the Source of the Aminopropyl Group .............................. 159 
5.3.3 Six-enzyme Biosynthesis of Amino Disaccharide, compound 7: the Aminopropyl 
Group Acceptor .............................................................................................................. 161 
5.3.4 Function Assignment of Mur23 and Mur24 .......................................................... 161 
5.3.5 Kinetic and Mutational Analysis of Mur24 and Mur23 ........................................ 166 
5.3.6 Mechanism Study of Mur24 .................................................................................. 167 
5.4 Discussion .................................................................................................................... 170 
5.4.1 Similarity between ACC Synthase and Mur24 ...................................................... 170 
5.4.2 Relationship of Mur24 and MocR Transcription Regulator .................................. 170 
5.4.3 Phosphorylation Modification is Also Required in Caprazamycin Biosynthetic 
Pathway .......................................................................................................................... 171 
5.5 Conclusion ................................................................................................................... 171 
5.6 Supporting Information ................................................................................................ 173 
Chapter 6 : Characterization of Mur15 as a Non-heme Fe(II), α-Ketoglutarate: Muraymycin 
Dioxygenase ........................................................................................................................... 190 
viii 
 
6.1 Introduction .................................................................................................................. 190 
6.2 Materials and Methods ................................................................................................. 191 
6.2.1 Cloning, Overexpression and Purification of Proteins .......................................... 191 
6.2.2 Fermentation, Extraction, Isolation, and Purification of Muraymycins ................ 191 
6.2.3 Activity Assay of Mur15 ....................................................................................... 191 
6.2.4 Activity Optimization ............................................................................................ 192 
6.2.5 Kinetics of Mur15 ................................................................................................. 192 
6.2.6 Antimicrobial Bioactivities .................................................................................... 193 
6.2.7 MraY Inhibition ..................................................................................................... 193 
6.3 Results and Discussion ................................................................................................. 193 
6.3.1 Bioinformatic Analysis of Mur15 .......................................................................... 193 
6.3.2 Functional Assignment and Activity Test .............................................................. 193 
6.3.3 Activity Optimization and Kinetics Analysis ........................................................ 199 
6.3.4 Bioactivity of the Mur15 Products ........................................................................ 201 
6.4 Discussion .................................................................................................................... 202 
6.4.1 Timing of Hydroxylation in Muraymycin Biosynthetic Pathway ......................... 202 
6.4.2 Repeated Hydroxylation by Multifunctional Enzyme ........................................... 202 
6.5 Conclusion ................................................................................................................... 203 
6.6 Supporting Information ................................................................................................ 204 
Chapter 7 : Ongoing Studies and Future Directions .............................................................. 216 
7.1 Biosynthetic Mechanism of the NRPS Assembly Line ................................................ 216 
7.2 Biosynthetic Mechanism of the Formation of the N-methyldiazepanone Moiety of 
Caparazamycin Like A-90289 ............................................................................................ 216 
7.3 Acyltransferase for the Fatty Acid Chain Appendage of Muraymycin ........................ 217 
References .............................................................................................................................. 219 





LIST OF TABLES 
Table 1.1 Summary of synthesized muraymycin analogues with good activity. ....................... 5 
Table 2.1 13C NMR data (100 MHz) of compounds 1−4. ........................................................ 24 
Table 2.2 1H NMR data (400 MHz, J in Hz) of compounds 1−3 and muraymycin C1. .......... 25 
Table 2.3 In vitro MraY assays and antimicrobial activities .................................................... 28 
Table 4.1 Kinetic parameters for Mur29 and Mur28 ............................................................. 111 
Table 4.2 Bacterial MraY assays and antimicrobial activities ............................................... 114 
Table 6.1 Bacterial MraY assays and antimicrobial activities of the substrate and product of 




LIST OF FIGURES 
Figure 1.1 Structure of muraymycin. ......................................................................................... 2 
Figure 1.2 Translocase I (MraY) catalyzed reaction. ................................................................. 4 
Figure 1.3 SAR results for structural variations of muraymycin scaffold. ................................ 6 
Figure 1.4 Structure of representative members from different classes of nucleoside antibiotics 
that target MraY. Similarities are highlighted in blue. ............................................................... 7 
Figure 1.5 The gene cluster identified for muraymycin biosynthesis. ....................................... 8 
Figure 2.1 Structures of representative muraymycins.............................................................. 20 
Figure 2.2 1H-1H COSY (▬) and selected HMBC (→) correlations of 1−3. .......................... 23 
Figure 2.3 Structures of synthesized muraymycin analogues. ................................................. 29 
Figure 3.1 Structure of muraymycin A1 and A-90289A containing similar ribofuranosylated 
glycyl-uridine moiety. .............................................................................................................. 47 
Figure 3.2 Proposed biosynthetic pathway towards ribofuranosylated glycyl-uridine moiety. 
Enzymes that were previously functionally characterized were labeled in black. ................... 47 
Figure 3.3 13C NMR spectrum (D2O, 100 MHz) and 
1H NMR spectrum (D2O, 400 MHz) of 2′-
methoxy-UMP. ......................................................................................................................... 50 
Figure 3.4 Characterization of Mur16. ..................................................................................... 56 
Figure 3.5 Activity optimization and kinetic analysis of Mur16. ............................................ 57 
Figure 3.6 Characterization of Mur17. ..................................................................................... 59 
Figure 3.7 Characterization of Mur20. ..................................................................................... 61 
Figure 3.8 Characterization of Mur26. ..................................................................................... 63 
Figure 3.9 Characterization of Mur18. ..................................................................................... 64 
xi 
 
Figure 3.10 Characterization of Mur19. ................................................................................... 66 
Figure 3.11 Characterization of Mur19 with 2'-fluoro-2'-deoxyuridine-5'-triphosphate. ........ 68 
Figure 3.12 Comparison of substrate promiscuity of Mur19 and LipN with 4a and 4b. ......... 69 
Figure 3.13 Characterization of one-pot enzymatic reaction with UMP and UTP as start 
substrates. ................................................................................................................................. 71 
Figure 3.14 Characterization of one-pot enzymatic reaction with GlyU, 2′-deoxy-UMP, UTP as 
start substrates. ......................................................................................................................... 72 
Figure 3.15 Biosynthetic pathway and substrate promiscuity towards ribofuranosylated glycyl-
uridne moiety of muraymycins. ............................................................................................... 73 
Figure 4.1 Structure of representative peptidyl nucleoside antibiotics consisting of an ADR-
GlyU disaccharide core. ........................................................................................................... 92 
Figure 4.2 Functional assignment of Mur29 .......................................................................... 104 
Figure 4.3 Biochemical characterization of Mur29. .............................................................. 106 
Figure 4.4 Functional assignment of Mur28. ......................................................................... 108 
Figure 4.5 Biochemical characterization of Mur28. .............................................................. 110 
Figure 5.1 Structure of representative nucleoside antibiotics containing an aminopropyl moiety 
(highlighted in red). ............................................................................................................... 148 
Figure 5.2 13C NMR spectrum of isotope labelled muraymycin D1. ..................................... 160 
Figure 5.3 Biosynthesis of the amino disaccharide moiety of muraymycins......................... 161 
Figure 5.4 Two proposed biosynthetic pathway of the incorporation of aminopropyl moiety of 
muraymycins. ......................................................................................................................... 163 
Figure 5.5 HPLC analysis of tandem enzymatic reaction with Mur23, Mur24 and Mur28. . 164 
xii 
 
Figure 5.6 Characterization of Mur24 and Mur23. ................................................................ 165 
Figure 5.7 Chemical shift assignment for compound 7, 8, 9 and 10. ..................................... 166 
Figure 5.8 Kinetic analysis of Mur24 and Mur23. ................................................................. 167 
Figure 5.9 Mechanistic proposal for Mur24 catalyzed aminopropyl incorporation reaction. 168 
Figure 5.10 LC-MS analysis of MBTH modified Mur24 catalyzed reactions. ...................... 169 
Figure 5.11 The biosynthesis of ethylene............................................................................... 170 
Figure 5.12 Structures of caprazol-3’’-phosphate. ................................................................. 171 
Figure 6.1 Characterization of Mur15 with muraymycin D1 (1). .......................................... 195 
Figure 6.2 Characterization of Mur15 with muraymycin B2 (5), B6 (7) and A1 (9). ............ 196 
Figure 6.3 Comparison of 1H NMR (DMSO-d6, 400 MHz) between muraymycin B2, 5 and 
Mur15 product hydroxyl muraymycin B2, 6. ........................................................................ 197 
Figure 6.4 Characterization of Mur15 with L-Arg-Leu dipeptide, 11. .................................. 198 
Figure 6.5 Activity optimization and kinetic analysis of Mur15. .......................................... 200 
Figure 6.6 Repeated hydroxylation catalyzed by Mur15. ...................................................... 203 
Figure 7.1 Biosynthetic pathway towards alkyl aminoribosyl-glycyluridine moiety of 
muraymycin. .......................................................................................................................... 216 
Figure 7.2 Proposed biosynthetic pathway towards N-methyldiazepanone moiety of A-90289.






LIST OF FIGURES IN SUPPORTING INFORMATION 
Figure S2.1 (+)-HR-ESI-MS (positive mode) of muraymycin B8 (1). .................................... 32 
Figure S2.2 1H NMR spectrum (DMSO-d6, 400 MHz) of muraymycin B8 (1). ..................... 32 
Figure S2.3 13C NMR spectrum (DMSO-d6, 100 MHz) of muraymycin B8 (1). .................... 33 
Figure S2.4 HSQC spectrum (DMSO-d6, 400 MHz) of muraymycin B8 (1). ......................... 33 
Figure S2.5 HMBC spectrum (DMSO-d6, 400 MHz) of muraymycin B8 (1). ........................ 34 
Figure S2.6 1H-1H COSY spectrum (DMSO-d6, 400 MHz) of muraymycin B8 (1). .............. 34 
Figure S2.7 TOCSY spectrum (DMSO-d6, 400 MHz) of muraymycin B8 (1). ....................... 35 
Figure S2.8 NOESY spectrum (DMSO-d6, 400 MHz) of muraymycin B8 (1). ...................... 35 
Figure S2.9 (+)-HR-ESI-MS (positive mode) of muraymycin B9 (2). .................................... 36 
Figure S2.10 1H NMR spectrum (DMSO-d6, 600 MHz) of muraymycin B9 (2). ................... 36 
Figure S2.11 13C NMR spectrum (DMSO-d6, 150 MHz) of muraymycin B9 (2). .................. 37 
Figure S2.12 HSQC spectrum (DMSO-d6, 600 MHz) of muraymycin B9 (2). ....................... 37 
Figure S2.13 HMBC spectrum (DMSO-d6, 600 MHz) of muraymycin B9 (2). ...................... 38 
Figure S2.14 1H-1H COSY spectrum (DMSO-d6, 600 MHz) of muraymycin B9 (2). ............ 38 
Figure S2.15 NOESY spectrum (DMSO-d6, 600 MHz) of muraymycin B9 (2). .................... 39 
Figure S2.16 (+)-HR-ESI-MS (positive mode) of muraymycin C6 (3). .................................. 39 
Figure S2.17 1H NMR spectrum (D2O, 400 MHz) of muraymycin C6 (3). ............................ 40 
Figure S2.18 13C NMR spectrum (D2O, 100 MHz) of muraymycin C6 (3). ........................... 40 
Figure S2.19 HSQC spectrum (D2O, 400 MHz) of muraymycin C6 (3). ................................ 41 
Figure S2.20 HMBC spectrum (D2O, 400 MHz) of muraymycin C6 (3). ............................... 41 
Figure S2.21 1H-1H COSY spectrum (D2O, 400 MHz) of muraymycin C6 (3)....................... 42 
Figure S2.22 NOESY spectrum (D2O, 400 MHz) of muraymycin C6 (3). ............................. 42 
Figure S2.23 (+)-HR-ESI-MS (positive mode) of muraymycin C1 (4). .................................. 43 
Figure S2.24 1H NMR spectrum (D2O, 400 MHz) of muraymycin C1 (4). ............................ 43 
Figure S2.25 13C NMR spectrum (D2O, 100 MHz) of muraymycin C1 (4). ........................... 44 
xiv 
 
Figure S2.26 HSQC spectrum (D2O, 400 MHz) of muraymycin C1 (4). ................................ 44 
Figure S2.27 HMBC spectrum (D2O, 400 MHz) of muraymycin C1 (4). ............................... 45 
Figure S2.28 1H-1H COSY spectrum (D2O, 400 MHz) of muraymycin C1 (4)....................... 45 
Figure S3.1 SDS-PAGE analysis of protein Mur16, Mur17, Mur18, Mur19, Mur20 and Mur26.
 ................................................................................................................................................. 77 
Figure S3.2 LC-MS analysis of Mur16 catalyzed reactions. ................................................... 78 
Figure S3.3 Detection of succinate production using LC-MS and an enzyme coupled reaction.
 ................................................................................................................................................. 79 
Figure S3.4 LC-MS analysis of Mur17 catalyzed reactions. ................................................... 80 
Figure S3.5 Comparative analysis of enzymatic and synthetic 3 diastereomers. .................... 81 
Figure S3.6 LC-MS analysis of AQC modified GlyU epimers and Mur17 catalyzed reactions.
 ................................................................................................................................................. 82 
Figure S3.7 (+)-HR-ESI-MS (positive mode) of purified Mur20 product amino uridine, 4a . 83 
Figure S3.8 LC-MS analysis of MBTH modified Mur20 catalyzed reactions. ....................... 84 
Figure S3.9 LC-MS analysis of Mur20 catalyzed reactions. ................................................... 85 
Figure S3.10 LC-MS analysis of Mur26 catalyzed reactions. ................................................. 86 
Figure S3.11 LC-MS analysis of Mur26 and Mur18 catalyzed reactions with HILIC column.
 ................................................................................................................................................. 87 
Figure S3.12 (+)-HR-ESI-MS (positive mode) of purified AQC modified 8b ........................ 88 
Figure S3.13 1H NMR spectrum (D2O, 400 MHz) of AQC modified 8b. ............................... 89 
Figure S3.14 1H-1H COSY spectrum (D2O, 400 MHz) of AQC modified 8b. ........................ 89 
Figure S4.1 SDS-PAGE analysis of purified Mur28, Mur29, TmrB, LipI and LipX. ........... 122 
Figure S4.2 (+)-HR-ESI-MS (positive mode) of muraymycin D1 ........................................ 123 
Figure S4.3 1H NMR spectrum (D2O, 400 MHz) of muraymycin D1. ................................. 123 
Figure S4.4 13C NMR spectrum (D2O, 100 MHz) of muraymycin D1. ................................. 124 
Figure S4.5 HSQC spectrum (D2O, 400 MHz) of muraymycin D1. ..................................... 124 
Figure S4.6 1H−1H COSY spectrum (D2O, 400 MHz) of muraymycin D1. .......................... 125 
Figure S4.7 HMBC spectrum (D2O, 400 MHz) of muraymycin D1. .................................... 125 
xv 
 
Figure S4.8 (+)-HR-ESI-MS (positive mode) of muraymycin D2 ........................................ 126 
Figure S4.9 1H NMR spectrum (D2O, 400 MHz) of muraymycin D2. .................................. 126 
Figure S4.10 13C NMR spectrum (D2O, 100 MHz) of muraymycin D2. ............................... 127 
Figure S4.11 HSQC spectrum (D2O, 400 MHz) of muraymycin D2. .................................... 127 
Figure S4.12 1H-1H COSY spectrum (D2O, 400 MHz) of muraymycin D2. ......................... 128 
Figure S4.13 (+)-HR-ESI-MS (positive mode) of muraymycin D3. (calcd for C37H61N11O15, 
expected (M+H)+ ion at m/z = 900.4421, found 900.4307; expected (M+2H)2+ ion at m/z = 
450.7247, found 450.7202). ................................................................................................... 128 
Figure S4.14 1H NMR spectrum (D2O, 400 MHz) of muraymycin D3. ................................ 129 
Figure S4.15 (+)-HR-ESI-MS (positive mode) of compound ADR-GlyU ............................ 129 
Figure S4.16 1H NMR spectrum (D2O, 100 MHz) of compound ADR-GlyU. ...................... 130 
Figure S4.17 13C NMR spectrum (D2O, 100 MHz) of compound ADR-GlyU. ..................... 130 
Figure S4.18 HSQC spectrum (D2O, 400 MHz) of compound ADR-GlyU. ......................... 131 
Figure S4.19 1H-1H COSY spectrum (D2O, 400 MHz) of compound ADR-GlyU. ............... 131 
Figure S 4.20 (+)-HR-ESI-MS (positive mode) of compound D1-AMP. .............................. 132 
Figure S4.21 1H NMR spectrum (D2O, 400 MHz) of muramycin D1-AMP. ........................ 132 
Figure S4.22 1H-1H COSY spectrum (D2O, 400 MHz) of muramycin D1-AMP. ................. 133 
Figure S4.23 Reaction catalyzed by Mur29 with muraymycin D2 and ATP. ........................ 134 
Figure S4.24 Reaction catalyzed by Mur29 with muraymycin D3 and ATP. ........................ 135 
Figure S4.25 Reaction catalyzed by Mur29 with muraymycin D1 and GTP. ........................ 136 
Figure S4.26 Reaction catalyzed by Mur29 with muraymycin D1 and CTP. ........................ 137 
Figure S4.27 Reaction catalyzed by Mur29 with muraymycin D1 and dATP. ...................... 138 
Figure S4.28 Reaction catalyzed by Mur29 with muraymycin D1 and dTTP. ...................... 139 
Figure S4.29 Reaction catalyzed by Mur29 with muraymycin D1 and UTP. ........................ 140 
Figure S 4.30 (+)-HR-ESI-MS (positive mode) of compound D2-PHOS ............................. 141 
Figure S4.31 1H NMR spectrum (D2O, 400 MHz) of muramycin D2-PHOS. ...................... 141 
Figure S4.32 1H-1H COSY spectrum (D2O, 400 MHz) of muramycin D2 -PHOS. .............. 142 
Figure S4.33 Reaction catalyzed by Mur28 with D2 and [γ-P18O4]ATP. ............................... 142 
xvi 
 
Figure S4.34 Reaction catalyzed by Mur28 with muraymycin D3 and ATP. ........................ 143 
Figure S4.35 Reaction catalyzed by Mur28 with ADR-GlyU and ATP ................................. 144 
Figure S4.36 Reaction catalyzed by Mur28 with muraymycin D2 and different phosphate 
donors. .................................................................................................................................... 145 
Figure S4.37 Reaction catalyzed by TmrB. ........................................................................... 146 
Figure S5.1 SDS-PAGE analysis of purified protein and UV/Vis spectrum of Mur23. ........ 177 
Figure S5.2 (+)-HR-ESI-MS (positive mode) of L-[13C5,15N] Met enriched muraymycin D1.
 ............................................................................................................................................... 178 
Figure S5.3 1H NMR spectrum (D2O, 100 MHz) of isotope enriched (L-[
13C5, 15N] Met or L-
13C4, 15N] Asp) muraymycin D1. ........................................................................................... 178 
Figure S5.4 Analysis of tandem enzymatic reaction with Mur23, Mur24 and Mur28 .......... 179 
Figure S5.5 ESI-MS spectrum of 7’ eluted at 23.325 min ..................................................... 180 
Figure S5.6 ESI-MS of 10’ eluted at 24.157min .................................................................... 180 
Figure S5.7 (+)-HR-ESI-MS (positive mode) of compound 8 .............................................. 181 
Figure S5.8 1H NMR spectrum (D2O, 100 MHz) of compound 8. ........................................ 181 
Figure S5.9 HSQC spectrum (D2O, 400 MHz) of compound 8. ............................................ 182 
Figure S5.10 1H-1H COSY spectrum (D2O, 400 MHz) of compound 8. ............................... 182 
Figure S5.11 (+)-HR-ESI-MS (positive mode) of compound 9 ............................................. 183 
Figure S5.12 1H NMR spectrum (D2O, 400 MHz) of compound 9. ...................................... 183 
Figure S5.13 HSQC spectrum (D2O, 400 MHz) of compound 9. .......................................... 184 
Figure S5.14 1H-1H COSY spectrum (D2O, 400 MHz) of compound 9. ............................... 184 
Figure S5.15 HMBC spectrum (D2O, 400 MHz) of compound 9.......................................... 185 
Figure S5.16 (+)-HR-ESI-MS (positive mode) of compound 10 .......................................... 186 
Figure S5.17 1H NMR spectrum (D2O, 400 MHz) of compound 10. .................................... 186 
Figure S5.18 1H-1H COSY spectrum (D2O, 400 MHz) of compound 10. ............................. 187 
Figure S5.19 (+)-HR-ESI-MS (positive mode) of 5’-deoxy-5’-(methylthio) adenosine ....... 187 
Figure S5.20 1H NMR spectrum (D2O, 400 MHz) of L-VG. ................................................ 188 
Figure S5.21 HPLC analysis of Mur24 reaction with or without PLP using 8 as substrates. 188 
xvii 
 
Figure S5.22 LC-MS analysis of MBTH modified Mur24 catalyzed reactions. ................... 189 
Figure S6.1 SDS-PAGE analysis of purified His6-Mur15 ..................................................... 204 
Figure S6.2 Identification of the Mur15 product with 1. ....................................................... 204 
Figure S6.3 Identification of the Mur15 product with 3. ....................................................... 205 
Figure S6.4 Identification of the Mur15 product with 1. ....................................................... 206 
Figure S6.5 Identification of the Mur15 product with 5. ....................................................... 207 
Figure S6.6 1H NMR spectrum (DMSO-d6, 400 MHz) of muraymycin B2 (5). ................... 208 
Figure S6.7 13C NMR spectrum (DMSO-d6, 100 MHz) of muraymycin B2 (5). .................. 208 
Figure S6.8 HSQC spectrum (DMSO-d6, 400 MHz) of muraymycin B2 (5). ....................... 209 
Figure S6.9 HMBC spectrum (DMSO-d6, 400 MHz) of muraymycin B2 (5). ...................... 209 
Figure S6.10 1H-1H COSY spectrum ((DMSO-d6, 400 MHz) of muraymycin B2 (5). ......... 210 
Figure S6.11 Identification of the Mur15 product with 7. ..................................................... 211 
Figure S6.12 1H NMR spectrum (DMSO-d6, 400 MHz) of muraymycin B6 (7). ................. 212 
Figure S6.13 13C NMR spectrum (DMSO-d6, 100 MHz) of muraymycin B6 (7). ................ 212 
Figure S6.14 HSQC spectrum (DMSO-d6, 400 MHz) of muraymycin B6 (7). ..................... 213 
Figure S6.15 HMBC spectrum (DMSO-d6, 400 MHz) of muraymycin B6 (7). .................... 213 
Figure S6.16 1H-1H COSY spectrum ((DMSO-d6, 400 MHz) of muraymycin B6 (7). ......... 214 
Figure S6.17 Identification of the Mur15 product with 9. ..................................................... 215 





LIST OF ABBREVIATIONS 
DMSO dimethyl sulfoxide 
2D two dimensional 
ACC 1-aminocyclopropanecarboxylic acid 
AdoMet S-adenosyl-L-methionine 
ADR 5″-amino-5″-deoxyribose 
AMP adenosine monophosphate 
AQC 6-aminoquinolyl-N-hydroxysuccinimidyl carbamate 
Arg arginine 
Asp aspartic acid 
ATP adenosine triphosphate 
COSY correlation spectroscopy 
CTP cytidine triphosphate 
dATP 2′-deoxy-adenosine triphosphate 
dTTP 2′-deoxy-thymidine triphosphate 
E. coli Escherichia coli 
GlyU (5′S,6′S)-5′-C-glycyluridine 
GTP guanosine triphosphate 
h hour 
His6 hexa-histidine 
HMBC heteronuclear multiple-bond correlation spectroscopy 
HPLC high performance liquid chromatography 
HR-ESI-MS high resolution-electrospray ionization-mass spectrometry 
HSQC heteronuclear single-quantum correlation spectroscopy 
IPTG  β-D-1-thiogalactopyranoside 
kD kilodalton 





MBP maltose binding protein 
MBTH 3-methyl-2-benzothiazolinone hydrazone hydrochloride 
MeOH methanol 
Met methionine 
MIC minimum inhibitory concentration 
min minute 
MTA methylthioadenosine 
MW molecular weight 
NDP nucleotidyl diphosphate 
NMR nuclear magnetic resonance 
NOESY nuclear overhauser effect spectroscopy 
NRPS nonribosomal peptide synthetase 
NTP nucleotidyl triphosphate 
OD optical density 
PCR polymerase chain reaction 
PHOS phosphate 
PLP pyridoxal phosphate 
rt room temperature 
S. aureus Staphylococcus aureus  
SAR structural-activity relationship 
SDS sodium dodecyl sulfate 
SMM [(3S)-3-Amino-3-carboxypropyl] (dimethyl)-sulfonium iodide 
TEA triethylamine 
TFA trifluoroacetic acid 
TOCSY total correlation spectroscopy 
UDP uridine diphosphate 
UMP uridine monophosphate 










Chapter 1 : Introduction and Background 
1.1 Muraymycins Discovery 
Muraymcyins were discovered from a Streptomyces sp. organism guided by cell-wall 
specific biological assays by Wyeth-Research in 2001.1 Structural elucidation revealed that the 
muraymycin family belongs to the lipopeptidyl nucleoside antibiotic family. The 22 
muraymycins that were discovered have a common peptide-appended, ribofuranoside uronic 
acid core structure (Figure 1.1). Discovered members of this family differ in one or more of 
three components: the fatty acyl chain, the aminoribose and the terminal amino acid in the 
peptide chain. Muraymycin A1 with a guanidino fatty acyl side chain is the most potent member 
of the family and showed good activity against Staphylococcal (MIC 2 to 16 μg/mL), 











1.2 Targets of Muraymycin 
Muraymycins inhibit peptidoglycan cell wall biosynthesis of Gram-positive as well as 
Gram-negative bacteria by inhibiting the activity of bacteria translocase I (MraY). MraY 
catalyzes the transfer and attachment of phospho-MurNAc-pentapeptide to a lipid carrier, 
undecaprenylphosphate, to form undecaprenyl-diphodpho-MurNAc-pentapeptide, also called 
Lipid I (Figure 1.2).3 Recently, the crystal structure of MraY from the Gram-negative bacteria 
Aquifex aeolicus (MraYAA) in complex with muraymycin D2 was solved.
4 Surprisingly, 
muraymycin D2 didn’t interact with any of the conserved amino acid residues (Asp117, Asp118, 
and Asp265) of MraYAA, which is essential for catalytic activity from previous studies.
5 Instead, 
muraymycin D2 bound with the nucleoside-binding pocket, which was formed by large 
conformational rearrangement of loops C and D of MraYAA.
4, 6
  
Recently, Kurosu’s group reported that besides MraY, muraymycin D1 also inhibited 
a second, distinct bacterial transferase, polyprenyl phosphate-GlcNAc-1-phosphate transferase 
(WecA), which is an essential enzyme in the biosynthesis of cell wall components of 




Figure 1.2 Translocase I (MraY) catalyzed reaction.  
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1.3 SAR of Muraymycins 
Antibacterial activity of the 22 discovered muraymycins showed that better activity 
was observed for acylated muraymycins, especially with longer and charged fatty acyl 
chains.Various structurally diverse muraymycin analogues have been synthesized, and, many 
of them showed comparable activity with natural muraymycins (Table 1.1). A graphical 
summary of SAR of muraymycin is shown in Figure 1.3 based on the activity of naturally 
occurring muraymycins and chemically synthesized or semisynthesized analogues.
7-17
 The SAR 
is, to some extent, consistent with the crystal structure of the binding pattern of muraymycin 
D2 with MraYAA.
4  
Table 1.1 Summary of synthesized muraymycin analogues with good activity. 
Compound IC50 (μM) MIC (μg/mL) 
1 MurX  0.011 M. tuberculosis  1.567 (1.68 μM) 
2 MurX  0.011 M. tuberculosis  1.567 (1.68 μM) 
3 MurX  0.0096 M. tuberculosis  6.25 7 (6.74 μM)  
4 MraY  0.0011 P. aeruginosa ATCC25619  >6418 
5 MraY  0.0008 P. aeruginosa ATCC25619  >648 
6 MraY  0.0007 P. aeruginosa ATCC25619  >648 
7 MraY  0.00024 P. aeruginosa ATCC25619  648 (68.0 μM) 
8 MraY  0.00022 P. aeruginosa ATCC25619  88 (8.5 μM) 
9 MraY  0.00014 P. aeruginosa ATCC25619  88 (9.18 μM) 
10 MraY  0.00060 P. aeruginosa ATCC25619  88 (9.18 μM) 
11 MraY  1.7-2.7 E. coli ∆tolC 50 13 (65.1 μM)  











1.4 Muraymycin Related Nucleoside Antibiotics 
Besides muraymycin, many other nucleoside antibiotics are known to inhibit 
peptidoglycan biosynthesis by targeting MraY. Four review articles10, 19-21 provide a broad 
overview of these nucleoside antibiotics. Figure 1.4 shows the structures of representative 
members of the different classes of nucleoside antibiotics inhibiting MraY.  
 
 
Figure 1.4 Structure of representative members from different classes of nucleoside antibiotics 




1.5 Biosynthetic Gene Cluster of Muraymycin 
The muraymycin biosynthetic gene cluster was identified by the Deng group in 2010 
from Streptomyces sp. NRRL30471.22 18F3 cosmid was introduced into S. lividans TK24 for 
heterologous production of muraymycin. The minimal muraymycin biosynthetic gene cluster 
(mur12-mur34) was determined by gene disruption (Figure 1.5). Mur34 was identified as a 
negative regulator involved in muraymycin biosynthesis.23 The function of the other genes in 
the cluster was preliminarily assigned by BLAST analysis. 
 
 
Figure 1.5 The gene cluster identified for muraymycin biosynthesis.  
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1.6 Contents of the Dissertation 
Our over-arching goal is to delineate the biosynthetic pathway of muraymycin in order 
to develop analogues through chemoenzymatic synthesis and mutasynthesis. Prior work has 
identified the gene cluster involved in the biosynthesis of muraymycin.22 However, the 
enzymatic mechanism of the muraymycin scaffold assembly has not been elucidated. This 
dissertation consists of seven chapters. Chapter 1 is the introduction of murymycins while 
chapter 7 discusses the future direction of the projects. In chapter 2, we report the isolation, 
structural elucidation, and biological activity of muraymycins. Three new muraymycin 
congeners were isolated and the antibacterial activity was evaluated. Chapters 3 to 6 focus on 
studying biosynthetic mechanism of the alkyl-ribofuranosylated glycyl-uridine scaffold and 
fatty acid side chain of muraymycin. In chapter 3, six enzymes that are responsible for the 
biosynthesis of the ribofuranosylated glycyl-uridine moiety of muraymycin were functionally 
assigned. In chapter 4, unique resistance pattern of muraymycin was defined. A complementary 
nucleotidyltransferase and phosphotransferase modifies identical position of muraymycin, but 
shows distinct temporal order. In chapter 5, two enzymes that are functionally assigned to 
modify the cryptic phosphorylated intermediate by attachment of an aminopropyl group are 
characterized. In chapter 6, one enzyme belonging to the cupin family is functionally assigned 
as an Fe(II)- and α-KG-dependent dioxygenase to catalyze the hydroxylation of the peptide 




Chapter 2 : Antibacterial Muraymycins from Streptomyces sp. NRRL 30473 
2.1 Introduction 
Muraymycins, initially reported as a mixture of nineteen congeners from the 
fermentation broth of Streptomyces sp. NRRL 30471,1 were discovered using biological assays 
to identify inhibitors of Lipid II and peptidoglycan cell wall biosynthesis.1-2, 24-25 Muraymycin 
A1, one of the more potent of the congeners, was shown to have good activity against 
Staphylococcal (MIC 2 to 16 μg/mL) and E. coli imp mutant (MIC <0.03 μg/mL), and was 
further shown to be effective in a murine model of Staphylococcus aureus infection (ED50 1.1 
mg/kg). Follow-up efforts have revealed that muraymycins likely exhibit antibacterial activity 
by directly inhibiting translocase I (MraY). MraY initiates the lipid cycle of cell wall 
biosynthesis by catalyzing the transfer and attachment of phospho-MurNAc-pentapeptide from 
UDP-MurNAc-pentapeptide to a lipid carrier, undecaprenylphosphate, to form UMP and 
undecaprenyl-diphospho-MurNAc-pentapeptide, also referred to as Lipid I.7, 9, 13-14, 26 Notably, 
several muraymycin synthetic variants have been screened against MraYs from different 
species, achieving IC50 values as low as 0.7 nM. However, only two naturally occurring 
muraymycins have been directly tested against MraY to date: muraymycin D1 and D2, both 
prepared by total synthesis and yielding IC50 values of 10 nM and 2.8 nM, respectively.
7, 14 Our 
understanding of muraymycin structure-activity relationship from these studies has recently 
been reviewed.10 
Muraymycins have several unique structural features when compared with clinically 
used antibiotics. They are classified as lipopeptidyl nucleoside antibiotics, consisting of a 
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(5′S,6′S)-glycyluridine (GlyU) core that is modified with two distinct components: an 
aminoribose attached by a traditional O-glycosidic bond and an unusual peptide attached by a 
propylamine linker.1, 27 The different congeners have been categorized into four types (series 
A-D) based on structural variation of a Leu residue of the peptide moiety. The D series, which 
includes the aforementioned muraymycins D1 and D2, contain an unmodified L-Leu and are 
structurally the simplest. The C series of muraymycins contain a (3S)-3-hydroxy-L-Leu, and 
the A and B series are O-acylated variants of the hydroxylated L-Leu. The B series are 
characterized by a branched, saturated fatty acid ranging from seven to ten linear carbons 
(represented by muraymycin B2 in Figure 1) and the A series characterized by a terminal 
guanidinium-substituted fatty acid ranging from fourteen to sixteen linear atoms in length 
(represented by muraymycin A1 in Figure 1).1  
As part of our on-going efforts to characterize the inhibitory properties and establish 
structure-activity relationships of naturally occurring muraymycins toward the target MraY, we 
report the discovery, structural elucidation, and activity of three new muraymycins (1-3) from 
Streptomyces sp. NRRL30473 and NRRL 30477, two strains previously derived from 
Streptomyces sp. NRRL 30471 by random, chemical mutagenesis. Importantly, a complete 
suite of 1D and 2D NMR spectroscopic analysis was performed, and the entirety of the NMR 
spectral data is provided in the public domain for the first time for any muraymycin congener. 
Compounds 1 and 2, named muraymycin B8 and B9, respectively, differ from other 
muraymycins by having an elongated fatty acid side chain. Both are shown to be potent 
inhibitors of Staphylococcus aureus and Aquifex aeolicus MraY in vitro. Compound 3, named 
muraymycin C6, is characterized by an N-acetyl modification of the primary amine of the 
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aminoribose. The inhibitory activity of 3 against MraY is significantly reduced, which is 
consistent with an important role of this amine in target binding and suggests acetylation as a 
possible means of self-resistance by the producing strain. 
2.2 Materials and Methods 
2.2.1 General Experimental Procedures  
UV spectra were recorded on an Ultraspec 8000 spectrometer (GE, Pittsburgh, PA, 
USA). All NMR data was recorded at 400 MHz for 1H and 100 MHz for 13C with Varian Inova 
NMR spectrometers (Agilent, Santa Clara, CA), and 600 MHz for 1H and 150 MHz for 13C 
with an Agilent DD2 NMR spectrometer (Agilent, Santa Clara, CA). LC-MS was conducted 
with an Agilent 6120 Quadrupole MSD mass spectrometer (Agilent Technologies, Santa Clara, 
CA) equipped with an Agilent 1200 Series Quaternary LC system and an Eclipse XDB-C18 
column (150 × 4.6 mm, 5 µm). HR-ESI-MS spectra were recorded on an AB SCIEX Triple 
TOF 5600 System (AB Sciex, Framingham, MA, USA). Analytic HPLC was performed with 
Waters Alliance 2695 separation module (Milford, MA) equipped with a Waters 2998 diode 
array detector and an analytical Apollo C18 column (250 mm x 4.6 mm, 5 µm). Semipreparative 
HPLC was performed with a Waters 600 controller and pump (Milford, MA) equipped with a 
996 diode array detector, 717 plus autosampler, and an Apollo C18 column (250 × 10 mm, 5 µm) 
purchased from Grace (Deerfield, IL). All solvents used were of ACS grade and purchased from 
Pharmco-AAPER (Brookfield, CT). Sephadex LH-20 (25-100 μm) was purchased from GE 
Healthcare (Little Chalfont, United Kingdom). A solution of resazurin sodium salt (Alfa aesar 
B21187) was prepared to 1 mg/mL in sterile distilled water. 
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2.2.2 Fermentation, Extraction, Isolation and Purification  
Streptomyces sp. NRRL 30473 and NRRL 30477 were cultivated on MS agar plates at 
28 °C for 7 days. Chunks of the corresponding agar with bacterial growth were added to five 
250 mL Erlenmeyer flasks, each containing 50 mL TSBG (Tryptic soy broth (Difco) 
supplemented with 20 g/L glucose), at 30 °C on a rotary shaker (250 rpm) for 72 h. The cultures 
were used to inoculate 200 flasks (250 mL), each containing 50 mL PM-1 medium.28 PM-1 was 
composed of glucose 2%, soluble starch 1%, pressed yeast 0.9%, peptone 0.5%, meat extract 
0.5%, NaCl 0.5%, CaCO3 0.3% and CB-442 (NOF Co., Ltd.) 0.01% (pH 7.4, before 
sterilization). The fermentation was continued for 7 days at 23 °C on a rotary shaker (210 rpm). 
All culture flasks were combined and centrifuged at 6000 x g for 15 min to separate the 
mycelium and water phase. The mycelial-cake portion was extracted with methanol (3 × 1 L) 
by sonication, and the organic phase was evaporated to afford 15 g of brown crude extract. 
Amberlite XAD-16 (4%, Sigma) resin was added to the water phase and stirred for 12 h. The 
resin was washed with water until the effluent became colorless, and then eluted with 3 L of 
methanol. The MeOH extract was concentrated under reduced pressure to obtain a crude extract 
(12 g). Components of the mycelium crude extract and water phase crude extract were subjected 
to Sephadex LH-20 column, and methanol was used to elute compounds at a flow rate at 2 
mL/min to yield twelve fractions. Fraction I was further purified by using a semipreparative 
HPLC (CH3CN−H2O, 0.01 % TFA; flow rate: 3.0 mL/min)to yield 1 (6 mg) and 2 (2 mg). 
Compound 3 (4 mg) and muraymycin C1 (5 mg) were isolated from fraction II by 
semipreparative HPLC (CH3CN−H2O, 0.01 % TFA; flow rate: 3.0 mL/min). 
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muraymycin B8 (1): white amorphous powder; UV (MeOH) λmax (log ε) 260 (3.83) nm; 
13C and 1H NMR data, see Tables 1 and 2; (+)-HR-ESI-MS: m/z 1184.6757 [M + H]+ (calcd for 
C64H94N11O18, 1184.6778). 
muraymycin B9 (2): white amorphous powder; UV (MeOH) λmax (log ε) 258 (1.93) nm; 
13C and 1H NMR data, see Tables 1 and 2; (+)-HR-ESI-MS: m/z 1156.6458 [M + H]+ (calcd for 
C62H90N11O18, 1156.6465). 
muraymycin C6 (3): white amorphous powder; UV (MeOH) λmax (log ε) 261 (3.95) nm; 
13C and 1H NMR data, see Tables 1 and 2; (+)-HR-ESI-MS: m/z 988.4598 [M + H]+ (calcd for 
C40H66N11O18, 988.4587).  
2.2.3 DNA Extraction, Genome Sequencing, and Analysis   
A single colony of Streptomyces sp. NRRL30473 from MS agar was used to inoculate 
50 mL TSBG in a 250 mL baffled flask and cultured for 3 days at 30 °C. Cells were harvested 
via centrifugation and washed once with TE buffer and resuspended with 5 mL of 2 mg/mL 
lysozyme (dissolved in TE buffer). Cells were incubated at 30 °C for 30 min and then 1.2 mL 
0.5 M EDTA was added and mixed. Proteinase K (6 ml of 0.2 mg/mL) was added to the solution 
and incubated at 37 °C for 2 h.  DNA was extracted using phenol-chloroform with the protocol 
shared by Pacific Biosciences with minor modifications. Phenol/chloroform/isoamyl alcohol 
solution (7 mL of 25: 24: 1) was added, and the mixture rotated for 10 min. The top aqueous 
solution was transferred after centrifugation and 7 mL chloroform/isoamyl alcohol solution 
(24:1) was added. After rotating for 5 min, the top aqueous solution was transferred after 
centrifugation. The solution was treated with RNase for 1 h at 37 °C. After mixing with 0.25 
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volume of 5 M NaCl, 30% PEG6000 was added to final concentration of 10%. Precipitated 
DNA was transferred with glass tube to a new tube and rinsed with 70% ethanol and air dried. 
DNA was re-dissolved in 2 mL TE buffer and stored at 4 °C.   
2.2.4 Antimicrobial Bioactivities  
The protocol used for the determination of the minimum inhibitory concentration (MIC) 
was as described previously with minor modifications.29 The bacterial strains S. aureus subsp. 
aureus (Newman strain), E. coli ∆tolC mutant JW5503 (E. coli genetic stock center), and E. 
coli BL21(DE3) were used as model strains for antimicrobial susceptibility assays. All strains 
were grown in appropriate liquid or on agar plates using LB media (BD244620) for S. aureus 
and LB media supplemented with 50 μg/mL kanamycin for E. coli ∆tolC mutant. Individual 
strains were grown in 5 mL of medium for 16 h at 37 °C with shaking (250 rpm), and then were 
diluted X1000 into 4.5 mL of medium and incubated until OD600 reaching 0.4. An aliquot of the 
suspensions was diluted X1000. Aliquots (90 μL) of each diluted culture and transferred into 
the individual well of a 96-well plate supplied with 5 μL of the tested compound. Maximum 
final concentration of 256 μg/mL or 32 μg/mL with serial dilutions was maintained to obtain 
the antimicrobial activities and compared to the negative control 1% DMSO or water alone. 
The culture plates were incubated at 37 °C for 16 h with shaking (160 rpm) for E. coli strains 
and (50 rpm) for S. aureus. The OD600 of each well measured using BioTek™ Synergy™ 2 
Multi-Mode Microplate Readers. The acquired OD600 values were normalized to the negative 
control wells (100% viability). Resazurin solution (5 μL) was also added to each well, and the 
plates were shaken for 10 s and incubated at 37 °C for another 3 h to allow resazurin to convert 
to resorufin by viable bacteria. The minimal concentration of the tested compound that caused 
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growth inhibition was recorded as the MIC. The MIC assay with S. aureus was carried out by 
Prof. Christian Ducho’s lab in Department of Pharmacy, Pharmaceutical and Medicinal 
Chemistry, Saarland University. 
2.2.5 MraY Inhibition Assay 
MraY inhibition to determine IC50 was carried out by Prof. Christian Ducho’s lab in 
Department of Pharmacy, Pharmaceutical and Medicinal Chemistry, Saarland University. 
Overexpression of MraY from S. aureus. The overexpression of SaMraY in E. coli was 
performed as described, and a crude membrane preparation was employed for in vitro MraY 
assays.13 
Overexpression of MraY from Aquifex aeolicus. For the overexpression of AaMraY 
from in E. coli, the plasmid previously reported by Lee and co-workers4-5 was used. This 
plasmid contained the codon-optimized mraY gene from Aquifex aeolicus encoding a fusion 
protein with decahistidine maltose-binding protein (His-MBP) and a PreScission protease 
cleavage site for removal of the tag. The plasmid was transformed into C41 (DE3) E. coli cells 
and MraY was expressed in terrific broth (TB) medium containing 35 μg/mL kanamycin. 
Protein expression was induced at OD600 ~1.0 at 37 °C for 3 h using 0.4 mM isopropyl-β-D-
thiogalactopyranoside (IPTG). Cells were harvested by centrifugation at 5750 x g. All further 
steps were carried out at 4 °C. The cells were resuspended in 10-20 mL resuspension buffer per 
liter culture (resuspension buffer: 50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 2 mM β-
mercaptoethanol (BME), lysozyme, DNAse I and one cOmplete™ EDTA-free Protease 
Inhibitor Cocktail tablet), the cells were lysed by sonication (30% amplitude, 3/10 s pulse, 7/10 
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s pause for 15 min). n-Dodecyl-β-D-maltoside (DDM, 30 mM) was added and the resultant 
lysate was stirred for 2 h. After centrifugation at 30000 x g for 45 min, the cleared lysate was 
loaded onto pre-equilibrated TALON Superflow™ resin (~0.5 mL/L culture), imidazole was 
added to a final concentration of 7 mM and the mixture was rotated at 4 °C overnight. 
Subsequently, the resin was washed with 20 column volumes of washing buffer (50 mM Tris-
HCl (pH 8.0), 150 mM NaCl, 2 mM BME, 10 mM imidazole, 1 mM DDM) and eluted with 
10-20 mL elution buffer (50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 2 mM BME, 250 mM 
imidazole, 1 mM DDM). Dithiothreitol (DTT, final concentration of 1 mM), 
ethylenediaminetetraacetic acid (EDTA, final concentration of 1 mM) and PreScission protease 
(ratio to His-MBP-MraY 1:100) were added and the solution was incubated at 4 °C overnight. 
The cleaved protein was separated on a HiLoad 16/600 Superdex 200 pg in a buffer containing 
20 mM Tris-HCl (pH 8.0), 150 mM NaCl, 2 mM DTT and 5 mM n-decyl-β-D-maltopyranoside 
(DM). The resultant solution was employed as a source of solubilized and purified AaMraY for 
in vitro MraY assays. 
Fluorescence-based MraY assay. In vitro MraY assays were performed using our 
previously reported adapted version30 of Bugg's fluorescence-based method.31-36 Fluorescence 
intensity over time was measured at ex = 355 nm and em = 520 nm (BMG Labtech 
POLARstar Omega, 384-well plate format). Each well contained a total volume of 20 L with 
100 mM Tris-HCl buffer (pH 7.5), 200 mM KCl, 10 mM MgCl2, 0.1% Triton X-100, 0-5% 
DMSO, 50 mm undecaprenyl phosphate, 7.5 mm dansylated Park’s nucleotide (synthetic or 




For SaMraY, 1 L of a crude membrane preparation with a total protein concentration 
of 1.0 mg/mL was used and the reaction was initiated by the addition of the protein preparation. 
For AaMraY, 1 L of a solution of purified protein was used and preincubated with the assay 
mixture (including the inhibitor but excluding the dansylated Park's nucleotide) at rt for 30 min. 
The reaction was then initiated by the addition of Park's nucleotide. Concentrations of the 
purified AaMraY was 0.1 mg/mL. The protein preparations of SaMraY and AaMray showed 
comparable activity in the absence of inhibitors.  
MraY activity at a certain inhibitor concentration was determined by a linear fit of the 
fluorescence intensity curve from 0 to 2 min. This measure of enzymatic activity was plotted 
against the logarithmic inhibitor concentration and fitted with a sigmoidal fit using the formula 
shown below, thus furnishing the reported IC50 values. 
𝑦 =  𝐴1 +  
(𝐴2 − 𝐴1)






2.3 Results  
Initial attempts to produce muraymycins using the published fermentation conditions1, 
24 were unsuccessful. Hence, a few different media were examined. Using analytical scale 
fermentation with LC-MS analysis, production of muraymycins was observed using PM-1 
media, which was previously employed for the production of capuramycin, a structurally 
distinct nucleoside antibiotic from a different Streptomyces sp.28 As a consequence, a 100 mL 
seed culture of Streptomyces sp. strain NRRL 30473 was grown for three days and used to 
inoculate 10 L of PM-1 media. After fermentation for seven days, followed by extraction, 
fractionation, and resolution of the components within the crude extract, five known 
muraymycins were identified by LC-MS analysis (A1, B1, B2, B3, and B6). Two congeners, 
muraymycins B8 (1, yield: 0.6 mg/L) and B9 (2, yield: 0.2 mg/L), with masses that did not 
match prior reports, were purified by reverse-phase HPLC. Using identical fermentation 
conditions with Streptomyces sp. strain NRRL 30477, one new congener, muraymycin C6 (3, 
yield: 0.4 mg/L), and one known muraymycin C1 (yield: 0.5 mg/L) were obtained and likewise 




Figure 2.1 Structures of representative muraymycins.  
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2.3.1 Structure Elucidation  
The molecular formula of 1 (C64H93N11O18) was determined by HR-ESI-MS (Figure 
S2.1). An initial analysis of the 13C and 1H NMR data (Tables 2.1 and 2.2) in conjunction with 
the HSQC spectra in DMSO-d6 showed the presence of 54 carbon resonances, which were 
ascribed to 7 methyls (including 1 methoxyl), 18 methylenes, 18 methines, 1 double bond and 
9 amide/acid carbonyls (Figures S2.2-S2.3). The NMR and UV data for 1 displayed typical 
features of a muraymycin compound, including the GlyU nucleoside, ribofuranoside, 
aminopropane, epicapreomycidine, urea, valine and hydroxy-leucine. Further interpretation of 
the 1D and 2D NMR data (including 1H- 1H COSY, HSQC, HMBC and TOCSY; Figures S2.4-
S2.7) revealed the structure of 1, which was quite similar with muraymycin B11, except for the 
fatty acid chain, which was identified as 14-methyl-pentadecanoic acid through 2D NMR 
(Figure 2.2). A strong HMBC correlation from H-22 (δH 4.92) to C-1′ (δC 172.0) unambiguously 
determined the position of pentadecanoic acyl group on hydroxy-leucine. Based on the NOESY 
spectrum (Figure S2.8), the relative configuration of 1 was assigned to be identical with that 
reported for muraymycin B1.1 Thus, the structure of compound 1 was established as a new 
member of the muraymycin B family and subsequently named muraymycin B8.  
Compound 2 was assigned the molecular formula C62H89N11O18 on the basis of HR-
ESI-MS (Figure S2.9). A difference of C2H4 with 1 and their similar NMR spectroscopic data 
was suggestive of 2 as a muraymycin B congener (Figures S2.10-S2.11). The fatty acid chain 
for 2 was identified as 12-methyl-tridecanoic acid from a thorough analysis of the 2D NMR 
data (Figures 2.12-S2.14). The relative configuration of 2 was also established by NOESY 
(Figure S2.15). Compound 2 was designated as muraymycin B9. 
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The UV and NMR spectroscopic data for 3 (C40H65N11O18) revealed characteristic 
features of muraymycin (Tables 2.1 and 2.2, and Figures S2.16-2.22) and were similar to that 
reported for muraymycin C1,1 which was likewise isolated from this strain (Figures S2.23-
S2.28).2 Specifically, 3 displayed an extra acetyl substitution of a methyl (δC 21.9 and δH 1.85) 
and a carbonyl (δC 174.1). The key HMBC correlations from H2-16 (δH 3.05 and 3.41) to δC 
174.1 established the N-acetyl at C-16. Based upon this analysis, the structure of 3 was 
established as 16-N-acetyl-muraymycin C1, a new muraymycin C congener and subsequently 
named muraymycin C6. Of note, 16-N-acetyl-muraymycin C1 was previously prepared from 
muraymycin C1 via chemical semisynthesis,24 and the 1H NMR spectrum of the naturally 
occurring congener matched the semisynthetic variant.  




Figure 2.2 1H-1H COSY (▬) and selected HMBC (→) correlations of 1−3.  
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Table 2.1 13C NMR data (100 MHz) of compounds 1−4. 
no. 1a 2a, b 3c C1c no. 1a 2a, b 3c C1c 
1 141.6, 
CH 
141.5, CH 141.9, CH 142.3, CH 21 53.4, 
CH 
53.4, CH 56.1, CH 56.0, CH 
2 101.7, 
CH 
101.7, CH 101.9, CH 102.2, CH 22 75.0, 
CH 
75.0, CH 74.4, CH 74.6, CH 
3 163.1, C 163.1, C 165.9, C 165.9, C 23 27.8, 
CH 
27.8, CH 29.1, CH 29.2, CH 


























72.5, CH 72.8, CH 72.5, CH 26 169.5, C 169.5, C 171.2, C 171.1, C 
7 70.0, 
CH 
69.9, CH 69.0, CH 69.1, CH 27 54.8, 
CH 
54.8, CH 55.3, CH 55.4, CH 
8 82.8, 
CH 
82.8, CH 83.4, CH 83.7, CH 28 50.0, 
CH 
50.0, CH 49.1, CH 49.1, CH 
9 76.3, 
CH 
























11 168.8, C 168.7, C 169.9, C 170.3, C 31 153.7, C 153.7, C 153.6, C 153.6, C 
12 105.2, 
CH 
105.1, CH 106.5, CH 106.7, CH 32 157.5, C 157.5, C 158.7, C 158.7, C 
13 84.1, 
CH 
84.1, CH 83.9, CH 83.6, CH 33 173.7, C 173.6, C 177.3, C 176.4, C 
14 71.8, 
CH 
71.7, CH 70.1, CH 70.5, CH 34 57.5, 
CH 
57.5, CH 59.4, CH 58.6, CH 
15 79.3, 
CH 
79.3, CH 82.9, CH 79.6, CH 35 30.3, 
CH 
30.3, CH 30.1, CH 29.9, CH 
16 42.1, 
CH 





































































  174.1, C  




  21.9, CH
3
  
Fatty acid for 1 
 
Fatty acid for 2 
 
ameasured in DMSO-d6; 





Table 2.2 1H NMR data (400 MHz, J in Hz) of compounds 1−3 and muraymycin C1. 
no
. 
1a 2a, b 3c C1c no. 1a 2a, b 3c C1c 
















27 4.39, m 4.38, m 4.19, m 4.20, d 
(6.2) 




28 3.60, m 3.61, m 3.71, m 3.71, m 
6 4.13, m 4.14, m 4.23, m 4.25, m 29 1.70, m 1.71, m 1.72, m 1.72, m 




3.15, m 3.12, 
3.19, m 
8 4.10, m 4.11, m 4.09, m 4.18, m 34 4.03, m 4.03, m 3.86, m 3.93, m 
9 4.42, m 4.42, m 4.30, m 4.43, dd  
(0.8, 3.1) 
35 2.02, m 2.03, m 1.96, m 1.98, m 




12 5.11, br 
s 








13 3.54, m 3.54, m 3.64, m 3.68, m 3-NH 11.42, s 11.39, s   
14 4.03, m 4.05, m 4.04, m 4.08, m 13-OCH3 3.27, s 3.28, s 3.22, s 3.25, s 
















2.98, m 2.95, 
3.03, m 














3.16, m 3.05, 
3.18, m 










22 4.92, dd  
(2.7, 
6.4) 
4.92, dd  
(1.1, 5.8) 
3.48, dd  
(3.3, 6.7) 
3.47, dd  
(3.5, 6.6) 














     
Fatty acid for 1 
 
Fatty acid for 2 
 
ameasured in DMSO-d6; bmeasured at 600 MHz; cmeasured in D2O; d,eoverlapped signals. 
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2.3.2 Antimicrobial Bioactivity 
The newly isolated muraymycins were evaluated for inhibition of MraY activity. An in 
vitro fluorescence-based assay for MraY was previously developed,35-39 which we have adapted 
and optimized for screening.30 In short, this assay required the synthesis of a dansylated 
derivative of the MraY substrate UDP-MurNAc-pentapeptide to generate a fluorescent readout, 
and overproduction of recombinant S. aureus and A. aeolicus MraY. The MraY homologue 
from S. aureus (SaMraY) was used as a crude membrane preparation as attempts to solubilize 
and purify the protein resulted in loss of activity. In contrast, the solubilization and purification 
of the MraY homologue from Aquifex aeolicus (AaMraY) was feasible,4-5 and the protein was 
used accordingly in the in vitro assays for MraY inhibition. The results for the inhibitory 
activities (IC50 values) of the new muraymycins 1-3 along with the known compound 
muraymycin C1 are listed in Table 2.3. To summarize, 1, 2, and muraymycin C1 had potent 
IC50 values ranging from 4-22 pM against SaMraY and 68-350 pM against AaMraY, which is 
significantly lower than IC50 values reported for synthetic analogues and naturally occurring 
muraymycins D1 and D2 (D1, 11 nM against crude Mycobacterium tuberculosis;7 D2, 10 nM 
against purified MraY from Bacillus subtilis,14 and 2.8 nM against SaMraY26). The comparable 
IC50 values with or without the acid chain is consistent with prior conclusions that a long chain, 
aliphatic component might not significantly contribute to MraY inhibition.10 Contrastingly, 
when compared with muraymycin C1, compound 3 showed reduced activity against both 
enzymes. This result is consistent with a significant role of the intact aminoribosyl group for 
MraY binding, which was postulated based upon analysis of the X-ray structure of muraymycin 
D2 in complex with AaMraY.4 It has been found that a conformational rearrangement occurs 
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upon muraymycin D2 binding that generates a pocket for opportune interactions with the 
aminoribose.4-5 
We also examined the bacterial growth inhibition of 1-3 against S. aureus and two 
strains of E. coli. Interestingly, the longer fatty acid side chains of 1 and 2 converted the B series 
from inactive against S. aureus (MIC > 32 μg/mL for muraymycin B2 and B6)1, 3 to active 
against S. aureus (MIC = 2-6 μg/mL for muraymycin B8 and B9). Furthermore, the lack of a 
fatty acid side chain for 3 yielded an inactive compound. Taken together with the IC50 values 
for MraY inhibition, this result suggests that the fatty acid unit indeed plays a role in cellular 
uptake as suggested.40 In contrast to the MIC data against S. aureus, the addition of the fatty 
acid side chain and increase in its length slightly reduced the activity against both efflux-
deficient E. coli tolC (MIC for the B series range from 1-4 μg/mL) and efflux-competent E. 
coli BL21(DE3) (MIC from 8-64 μg/mL). Similarly to the trends observed with the IC50 values, 
however, acetylation of muraymycin C1 at the aminoribose significantly reduced the MIC 
against all strains. 
Self-resistance mechanisms to muraymycins remain undefined. The discovery and 
assessment of muraymycin C6 suggests that acetylation might be such a mechanism, not unlike 
acetyltransferases involved in aminoglycoside resistance. Interestingly, two potential resistance 
genes that encode enzymes predicted to covalently modify muraymycins are found in the 
biosynthetic gene cluster.22 However, neither would be expected to catalyze acetylation: mur28 
is predicted to encode a TmrB-like ATP-dependent phosphotransferase and mur29 a putative 
nucleotidyltransferase. Thus, the role of these two genes and relationship to resistance and/or 
acetylation, if any, await further examination. 
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S. aureus  
growth 
inhibition 







IC50 (pM) IC50 (pM) MIC (μg/mL) MIC (μg/mL) MIC (μg/mL) 
1 4.0±0.7 (6.8±0.5)×101 2 4 64 
2 22.1±3.2 (3.2±0.2)×102 6 2 32 
3 93±8 (1.8±0.4)×103 >32 16 256 
muraymycin 
C1 






2.4.1 Synthesized Muraymycin B9 Analogue with Good Antibacterial Activity 
Tanino et al.18 reported the synthesis and biological evaluation of muraymycin 
analogues with different lipophilic side chain (Figure 2.3). Among these analogues, MRY1 with 
similar lipophilic side chain as muraymycin B8 showed the best activity. Compared to MRY3, 
which showed no activity to methicillin-resistant S. aureus and vancomycin-resistant E. faecalis 
up to 64 µg/mL, the MIC of MRY1 to both strains were 2~4 µg/mL, which was 2~4 times lower 




Figure 2.3 Structures of synthesized muraymycin analogues.  
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2.4.2 Resistant Modifications of Muraymycin 
The isolation of muraymycin C6, the acetylated muraymycin C1, is proposed to be one 
of the resistance modification of muraymycins. We sequenced the genome of Streptomyces sp. 
NRRL30473. AntiSMASH analysis41-42 enabled us to identify the muraymycin biosynthetic 
gene cluster, which spans ~31 kb on a single contig (~96 kb). However, a gene encoding an N-
acetyltransferase was not found in the biosynthetic gene cluster. The N-acetylation modification 
is possibly catalyzed by a N-acetyltransferase located outside the gene cluster. Genome 
sequencing of Streptomyces sp. NRRL30473 also showed several N-acetyltransferases located 
outside the gene cluster, one of which might be responsible for the modification.  
Moreover, two muraymycin resistance genes were found in the biosynthetic gene 
cluster of muraymycin from Streptomyces sp. NRRL 30473, one encoding a TmrB-like ATP-
dependent muraymycin phosphotransferase, and another encoding a muraymycin 
nucleotidyltransferase. As the disaccharide moiety of muraymycin is technically an 
aminoglycoside, the three kinds of aminoglycoside resistance modification43-44 are also 
discovered in muraymycin. Functional assignment of muraymycin phosphotransferase and 
muraymycin nucleotidyltransferase is presented in chapter 4. 
2.5 Conclusion 
With the goal of developing a muraymycin production platform and expanding upon 
the known family of muraymycins, we examined the metabolic profile of Streptomyces sp. 
strain NRRL 30473 and Streptomyces sp. strain NRRL 30477. Four muraymycins were 
characterized by a suite of spectroscopic methods, including three new members of the 
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muraymycin family: B8, B9 and C6 (1−3). Muraymycin B8 and B9 showed promising 
antibacterial activity and pM inhibition against SaMraY and AaMraY. Remarkably, the newly 
discovered muraymycins B8 and B9 were the first congeners of the B series to display 
antibacterial activity against S. aureus. In our hands muraymycin B8 and B9 have activity 
against S. aureus that is comparable to or better than muraymycin A1,45 which was previously 
noted as the most potent muraymycin,1-2 hence warranting a continued evaluation of these new 
muraymycins as antistaphylococcal antibiotics. Contrastingly, muraymycin C6, the first N-
acetylated version of muraymycin to be isolated, showed reduced activity in all screens 




2.6 Supporting Information 
 
Figure S2.1 (+)-HR-ESI-MS (positive mode) of muraymycin B8 (1). 
 




Figure S2.3 13C NMR spectrum (DMSO-d6, 100 MHz) of muraymycin B8 (1). 
 




Figure S2.5 HMBC spectrum (DMSO-d6, 400 MHz) of muraymycin B8 (1). 
 




Figure S2.7 TOCSY spectrum (DMSO-d6, 400 MHz) of muraymycin B8 (1). 
 




Figure S2.9 (+)-HR-ESI-MS (positive mode) of muraymycin B9 (2). 
 
 




Figure S2.11 13C NMR spectrum (DMSO-d6, 150 MHz) of muraymycin B9 (2). 
 
 




Figure S2.13 HMBC spectrum (DMSO-d6, 600 MHz) of muraymycin B9 (2). 
 




Figure S2.15 NOESY spectrum (DMSO-d6, 600 MHz) of muraymycin B9 (2). 
 
 




Figure S2.17 1H NMR spectrum (D2O, 400 MHz) of muraymycin C6 (3). 
 
 




Figure S2.19 HSQC spectrum (D2O, 400 MHz) of muraymycin C6 (3). 
 
 




Figure S2.21 1H-1H COSY spectrum (D2O, 400 MHz) of muraymycin C6 (3). 
 
 




Figure S2.23 (+)-HR-ESI-MS (positive mode) of muraymycin C1 (4). 
 
 




Figure S2.25 13C NMR spectrum (D2O, 100 MHz) of muraymycin C1 (4). 
 
 




Figure S2.27 HMBC spectrum (D2O, 400 MHz) of muraymycin C1 (4). 
 
 
Figure S2.28 1H-1H COSY spectrum (D2O, 400 MHz) of muraymycin C1 (4). 
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Chapter 3 : Enzymatic Formation of Ribofuranosylated Glycyl-uridine Scaffold of 
Antibiotic Muraymycin 
3.1 Introduction 
According to bioinformatics analysis of the muraymycin gene cluster, six enzymes, 
Mur16 (encoding a putative dioxygenase), Mur17 (encoding a putative transaldolase), Mur20 
(encoding a putative aminotransferase), Mur26 (encoding a putative phosphorylase), Mur18 
(encoding a putative nucleotidylyltransferase) and Mur19 (encoding a putative 
glycosyltransferase) are proposed to be critical for the biosynthesis of the core structure, 
ribofuranosylated glycyl-uridine, of muraymycin. Respective enzyme homologs from the 
biosynthetic pathway of A-90289, a structurally related nucleoside antibiotic (Figure 3.1), have 
been characterized (Figure 3.2).46-51 As muraymycin has similar disaccharide scaffold with A-
90289, we expect the muraymycin homologs to have a similar function. However, unlike A-
90289, the muraymycin nucleoside is not 2′-O-sulfated and the 2′′-OH of the aminoribose is 
differentially modified, suggesting the possibility that the homologues have unique biochemical 
properties. Moreover, the ribosyltransferase in the biosynthetic pathway of A-90289 was only 
tested by utilizing its surrogate acceptor. In this chapter, the function of the six enzymes (Mur16, 
17, 18, 19, 20 and 26) was identified and characterized. The ribosyltransferase Mur19 in 
muraymycin biosynthetic pathway and LipN in A-90289 biosynthetic pathway were also tested, 
for the first time, with its genuine aminoribose acceptor. A one-pot enzymatic reaction was 








Figure 3.2 Proposed biosynthetic pathway towards ribofuranosylated glycyl-uridine moiety. 
Enzymes that were previously functionally characterized were labeled in black.  
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3.2 Materials and Methods 
3.2.1 Cloning, Overexpression and Purification of Proteins 
The genes mur16, 17, 18, 19, 20 and 26 were amplified by PCR from genomic DNA 
extracted from Streptomyces sp. NRRL30473 using Phusion Hot Start II DNA Polymerase from 
Thermo Scientific with supplied HF buffer. Purified PCR products were ligated to pET30 
Xa/LIC (Novagen) or pXY200 following the standard protocol and confirmed by DNA 
sequencing (ACGT, INC).  
Plasmids pET30-mur16, pET30-mur18, pET30-mur20 and pET30-mur26 were 
introduced into E. coli BL21(DE3) cells, and the transformed strains were grown in LB 
supplemented with 50 μg/mL kanamycin. Following inoculation of 500 mL of LB with 50 
μg/mL kanamycin, the cultures were grown at 37 °C until the cell density reached an OD600 ~ 
0.5 when expression was induced with 0.1 mM IPTG. Cells were harvested after an overnight 
incubation at 18 °C and lysed in Buffer A (100 mM KH2PO4, 300 mM NaCl, 10 mM imidazole, 
pH 8.3) using a Qsonica sonicator (Qsonica LLC, Newtown, CT) for sonication for a total of 6 
min at 40% amplitude with 30 s pulses separated by 30 s rest periods. Following centrifugation 
the protein was purified using affinity chromatography with HisPurTM Ni-NTA agarose 
(Thermo Scientific, Rockford, IL), and proteins were eluted with increasing concentrations of 
imidazole in Buffer A. Purified proteins were concentrated and buffer exchanged into Buffer B 
(25 mM KH2PO4, 100 mM NaCl, pH 8.3) using Amicon Ultra 10000 MWCO centrifugal filter 
(Millipore) and stored as glycerol stocks (40%) at -20 °C. Protein purity was assessed as by 12% 
acrylamide SDS-PAGE; His6-tagged proteins were utilized without further modifications. 
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Protein concentration was determined using UV/Vis spectroscopy, and the extension 
coefficients were calculated using the ProtParam tool available from ExPASY. 
Plasmids pXY200-mur17 and pXY200-mur19 were transformed into S. lividans TK24 
using PEG-mediated protoplast transformation and plated on R2YE supplemented with 50 
μg/mL apramycin. After 6 days at 28 °C, positive transformants were confirmed by colony PCR 
using InstaGene Matrix from Bio-Rad (Hercules, CA) and LA-Taq polymerase with GC buffer 
I. 
The recombinant strain was utilized to inoculate 50 mL R2YE containing 50 
μg/mL apramycin, grown for 3 days at 28 °C at 250 rpm, and 2 mL transferred to fresh 
100 mL containing 50 μg/mL apramycin. Following growth for 3 days at 28 °C at 250 
rpm, protein expression was induced by addition of thiostrepton (5 μg/mL) and the 
culture was incubated for another 24 h before harvesting. The cells from 400 mL of 
culture were collected by centrifugation. The pellet was thoroughly resuspended in ice-
cold Buffer A supplemented with 4 mg/mL of lysozyme was subsequently added to the 
suspension. After incubation at 30 °C for 30 min, the cell suspension was mixed by 
pipetting and lysed using a Qsonica sonicator (Qsonica LLC, Newtown, CT) for 
sonication for a total of 10 min at 40% amplitude with 30 s pulses separated by 30 s 
rest periods. The protein purification and storage was as described above.  
3.2.2 Synthesis of 2'-Methoxy-UMP, 1c. 
The synthesis of 1c followed a previously described procedure.52 Pyrophosphoryl 
chloride (0.1 mL) was added to a cool solution (4 °C) of 2′-O-methyluridine (52 mg) in m-
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cresol (2 mL). The mixture was stirred for 2 h at 4 °C and diluted with ice water (7 mL). The 
product was extracted with diethyl ether (3 mL). The aqueous layer was adjusted to pH = 2 with 
4 N sodium hydroxide. After freeze-drying, the product was purified by semipreparative HPLC 
(Waters 600) with gradient shown in Table S3.7 to yield 30 mg.  
 
 
Figure 3.3 13C NMR spectrum (D2O, 100 MHz) and 
1H NMR spectrum (D2O, 400 MHz) of 2′-
methoxy-UMP. 
 
3.2.3 Activity Assay of Mur16 
Reactions consisted of 50 mM HEPES (pH 7.5), 2.5 mM α-KG, 2 mM ascorbic acid, 
0.2 mM FeCl2, 1 mM UMP, dUMP or 2′-methoxy-UMP, and 100 nM Mur16 at 30 °C. Reactions 
were terminated by ultrafiltration using Amicon® Ultra centrifugal filter units. Following 
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centrifugation to remove protein, the reaction was analyzed by HPLC or LC-MS with the 
gradient shown in Table S3.2. 
3.2.4 Kinetics of Mur16 
To determine the kinetic constants with respect to UMP and dUMP, reactions were 
carried out in 50 mM Tris-HCl (pH 7.5), 2 mM α-KG, 2 mM ascorbic acid, 0.4 mM FeCl2 with 
variable concentration of UMP (1 µM-500 µM), dUMP (1 µM-500 µM) or 2′-methoxy-UMP 
and 40 nM Mur16 at 30 °C for 4 min and analyzed under initial velocity conditions using the 
malachite green binding assay or at 30 °C for 1 h and analyzed by HPLC with gradient shown 
in Table S3.2 at 260 nm. Each data point represents three replicate end point assays. Kinetic 
constants were obtained by nonlinear regression analysis using GraphPad Prism 7 (GraphPad 
Software, La Jolla, CA). 
3.2.5 Activity Assay of Mur17 
Reactions of Mur17 consisted of 50 mM HEPES (pH 7.5), 2 mM uridine-5′-aldehyde 
2a, 5 mM L-threonine, 0.1 mM PLP and 1 μM Mur17 at 30 °C. Following removal of the 
protein by ultrafiltration, the reaction was analyzed by LC-MS. 
AQC, 6-aminoquinolyl-N-hydroxysuccinimidyl carbamate, a derivatizing reagent for 
amines, was used for the modification of 5′- and 6′-epimers of GlyU (synthesized by Christian 
Ducho’s lab53). The reaction (20 μL) was mixed with 60 μL of 0.2 M sodium borate buffer 
(pH8.8) and 20 μL of 3 mg/mL AQC acetonitrile solution. The mixtures were incubated at 55 °C 
for 10 min and then allowed to cool to rt. The AQC-derivatized samples (50 μL) were applied 
to LC-MS with the gradient shown in Table S3.3. 
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3.2.6 Activity Assay of Mur20 
Reactions of Mur20 consisted of 50 mM potassium phosphate (pH 7.5), 1 mM uridine 
aldehyde with different 2′ modification (2a synthesized by previous lab members, 2b or 2c), 1 
mM L-amino acid (methionine, alanine, arginine, etc.) and 1 μM Mur20 or LipO at 30 °C. 
Following removal of the protein by ultrafiltration, the reaction was analyzed by LC-MS with 
the gradient shown in Table S3.2. 
To identify the production of α-keto-γ-methylthiol butyric acid, reaction mixtures or 
the positive control (α-keto-γ-methylthiol butyric acid) were treated with reagent 3-methyl-2-
benzothiazolinone hydrazone hydrochloride (MBTH) according to the method described by 
Tanaka.54 Following removal of the protein by ultrafiltration, 50 μL reaction mixtures were 
mixed with 50 μL of 1 M sodium acetate (pH 5.0) and 50 μL of 8 mM MBTH aqueous solution. 
The mixtures were then incubated at 50 °C for 30 min and then analyzed by LC-MS with the 
gradient shown in Table S3.4 with detection at 350 nm. 
3.2.7 Activity Assay of Mur26 
Reactions of Mur26 consisted of 50 mM potassium phosphate (pH 7.5), 2 mM 5′-
amino-5′deoxy-uridine with different 2′ modification (4a, 4b, 4c) and 1 μM Mur26 or LipP at 
30 °C. Following removal of the protein by ultrafiltration, reactions were analyzed by LC-MS 
with the gradient shown in Table S3.2. 
3.2.8 Activity Assay of Mur18 
Reactions of Mur18 consisted of 50 mM potassium phosphate (pH 7.5), 2 mM 5′-
amino-5′-deoxy-uridine 4a or 5′-amino-2′, 5′dideoxy-uridine 4b (synthesized by previous lab 
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members), 5 mM MgCl2, 2 mM UTP, 1 μM Mur26 or LipP and 1 μM Mur18. Following 
removal of the protein by ultrafiltration, reactions were analyzed by HPLC with the gradient 
shown in Table S3.5 or Table S3.6. 
3.2.9 Activity Assay of Mur19 
Reactions of Mur19 consisted of 50 mM potassium phosphate (pH 7.5), 2 mM 5′-
amino-5′-deoxy-uridine 4a or 5′-amino-2′, 5′-dideoxy-uridine 4b, 5 mM MgCl2, 2 mM UTP or 
2′-F-dUTP, 1 mM GlyU 3, 1 μM Mur26 or LipP, 1 μM Mur18 or LipM and 1 μM Mur19 or 
LipN. Following the removal of the protein by ultrafiltration, reactions were analyzed by HPLC 
with the gradient shown in Table S3.5. 
Large-scale production of 8b (30 mL reaction) was identical to reactions 
described above using 3, 4b and UTP. The isolation of AQC-modified 8b was carried 
out with semipreparative HPLC with the gradient shown in Table S3.8 with detection.  
3.2.10 MIC assay of AQC modified 8b 
The protocol used for the determination of the minimum inhibitory 
concentration (MIC) was as described previously with minor modifications.29 
Escherichia coli ∆tolC mutant JW5503 (E. coli genetic stock center) was used as model 
strains for antimicrobial susceptibility assays.  E. coli ∆tolC mutant were grown in 5 
mL of LB medium with 50 μg/mL kanamycin for 16 h at 37 °C with shaking (250 rpm), 
and then were diluted (ⅹ1000) into 4.5 mL of medium and incubated until OD600 
reaching 0.4. An aliquot of the suspension was diluted (ⅹ1000) and 90 μL aliquots of 
diluted culture were transferred into the individual well of a 96-well plate supplied with 
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10 μL of the AQC modified 8b. Maximum final concentration of 32 μg/mL with serial 
dilutions was added to obtain the antimicrobial activities and compared to the negative 
control containing water alone. Resazurin solution (5 μL) was added to each well, and 
the plates were shaken for 10 s and incubated at 37 °C for another 3 h to allow resazurin 
to convert to resorufin by viable bacteria. The minimal concentration of the tested 
compound that caused growth inhibition was recorded as the MIC.  
3.2.11 One-Pot Enzymatic Reaction for the Biosynthesis of 8a 
Reactions consisted of 50 mM Hepes buffer (pH 7.5), 2.5 mM α-KG, 2 mM ascorbic 
acid, 0.2 mM FeCl2, 4 mM UMP, 2 mM L-threonine, 0.1 mM PLP, 2 mM L-methionine, 1 mM 
MgCl2, 2 mM UTP, 1 μM Mur16, Mur17, LipO, LipP, Mur18 and Mur19 was added accordingly. 
Following removal of the protein by ultrafiltration, reactions were analyzed by HPLC with the 
gradient shown in Table S3.5. 
3.2.12 One-Pot Enzymatic Reaction for the Biosynthesis of 8b 
Reactions consisted of 50 mM HEPES buffer (pH 7.5), 2.5 mM α-KG, 2 mM ascorbic 
acid, 0.2 mM FeCl2, 4 mM dUMP, 100 μM GlyU, 0.1 mM PLP, 2 mM L-methionine, 1 mM 
MgCl2, 2 mM UTP. 1 μM Mur16, LipO, LipP, Mur18 and Mur19 was added accordingly. 
Following removal of the protein by ultrafiltration, reactions were analyzed by HPLC with the 
gradient shown in Table S3.5. 
3.3 Results and Discussion 




Bioinformatic analysis revealed that Mur16 has a sequence similarity to dioxygenases 
including LipL and Cpr19,55-56 which utilizes UMP, α-KG and FeCl2 to form uridine-5′- 
aldehyde.25,36 The mur16 gene was cloned and expressed in E. coli BL21(DE3) to yield soluble 
protein (Figure S3.1). Using HPLC for detection, the activity of Mur16 was tested with UMP 
and a new peak corresponding to uridine-5′-aldehyde, 2a was formed in the presence of α-KG 
and FeCl2 (Figure 3.4A, Figure S3.2A). Mur16 also catalyzed oxidative decarboxylation of α-
KG to form succinate from the LC-MS result (Figure S3.3A). The enzyme-coupled assay to 
detect succinate production was also employed to confirm the production of succinate. Mur16 
was previously proposed to utilize L-arginine as substrate,22 however, LC-MS analysis and the 
enzyme-coupled assay to detect succinate revealed that L-arginine cannot be utilized by Mur16 
(Figures S3.3B-C). 
Different from LipL, which was unable to utilize deoxy-or 2′modified ribonucleoside 
monophosphate, Mur16 can also utilize dUMP, 1b and 2′-methoxy-UMP, 1c as substrates to 
form corresponding aldehyde 2b and 2c (Figures 3.4B-C, S3.2B-C). Mur16 was found to have 
optimal activity at 2 mM ascorbate using 40 µM FeCl2 (Figure 3.5A). Steady-state kinetic 
analysis with substrate UMP and dUMP was performed using the malachite green binding assay 
to detect phosphate formation. Single-substrate kinetic experiments of Mur16 with UMP and 
dUMP revealed typical Michaelis-Menten kinetics, yielding kinetic constants of Km = 20.81 ± 
3.93 µM and kcat = 4.37 ± 0.23 s
-1 with UMP and Km = 6.30 ± 2.13 µM and kcat = 2.3 ± 0.16 s
-1 
with dUMP (Figures 3.5B-C). However, kinetic experiments of Mur16 with 1c showed strong 
substrate inhibition with the increased concentration of 1c (Figure 3.5D), which indicated that 
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Figure 3.4 Characterization of Mur16.  
 (A) Reaction catalyzed by Mur16. (B) HPLC analysis using UMP (1a) after I, 12 h reaction 
w/ UMP, w/o Mur16; II, 12 h reaction w/ UMP, w/o Mur16; III, 12 h reaction w/ dUMP (1b), 
w/o Mur16; IV, 12 h reaction w/dUMP, w/o Mur16; V, 12 h reaction w/ 2′-methoxy-UMP (1c), 
























































































Figure 3.5 Activity optimization and kinetic analysis of Mur16. 
(A) Optimal activity of Mur16 with respect to varied ascorbate in reactions containing of 40 
µM FeCl2 and 40 nM Mur16. (B) Single-substrate kinetic analysis using variable UMP (1 µM-
500 µM), near saturating α-KG and 40 nM Mur16. (C) Single-substrate kinetic analysis using 
variable dUMP (1 µM-500 µM), near saturating α-KG and 40 nM Mur16. (D) Single-substrate 
kinetic analysis using variable 2′-methoxy-UMP (1 µM-1000 µM), near saturating α-KG and 






3.3.2 Functional Assignment of Mur17 as an L-Threonine: Uridine-5′-aldehyde Transaldolase 
Bioinformatic analysis of Mur17 revealed sequence similarity to LipK49, which was 
previously assigned as a transaldolase that utilizes uridine-5’-aldehyde 2a and L-threonine to 
generate GlyU, 3 (Figure 3.6A). Similar to LipK, the gene product of mur17 was only soluble 
when expressed in S. lividans TK24 (Figure S3.1). Activity tests analysis using HPLC with 
uridine-5’-aldehyde revealed a new peak (Figure 3.6B). LC-MS analysis of the purified new 
peak revealed an (M+H) + ion at m/z = 318.1, consistent with the product of LipK (Figure S3.4). 
However, Mur17 cannot utilize 2b or 2c as substrate, which potentially explains why all 
discovered muraymycin congeners have the same GlyU core structure. 6-aminoquinolyl-N-
hydroxysuccinimidyl carbamate (AQC) modification, which generates 6-
quinolinylaminocarbonyl amines without alteration of the stereochemistry of the starting 
material, of synthetically prepared 5′- and 6′-epimers of 3 all showed different elution time 
(Figure S3.5). LC-MS analysis of AQC modified Mur17 reaction revealed enzymatic produced 
3 showed same elution time with (5′S, 6′S)-3, which confirmed the stereo chemical assignment 
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Figure 3.6 Characterization of Mur17. 
(A) Reaction catalyzed by Mur17. (B) HPLC analysis using uridine aldehyde (2a) after I, 12 h 






3.3.3 Functional Assignment of Mur20 as an L-Methionine: 2-Aminotransferase. 
Bioinformatic analysis revealed that Mur20 has a sequence similarity to LipO47, which 
was previously assigned as a pyridoxal-phosphate (PLP)-dependent aminotransferase that 
catalyzes amino transfer utilizing nucleoside 2 as the amine acceptor (Figure 3.7A). The mur20 
gene was cloned and expressed in E. coli BL21(DE3) to yield soluble protein (Figure S3.1). 
HPLC analysis of the activity test of Mur20 with 2a and L-methionine revealed a new peak 
(Figure 3.7B) with (M+H) + ion at m/z = 244.0902 (Figure S3.7), corresponding to amino 
uridine, 4a, which is consistent with the product of LipO. Reagent 3-methyl-2-
benzothiazolinone hydrazone hydrochloride (MBTH) was used to confirm the production α-
keto-γ-methylthiol butyric acid from L-methionine in the transamination reaction (Figure S3.8). 
Further analysis revealed that 2′-deoxy-5′-uridine aldehyde 4b and 2′-methoxy-5′-uridine 
aldehyde 4c were also amine acceptors of Mur20 (Figures 3.7C-D, S3.9A-B). Several other 
potential amine donors like AdoMet, L-Arg or L-Ala can also be utilized as the amine donors 
by Mur20. However, GlyU cannot serve as amine donor for the reaction, which possibly 
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Figure 3.7 Characterization of Mur20. 
(A) Reaction catalyzed by Mur20. (B) HPLC analysis using uridine aldehyde (2a) after I, 6 h 
reaction without Mur20; II, 6 h reaction with Mur20; III, 6 h reaction with LipO. (C) LC-MS 
analysis using 2′-deoxy uridine aldehyde (2b) after I, 6 h reaction without Mur20; II, 6 h 
reaction with Mur20. (D) LC-MS analysis using 2′-methoxy uridine aldehyde (1c) after I, 6 h 








3.3.4 Functional Assignment of Mur26 as a Low Specificity Uridine Nucleoside Phosphorylase 
Bioinformatic analysis of Mur26 revealed a sequence similarity to LipP47, which 
catalyzes the phosphorolysis of uridine or 5′-amino-5′-deoxy uridine to generate the respective 
ribose-1-phosphate and uracil. The mur26 gene was cloned and expressed in E. coli to yield 
soluble protein (Figure S3.1). Activity tests revealed that, identically to LipP, Mur26-catalyzed 
reaction proceeded with uridine, 5′-amino-5′-deoxy-uridine 4a and 2′,5′-dideoxy-5′-amino-
uridine 4b (Figures 3.8, S3.10). Additional activity tests revealed that Mur26 didn’t utilize 2′-
methoxy-5′-amino-5′-deoxy-uridine 4c, which, combined with the kinetic experiment of Mur16 
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Figure 3.8 Characterization of Mur26. 
(A) Reaction catalyzed by Mur26. (B) LC-MS analysis of reaction catalyzed by Mur26. I, 6 h 
reaction w/ 5′-deoxy-5′-amino-uridine (4a) w/o Mur26; II, 6 h reaction w/ 4a w/ Mur26; III, 6 
h reaction w/ 4a w/ LipP; IV, 6 h reaction w/ 2′, 5′-dideoxy-5′-amino-uridine (4b) w/o Mur26; 
V, 6 h reaction w/ 4b w/ Mur26; VI, 6 h reaction w/ 4b w/ LipP. 
3.3.5 Functional Assignment of Mur18 as a Primary Amine-requiring Nucleotidylyltransferase. 
Bioinformatic analysis revealed that Mur18 has a sequence similarity to LipM47, 51, 
which has already been demonstrated as nucleotidylyltransferase by utilizing 5′-amino-5′-
deoxy-α-D-ribose-1-phosphate 5a or 5′-amino-2′,5′-dideoxy-α-D-ribose-1-phosphate 5b and 
UTP to generate the activated sugar. Different from LipM, which was only soluble when 
expressed in S. lividans TK64, Mur18 is soluble when expressed in E. coli with either an N-





study. Activity test revealed that Mur18 utilized 5b, which was generated in situ with LipP from 
4b and UTP, to generate UDP-5-amino-2, 5-dideoxyribose 7b (Figures 3.9- S3.11).  
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Figure 3.9 Characterization of Mur18. 
(A) Reaction catalyzed by Mur26 (or LipP) and Mur18. (B) HPLC analysis of Mur18 reaction. 
I, UTP; II, 2′, 5′-dideoxy-5′- amino-uridine (4b); III, 6 h reaction with LipP; IV, 6 h reaction 






3.3.6 Functional Assignment of Mur19 as a GlyU: 5-Amino-5-Deoxyribosyltransferase 
Bioinformatic analysis revealed that Mur19 has a sequence similarity to LipN47, which 
has already been characterized as a ribosyltransferase that utilizes uridine as a surrogate 
acceptor and the genuine sugar donor 7a (generated in situ with LipP and LipM) as substrates. 
Both muraymycin and A-90289 have the GlyU moiety, which can be produced by Mur17 or 
LipK, and thus, we propose that GlyU is the genuine sugar acceptor for both Mur19 and LipN. 
Similar to LipN, soluble Mur19 was only obtained in S. lividans TK24 by heterologous 
expression. HPLC analysis of Mur19 reactions using genuine acceptor 3 and in situ generated 
sugar donor 7a revealed a new peak, which co-eluted with chemically synthesized standard 8a 
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Figure 3.10 Characterization of Mur19.  
(A) Reaction catalyzed by Mur26, Mur18 and Mur19. (B) HPLC analysis of Mur19 reaction. I, 
chemically synthesized 8a; II, 6 h reaction with Mur26; III, 6 h reaction with Mur26 and Mur18; 






2′-Fluoro-2′-deoxyuridine-5′-triphosphate (2′-F-dUTP), was used to replace UTP in 
order to form a more, stable activated sugar 7a′ and 7b′. Activity tests showed that 2′-F-dUTP 
can be utilized by Mur18 to generate activated aminoribose, which was utilized by Mur19 to 
generate 8a and 8b (Figure 3.11). The production of 8b was confirmed by HR-ESI-MS and 1H 
NMR after large-scale purification of AQC derived reaction (Figures S3.12-S3.14). Activity of 
LipN with genuine sugar acceptor GlyU was also tested for the first time. Surprisingly, different 
from Mur19, LipN only accepted activated 5′-amino-5′-deoxy-amino ribose to generate 8a, 
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Figure 3.11 Characterization of Mur19 with 2'-fluoro-2'-deoxyuridine-5'-triphosphate.  
(A) HPLC analysis of Mur19 reaction with 4a. I, 6 h reaction without enzyme; II, 6 h reaction 
with LipP; III, 6 h reaction with LipP and Mur18; IV, 6 h reaction with LipP, Mur18, and Mur19. 
(B) HPLC analysis of Mur19 reaction with 4b. I, 6 h reaction without enzyme; II, 6 h reaction 
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Figure 3.12 Comparison of substrate promiscuity of Mur19 and LipN with 4a and 4b. 
(A) Comparison of substrate promiscuity of Mur19 and LipN with 4a. I, 6 h reaction with LipP, 
LipM and LipN; II, 6 h reaction with LipP, Mur18 and LipN; III, 6 h reaction with LipP, LipM 
and Mur19; IV, 6 h reaction with LipP, Mur18 and Mur19. (B) Comparison of substrate 
promiscuity of Mur19 and LipN with 4b. I, 6 h reaction with LipP, LipM and LipN; II, 6 h 
reaction with LipP, Mur18 and LipN; III, 6 h reaction with LipP, LipM and Mur19; IV, 6 h 






3.3.7 One-Pot Six-enzyme Synthesis of Ribofuranosylated Uronic Acid Moiety of Muraymycin  
Aminoribofuranosylated uronic acid 8a was generated in vitro by six proteins Mur16, 
Mur17, LipO, LipP, Mur18 and Mur19 using UMP as the starting substrate (Figure 3.13). With 
the addition of each enzyme, a new peak corresponding to respective product was revealed in 
the HPLC traces except for the product of Mur18 7a, which was unstable and degraded into 
UMP via intramolecular attack of the 2-hydroxy group of the aminoribosyl unit on the proximal 
phosphate as our group has previously reported.47 The degradation product UMP was further 
utilized by Mur16 followed by LipO and LipP, which resulted in the generation of twice the 
amount of uracil. HPLC analysis of the six-enzyme one pot reaction revealed a small new peak 
corresponding to the generation of 8a. 
2″-Deoxy-aminoribofuranosylated uronic acid 8b was also generated using dUMP and 
GlyU as starting substrates by five enzymes Mur16, LipO, LipP, Mur18 and Mur19. Mur17 was 
omitted in this reaction with the supplementation of its product GlyU because Mur17 couldn’t 
utilize 2′-deoxy-uridine aldehyde 2b, generated by Mur16 from dUMP, as a substrate. The 
generation of UDP-5-amino-2,5-dideoxyribose 7b by Mur18 was observable in HPLC traces. 
HPLC analysis of the five-enzyme one pot reaction revealed a small new peak corresponding 
to the generation of 8b (Figure 3.14, Figures S3.11-S3.13).  
Different from the one-pot enzymatic reaction I (reaction to produce 8a), the 
equilibration of the reaction shows the similar amount of 3,4a and 8a, one pot enzymatic 
reaction II (reaction to produce 8b) uses up all the synthetic 3 to produce 8b, and the excess of 
dUMP was totally converted to 2b rather than 4b or uracil. It seems that, by only adding the 
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UMP as start substrate, six enzymes added in one pot reaction I created a balance for the 
production of 8a with similar amount of 3 and 4a.  
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Figure 3.13 Characterization of one-pot enzymatic reaction with UMP and UTP as start 
substrates. 
(A) One pot enzymatic reaction catalyzed by Mur16, Mur17, LipO, LipP, Mur18 and Mur19. 
(B) HPLC analysis of one pot enzymatic reaction. I, no enzyme control; II, 12 h reaction with 
Mur16; III, 12 h reaction with Mur16 and Mur17; IV, 12 h reaction with Mur16, Mur17 and 
LipO; V, 12 h reaction with Mur16, Mur17, LipO and LipP; VI, 12 h reaction with Mur16, 
Mur17, LipO, LipP and Mur18; VII, 12 h reaction with Mur16, Mur17, LipO, LipP, Mur18 and 
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Figure 3.14 Characterization of one-pot enzymatic reaction with GlyU, 2′-deoxy-UMP, UTP 
as start substrates. 
(A) One pot enzymatic reaction catalyzed by Mur16, Mur17, LipO, LipP, Mur18 and Mur19. 
(B) HPLC analysis of one pot enzymatic reaction. I, no enzyme control; II, 12 h reaction with 
Mur16; III, 12 h reaction with Mur16 and LipO; IV, 12 h reaction with Mur16, LipO and LipP; 
V,12 h reaction with Mur16, LipO, LipP and Mur18; VI, 12 h reaction with Mur16, LipO, LipP, 






In this chapter, six enzymes were functionally assigned and characterized: Mur16, a 
non-heme, Fe(II)-dependent α-ketoglutarate: UMP dioxygenase; Mur17, an L-threonine: 
uridine-5′-aldehyde transaldolase; Mur20, an L-methionine: 1-aminotransferase; Mur26, a low 
specificity pyrimidine nucleoside phosphorylase; Mur18, a primary amine-requiring 
nucleotidylyltransferase; Mur19, a 5-amino-5-deoxyribosyltransferase. Substrates promiscuity 
for each enzyme was studied. Substrate promiscuity was preliminarily discussed. For the first 
time a one pot enzyme reaction was utilized to produce two distinct disaccharide moieties, both 
of which are potential biosynthetic intermediates that lead to the mature muraymycins (Figure 
3.15). 
 
Figure 3.15 Biosynthetic pathway and substrate promiscuity towards ribofuranosylated glycyl-




3.5 Supporting Information 
Table S3.1 Primers used in this study.  
Primer Sequence Note 
mur16_pET30F 5′- GGTATTGAGGGTCGCGTGGTCCGCGCTGAC -3′ Used for 
mur16 
expression 
mur16_pET30R 5′- AGAGGAGAGTTAGAGCC TCAGGGGCTCTCCAG-3′ 
























mur19_BamHI 5′- AAAAAAGGATCCTCACAGGGTCGTAGTTCTCAG-3′ 
mur20_pET30F 5′- GGTATTGAGGGTCGC GTGAGCCCCCAGAGCG-3′ Used for 
mur20 
expression 
mur20_pET30R 5′- AGAGGAGAGTTAGAGCC TCAGGCCGTCGCCTCG-3′ 











Table S3.2 Gradient used for HPLC or LC-MS analysis of reactions with an analytical Apollo 
C18 column (250 mm x 4.6 mm, 5 µm). 
Solvent A = ddH2O with 0.1% formic acid; Solvent B = acetonitrile with 0.1% formic acid; 
A260 
 
Time (min) % Solvent B Flow Rate (mL/min) 
0 1 0.5 
16 20 0.5 
28 100 0.5 
37 100 0.5 
38 1 0.5 
41 1 0.5 
 
Table S3.3 Gradient used for LC-MS analysis of AQC modified reactions with an analytical 
AcclaimTM 120 C18 column (100 mm x 4.6 mm, 5 µm). 
Solvent A = ddH2O with 0.1% formic acid; Solvent B = acetonitrile with 0.1% formic acid; 
A260 
 
Time (min) % Solvent B Flow Rate (mL/min) 
0 1 0.4 
40 20 0.4 
41 100 0.4 
44 100 0.4 
45 1 0.4 
47 1 0.4 
 
Table S3.4 Gradient used for LC-MS analysis of MBTH modified reaction with an analytical 
AcclaimTM 120 C18 column (100 mm x 4.6 mm, 5 µm). 
Solvent A = ddH2O with 0.1% formic acid; Solvent B = acetonitrile with 0.1% formic acid; 
A350. 
 
Time (min) % Solvent B Flow Rate (mL/min) 
0 10 0.4 
10 40 0.4 
20 100 0.4 
27 100 0.4 
28 10 0.4 





Table S3.5 Gradient used for HPLC analysis of reactions with an analytical Apollo C18 column 
(250 mm x 4.6 mm, 5 µm). 
Solvent A = 40 mM acetic acid-triethylamine pH 6.5; Solvent B = 40 mM acetic acid-
triethylamine, 20% methanol, pH 6.5; A260 
 
Time (min) % Solvent B Flow Rate (mL/min) 
0 0 1.0 
8 100 1.0 
18 60 1.0 
19 60 1.0 
 
Table S3.6 Gradient used for HPLC analysis of reactions with an analytical ZIC®-HILIC 
column (250 mm x 4.6 mm, 5 µm). 
Solvent A = ddH2O with 0.1% formic acid; Solvent B = acetonitrile with 0.1% formic acid; 
A260 
 
Time (min) % Solvent B Flow Rate (mL/min) 
0 80 0.4 
12 50 0.4 
26 50 0.4 
27 80 0.4 
35 80 0.4 
 
Table S3.7 Gradient used for semipreparative HPLC analysis of reactions with an 
analytical Apollo C18 column (250 mm x 10 mm, 5 µm). 
Solvent A= ddH2O with 0.025% trifluoroacetic acid; Solvent B= acetonitrile with 0.025% 
trifluoroacetic acid; A260 
 
Time (min) % Solvent B Flow Rate (mL/min) 
0 3 3.5 
8 10 3.5 
9 100 3.5 
13 100 3.5 
14 3 3.5 






Table S3.8 Gradient used for semipreparative HPLC analysis of reactions with an 
analytical Apollo C18 column (250 mm x 10 mm, 5 µm). 
Solvent A= ddH2O with 0.025% trifluoroacetic acid; Solvent B= acetonitrile with 0.025% 
trifluoroacetic acid; A260 
Time (min) % Solvent B Flow Rate (mL/min) 
0 12 4 
15 12 4 
16 100 4 
19 100 4 
20 12 4 
24 12 4 
 
 
Figure S3.1 SDS-PAGE analysis of protein Mur16, Mur17, Mur18, Mur19, Mur20 and Mur26.  
Mur 16 (expected MW of 33 kD), Mur18 (expected MW of 25 kD), Mur20 (expected MW of 
46 kD) and Mur26 (expected MW of 48 kD) purified from E. coli BL21 (DE3) and Mur17 
(expected MW of 47 kD), Mur19 (expected MW of 42 kD) purified from Streptomyces lividans 
























































   
Figure S3.2 LC-MS analysis of Mur16 catalyzed reactions.  
(A) Mass spectrum for the ion peak eluting at time t = 10.274 min of Mur16 reaction with UMP 
(uridine aldehyde expected (M+H)+ ion at m/z = 243.06, found: 243.1). (B) Mass spectrum for 
the ion peak eluting at time t = 13.404 min of Mur16 reaction with dUMP (2′- deoxy-uridine 
aldehyde expected (M+H)+ ion at m/z = 227.07, found: 227.1). (C) Mass spectrum for the ion 
peak eluting at time t = 14.116 min of Mur16 reaction with 2′-methoxy-UMP (2′-methoxy-
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Figure S3.3 Detection of succinate production using LC-MS and an enzyme coupled reaction.  
(A) Mass spectrum for the peak at elution time t = 14.358 min corresponding to succinate 
(succinate expected (M-H)- ion at m/z = 117.02, Found: 117.2). (B) Scheme of reactions 
catalyzed by three additional enzymes that lead to oxidation of NADH for detection by UV/Vis 
spectroscopy at 340 nm. (C) Mur16-catalyzed reaction with or without addition of UMP. In 
























Figure S3.4 LC-MS analysis of Mur17 catalyzed reactions. 
Mass spectrum for the ion peak eluting at time t = 7.111 min of Mur17 reaction with uridine 
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Figure S3.5 Comparative analysis of enzymatic and synthetic 3 diastereomers. 
(A) Primary amine of 3 reacts with AQC. (B) LC-MS analysis of AQC modified Mur17 reaction 
and synthetic 3 diastereomers. I, Synthetic (5′S, 6′S)-3 modified by AQC; II, (5′S, 6′R)-3 
modified by AQC; III, (5′R, 6′S)-3 modified by AQC; IV, AQC modified reaction using uridine 








































































Figure S3.6 LC-MS analysis of AQC modified GlyU epimers and Mur17 catalyzed reactions.  
(A) Mass spectrum for the ion peak eluting at time t = 16.169 min of AQC modified Mur17 
reaction (aqc modified (5′S, 6′S)-3, expected (M+H) + ion at m/z = 488.14, found: 488.2). (B) 
Mass spectrum for the ion peak eluting at time t = 16.169 min of AQC modified synthetic (5′S, 
6′S)-3 (AQC modified synthetic (5′S, 6′S)-3, expected (M+H) + ion at m/z = 488.14, found: 
488.0). (C) Mass spectrum for the ion peak eluting at time t = 19.484 min of AQC modified 
synthetic (5′S, 6′R)-3 (AQC modified synthetic (5′S, 6′R)-3, expected (M+H) + ion at m/z = 
488.14, found: 488.1). (D) Mass spectrum for the ion peak eluting at time t = 25.081 min of 




Figure S3.7 (+)-HR-ESI-MS (positive mode) of purified Mur20 product amino uridine, 4a 







1 0 1 2 1 4 1 6 1 8 2 0











































     
Figure S3.8 LC-MS analysis of MBTH modified Mur20 catalyzed reactions. 
(A) α-keto-γ-methylthiol butyric acid reacts with MBTH. (B) LC traces of MBTH modified 
reaction. I, control reaction without Mur20; II, MBTH modified 6 h reaction with Mur20; III, 
MBTH modified 6 h reaction with LipO; IV, MBTH modified α-keto-γ-methylthiol butyric acid. 
(C) Mass spectrum for the ion peak eluting at time t = 15.485 min of MBTH modified Mur20 
reaction (MBTH modified α-keto-γ-methylthiol butyric acid, expected (M+H)+ ion at m/z = 
310.06, found: 311.0). (D) Mass spectrum for the ion peak eluting at time t = 16.427 min of 







































   
Figure S3.9 LC-MS analysis of Mur20 catalyzed reactions.  
(A) Mass spectrum for the ion peak eluting at time t = 7.824 min of Mur20 reaction with 2′-
deoxy uridine aldehyde, 2b (2′, 5′-dideoxy-5′-amino uridine,4b, expected (M+H) + ion at m/z = 
228.10, found: 228.1). (B) Mass spectrum for the ion peak eluting at time t = 7.824 min of 
Mur20 reaction with 2′-deoxy uridine aldehyde, 2c produced by Mur16 with 1c (2′-methoxy-
5′-deoxy-5′-amino uridine, 4c, expected (M+H)+ ion at m/z = 258.11, found: 258.1). 
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Figure S3.10 LC-MS analysis of Mur26 catalyzed reactions. 
(A) Mass spectrum for the ion peak eluting at time t = 8.289 min of Mur26 reaction with 4a 
(4a, (M+H) + ion at m/z = 244.10, found: 243.9). (B) Mass spectrum for the ion peak eluting at 
time t = 12.971 min of Mur26 reaction with 4b (4b, (M+H) + ion at m/z = 228.1, found: 227.9). 
(C) Mass spectrum for the ion peak eluting at time t = 16.276 min of Mur26 reaction with 4a 
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Figure S3.11 LC-MS analysis of Mur26 and Mur18 catalyzed reactions with HILIC column. 
(A) Extracted ion chromatograms showing the production of 7b. I, 6 h reaction w/o enzyme; II, 
6 h reaction w/ Mur26; III, 6 h reaction w/ Mur26 and Mur18. (B) Mass spectrum for the ion 
peak eluting at time t = 19.867 min of Mur26 and Mur18 reaction with 4a (7b, (M-H)- ion at 






Figure S3.12 (+)-HR-ESI-MS (positive mode) of purified AQC modified 8b 






Figure S3.13 1H NMR spectrum (D2O, 400 MHz) of AQC modified 8b. 
 




Chapter 4 : Self-Resistance During Muraymcyin Biosynthesis: A Complementary 
Nucleotidyltransferase and Phosphotransferase with Identical Modification Sites and 
Distinct Temporal Order 
4.1 Introduction 
Muraymycins, produced as a mixture of nearly 20 congeners by Streptomyces sp. 
NRRL 30471 (also known as Streptomyces sp. LL-AA896), are peptidyl nucleoside antibiotics 
that were discovered using a screen to identify inhibitors of the lipid cycle of peptidoglycan 
cell wall biosynthesis.1-2 Detailed investigations into their mechanism of action has 
subsequently revealed muraymycins to be potent and selective inhibitors of translocase 1 
(MraY), which catalyzes the initiating step of the lipid cycle.7, 40 As a consequence of MraY 
inhibition, many muraymycin congeners are endowed with antibacterial activity. Notably, 
muraymycin A1, one of the more active of the congeners, displays a relatively broad 
antibacterial spectrum with modest activity against Gram-positive bacteria including strains of 
Staphylococcus aureus and Mycobacterium tuberculosis and Gram-negative bacteria including 
strains of Escherichia coli and Pseudomonas aeruginosa.7-8, 25  
Structurally, muraymycins belong to a larger family of peptidyl nucleoside MraY 
inhibitors that share a common core consisting of a 5′-C-glycyluridine (GlyU) that is appended 
with a 5′′-amino-5′′-deoxyribose (ADR) moiety via a standard O-glycosidic bond (ADR-GlyU 
disaccharide, Figure 4.1). FR-900493 is structurally the simplest of this family known to be 
endowed with antibacterial activity, and consists of the ADR-GlyU disaccharide core that is 6′-
N-alkylated with an aminopropyl group.57 A-90289s, caprazamycins, and liposidomycins 
91 
 
(herein collectively termed A-90289-type),58-60 sphaerimicins,61 and muraymycins also contain 
an aminopropyl group that is further modified leading to structural distinctions among these 
three (Figure 4.1). Notably, muraymycins are the sole member of this family to have a linear 
peptide attached to the aminopropyl linker, and variations within this peptide lead to the 
different series of muraymycin congeners that were initially reported.1 The D series of 
muraymycins contain L-Leu as part of the peptide, while the C series contain a β-hydroxylated 
L-Leu that can be acylated with an aliphatic, branched chain fatty acid (B series) or an acyl 
group containing a terminal-guanidium (A series). In addition to the standard 2′′-OH version of 
the ADR moiety that is exemplified in muraymycin D2, congeners have also been isolated with 
a 2′′-methoxy ADR (for example, muraymycin D1) or a 2′′-deoxy ADR (for example, 
muraymycin D3). Although they tend to be the least potent, the D series muraymycins are 
nonetheless strong inhibitors of MraY with IC50s near 10 nM depending upon the source of 
MraY.7, 14 Hydroxylation and acylation that leads to the A-C series, however, significantly 






Figure 4.1 Structure of representative peptidyl nucleoside antibiotics consisting of an ADR-
GlyU disaccharide core. 
 
Recently, a new muraymycin (C6) was isolated that was acetylated at the 5′′-amine of 
the ADR moiety, yielding a compound with modestly reduced (≥ 6-fold) IC50 against MraY 
from different strains (Chapter 2). In a separate report, a 3′′-O-phosphorylated caprazamycin 
precursor called caprazol-3′′-phosphate was unexpectedly isolated following inactivation of 
cpz23 encoding a putative SGNH hydrolase, although in this case the inhibitory or antibacterial 
activity of the phosphorylated variant was not tested.62 Covalent modification of these types 
(phosphorylation and acetylation), along with nucleotidylation, are often found as resistance 
mechanisms to antibiotics, most notably for aminoglycosides.63-66 The same types of covalent 
modifications appear to be utilized by aminoglycoside producing strains, as homologous genes 
encoding for such resistance enzymes are often clustered with the biosynthetic genes.67-69 
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However, the reported muraymycin gene cluster lacked any candidate gene encoding for an 
acetyltransferase.22 Instead, the gene cluster does encode for a pair of proteins—Mur29 and 
Mur28—that potentially catalyze the remaining two types of covalent modifications that are 
commonplaces for aminoglycoside resistance, namely nucleotidylation and phosphorylation, 
respectively. Of the known biosynthetic gene clusters for peptidyl nucleoside MraY inhibitors, 
Mur28 homologs are encoded in all of the biosynthetic gene clusters with two homologs 
encoded within the gene cluster for A-90289-type MraY inhibitors46, 51, 70-71. The only exception 
to this is the sphaerimicin gene cluster, which lacks a Mur28 homolog. Conversely, a Mur29 
homolog is only encoded within the sphaerimicin gene cluster61. 
As part of our goal to elucidate potential resistance mechanisms toward the peptidyl 
nucleoside antibiotics, we now provide in vitro data to support the functional assignment of 
Mur29 and Mur28 as a Mg·ATP-dependent nucleotidyltransferase and a Mg·ATP-dependent 
phosphotransferase, respectively, that covalently modify the same site: the 3′′-OH of the ADR 
component of muraymycins. Examination of the substrate specificity along with single-
substrate kinetic analysis using muraymycins D1-D3 and a hypothetical biosynthetic 
intermediate prepared through synthesis, however, suggests a distinct temporal order for Mur29 
and Mur28 catalysis during biosynthesis. The antimicrobial and MraY inhibitory activity using 
the adenylated or phosphorylated products compared with the respective unmodified versions 
are reported, enabling us to propose a distinct and complementary role for Mur29 and Mur28 
in the resistance and biosynthesis of muraymycin. Finally, a preliminary attempt to functionally 




4.2 Materials and Methods 
4.2.1 Chemicals, reagents, and instrumentation 
Nucleotides, buffers, salts, and media components were purchased from Sigma-Aldrich 
(St. Louis, MO) or Alfa-Aesar (Ward Hill, MA, USA). Synthetic oligonucleotides were 
purchased from Integrated DNA Technologies (Coralville, IA) and are listed in Table S4.2. 
Genomic DNA from Streptomyces sp. NRRL30473 was extracted using UltraClean Microbial 
DNA Isolation Kit (MoBio laboratories, Inc) following the manufacturer’s protocol. DNA 
quality and concentration were confirmed using Nanodrop 2000c spectrophotometer (Thermo 
Scientific) and gel electrophoresis. The tmrB gene from Bacillus subtilis (accession number 
WP_042977443) was synthesized by Genscript to give pET28-tmrB. 
Analytical HPLC was performed with Agilent 1200 series (Agilent Technologies, Santa 
Clara, CA) or Dionex Ultimate 3000 HPLC system equipped with a diode array detector and 
an analytical Apollo C18 column (250 x 4.6 mm, 5 µm) purchased from Grace (Deerfield, IL). 
Semipreparative HPLC was performed with a Waters 600 controller and pump (Milford, MA) 
equipped with a 996 diode array detector, 717 plus autosampler, and an Apollo C18 column 
(250 × 10 mm, 5 µm). LC-MS was conducted with an Agilent 6120 Quadrupole MSD mass 
spectrometer (Agilent Technologies, Santa Clara, CA) equipped with an Agilent 1200 Series 
Quaternary LC system and an Eclipse XDB-C18 column (150 × 4.6 mm, 5 µm). HR-ESI-MS 
spectra were acquired with an AB SCIEX Triple TOF 5600 System (AB Sciex, Framingham, 
MA, USA). All solvents used were minimally of ACS grade and purchased from Pharmco-
AAPER (Brookfield, CT) or Fisher Scientific (Pittsburgh, PA). NMR data were recorded at 400 
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MHz for 1H and 100 MHz for 13C with a Varian Inova NMR spectrometer (Agilent, Santa Clara, 
CA). 
4.2.2 Cloning Genes of mur28, mur29 and tmrB 
The genes encoding Mur28 and Mur29 were amplified from genomic DNA extracted 
from Streptomyces sp. NRRL 30473 by PCR using Phusion DNA polymerase. The gene 
encoding TmrB was amplified from pET28a-tmrB. The gel-purified PCR product was inserted 
into pET-30 Xa/LIC using ligation-independent cloning as described in the provided protocol 
to yield pET30-mur28 and pET30-mur29 or digested with NdeI-BamHI and ligated to the 
identical sites of pXY200 or pDB.His.MBP to yield pXY200-mur28, pDB.His.MBP-mur28, 
pDB.His.MBP-mur29 and pDB.His.MBP-tmrB. The identity of the cloned genes was 
confirmed by DNA sequencing. Plasmids pDB.His.MBP-mur28, pDB.His.MBP-mur29, 
pET28-tmrB and pDB.His.MBP-tmrB were expressed in E. coli BL21(DE3) cells and plasmid 
pXY200-mur28 was expressed in S. lividans TK24.  
Plasmids were introduced into E. coli BL21(DE3) cells, and the transformed strains 
were grown in LB supplemented with 50 μg/mL kanamycin. Following inoculation of 500 mL 
of LB with 50 μg/mL kanamycin, the cultures were grown at 37 °C until the cell density reached 
an OD600 ~ 0.5 when expression was induced with 0.1 mM IPTG. Cells were harvested after an 
overnight incubation at 18 °C and lysed in Buffer A (100 mM KH2PO4, 300 mM NaCl, 10 mM 
imidazole, pH 8.3) using a Qsonica sonicator (Qsonica LLC, Newtown, CT) for sonication for 
a total of 6 min at 40% amplitude with 30 s pulses separated by 30 s rest periods. Following 
centrifugation the protein was purified using affinity chromatography with HisPurTM Ni-NTA 
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agarose (Thermo Scientific, Rockford, IL), and proteins were eluted with increasing 
concentrations of imidazole in Buffer A. Purified proteins were concentrated and buffer 
exchanged into Buffer B (25 mM KH2PO4, 100 mM NaCl, pH 8.3) using Amicon Ultra 10000 
MWCO centrifugal filter (Millipore) and stored as glycerol stocks (40%) at -20 °C. Protein 
purity was assessed by 12% acrylamide SDS-PAGE; His6-tagged proteins were utilized without 
further modifications. Protein concentration was determined using UV/Vis spectroscopy, and 
the extension coefficients were calculated using the ProtParam tool available from ExPASY. 
Plasmids were transformed into Streptomyces lividans TK-24 using PEG-mediated 
protoplast transformation and plated on R2YE supplemented with 50 μg/mL apramycin. After 
6 days at 28 °C, positive transformants were confirmed by colony PCR using InstaGene Matrix 
from Bio-Rad (Hercules, CA) and LA-Taq polymerase with GC buffer I. The recombinant 
strain was utilized to inoculate 50 mL R2YE containing 50 μg/mL apramycin, grown for 3 days 
at 28 °C at 250 rpm, and 2 mL transferred to fresh 100 mL containing 50 μg/mL apramycin. 
Following growth for 3 days at 28 °C at 250 rpm, protein expression was induced by addition 
of thiostrepton (5 μg/mL) and the culture was incubated for another 24 h before harvesting. The 
cells from 400 mL of culture were collected by centrifugation. The pellet was thoroughly 
resuspended in ice-cold Buffer A supplemented with 4 mg/mL of lysozyme. After incubation at 
30 °C for 30 min, the cell suspension was mixed by pipetting and lysed using a Qsonica 
sonicator (Qsonica LLC, Newtown, CT) for sonication for a total of 10 min at 40% amplitude 
with 30 s pulses separated by 30 s rest periods. Protein purification and storage was described 




4.2.3 Production of muraymycin D congeners 
Streptomyces sp. NRRL 30475 was cultivated in 250 mL Erlenmeyer flasks containing 
50 mL TSBG [Tryptic soy broth (Difco) supplemented with 20 g/L glucose] at 30 °C on a rotary 
shaker (250 rpm) for 72 h. The seed culture was used to inoculate flasks (250 mL) containing 
50 mL PM-1 medium. PM-1 was composed of glucose 2%, soluble starch 1%, pressed yeast 
0.9%, peptone (Bacto) 0.5%, meat extract (Fluka) 0.5%, NaCl 0.5%, CaCO3 0.3% and CB-442 
(NOF Co., Ltd.) 0.01% (pH 7.4, before sterilization). The fermentation was continued for 7 
days at 23 °C on a rotary shaker (210 rpm). 
All culture flasks were combined and centrifuged at 5000 rpm for 15 min to separate 
the mycelium and water phase. The mycelial-cake portion was extracted with methanol by 
sonication, and the organic phase was evaporated to obtain brown crude extract. Amberlite 
XAD-16 (4%) resin was added to the water phase and stirred for 12 h. The resin was washed 
with water until the effluent became colorless, and then eluted with methanol. The methanol 
extract was concentrated under reduced pressure to obtain a crude extract. Components of the 
mycelium crude extract and water phase crude extract were subjected to Sephadex LH-20 (25-
100 μm, GE Healthcare) column, and methanol was used to elute compounds at a flow rate at 
2 mL/min. The major fraction was further purified by using semipreparative HPLC. A series of 
linear gradients was developed from 0.025% trifluoroacetic acid in water (A) to 0.025% 
trifluoroacetic acid in acetonitrile (B) in the following manner: 0 min, 10% B; 0-25 min, 22% 
B; 25-26 min, 100% B; 26-31 min, 100% B; 31-32 min, 10% B; and 31-32 min, 10% B 
(beginning time and ending time with linear increase to % B). The flow rate was kept constant 
at 3.5 mL/min. 
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4.2.4 Enzyme reactions 
Reactions consisted of 50 mM Tris (pH 7.5), 10 mM MgCl2, 1 mM NTP (ATP, dATP, 
dTTP, GTP, CTP or UTP) or dATP, 1 mM muraymycin D1, D2, D3 or 0.5 mM ADR-GlyU 
disaccharide and 1 μM Mur29, Mur28, or TmrB at 30 °C. The reaction was terminated by 
adding twice volume of methanol followed by centrifugation (14000 rpm, 30 min) to remove 
the precipitated protein. Following centrifugation to remove protein, the reaction was analyzed 
by HPLC or LC-MS using one of four gradient programs provided in the Supporting 
Information. 
4.2.5 Single-substrate kinetics 
For Mur29 assays consisted of 50 mM Tris (pH 7.5), 10 mM MgCl2, near saturating 
ATP (1 mM) with variable muraymycin D1 (1 μM–1000 μM), muraymycin D2 (1 μM–1000 
μM) or muraymycin D3 (5 μM–500 μM). Reactions were performed at 30 °C with 200 nM 
Mur29 for 4 h with muraymycin D1, D2 or D3. For Mur28 assays consisted of 50 mM Tris (pH 
7.5), 10 mM MgCl2, near saturating ATP (1 mM) with variable muraymycin D2 (1 μM–1000 
μM), muraymycin D3 (5 μM–500 μM) or disaccharide (5 μM–500μM). Reactions were 
performed at 30 °C with 200 nM Mur28 for 4 h with muraymycin D2 or D3 and for 15 min 
with disaccharide. Product formation was determined using HPLC with GP2. All reactions were 
analyzed under near initial velocity conditions (≤ 10% product). Each data point represents a 
minimum of three replicate end point assays; kinetic constants were obtained by nonlinear 
regression analysis using GraphPad Prism (GraphPad Software, La Jolla, CA) by fitting the 











4.2.6 Antimicrobial Bioactivity  
The protocol used for the determination of the minimum inhibitory concentration (MIC) 
was as described previously with minor modifications29. The bacterial strains Mycobacterium 
smegmatis ATCC 14468, E. coli DH5α/ΔtolC, and E. coli BL21(DE3) introduced with plasmids 
pET30-mur28, pET30-mur29, pET28a-tmrB, or pET30-mur20 were used as model strains for 
antimicrobial susceptibility assays. All strains were grown in appropriate liquid or on agar 
plates using Middlebrook 7H9 with ADC enrichment for M. smegmatis or LB medium 
supplemented with 50 μg/mL kanamycin for E. coli. Individual strains were grown in 5 mL of 
medium for 16 h at 37 °C with shaking (250 rpm), and then were diluted ×1000 into 4.5 mL of 
medium and incubated until OD600 reaching 0.4. An aliquot of the suspensions was diluted 
×1000. Aliquots (90 μL) of each diluted culture and transferred into the individual well of a 96-
well plate supplied with 10 μL of the tested compound. Maximum final concentration of 256 
μg/mL with serial dilutions was maintained to obtain the antimicrobial activities and compared 
to the negative control (water). The culture plates were incubated at 37 °C for 16 h with shaking 
(160 rpm) for E. coli and without shaking for M. smegmatis. The OD600 of each well measured 
using BioTek™ Synergy™ 2 Multi-Mode Microplate Readers. The acquired OD600 values were 
normalized to the negative control wells (100% viability). Resazurin solution (5 μL) was also 
added to each well, and the plates were shaken for 10 s and incubated at 37 °C for another 3 h. 
The minimal concentration of the tested compound that caused growth inhibition was recorded 
as the MIC. 
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4.2.7 MraY Inhibition 
Inhibition against SaMraY was performed as previously reported (S. Koppermann, Z. 





4.3 Results  
4.3.1 Functional insight through bioinformatic analysis 
Mur29 consists of two conserved domains: an N-terminal nucleotidyltransferase 
domain of DNA polymerase subunit beta and C-terminal DUF4111 superfamily/PRK13746 
domain. PRK13746 domain-containing proteins are provisionally annotated as aminoglycoside 
resistance proteins. Secondary structure-based prediction using HHPred suggested structural 
similarity to Salmonella enteric aminoglycoside O-adenylyltransferase (annotated as AadA; 
PDB 4CS6), which catalyzes a Mg·ATP-dependent adenylation of spectinomycin and 
streptomycin72, and Staphylococcus aureus kanamycin nucleotidyltransferase (annotated as 
ANT(4′); PDB 1KNY), which adenylates several distinct aminoglycosides at the 4′- or 4′′-
hydroxyl substituent depending upon the identity of the aminoglycoside73. Pairwise alignment, 
however, revealed only 17% sequence identity to these proteins. Sequence alignment of Mur29 
and the homologous gene product SphT encoded in the sphaerimicin gene cluster revealed a 
48% sequence identity.  
Bioinformatic analysis suggests Mur28 likely belongs to the conserved domain of P-
loop-containing nucleoside triphosphate hydrolases that include several types of 
nucleoside/nucleotide kinases. Proteins with the highest sequence identity (~47%)—notably 
present in both Gram-positive and Gram-negative bacteria—are annotated as tunicamycin 
resistance proteins, TmrB. Pairwise alignment of Mur28 with Bacillus subtilis TmrB 
(BsTmrB)74-76, which consists of the same conserved domain and confers resistance to 
tunicamycin upon heterologous expression of the gene, had a lower sequence identity, yet was 
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nonetheless significant at 34% (Table S4.1). Sets of homologous genes encoding proteins with 
similarity to Mur28 are located in each of the A-90289-type gene clusters, represented by LipX 
(36% sequence identity) and LipI (23% sequence identity) for A-90289 (Table S4.1). 
4.3.2 In vitro functional assignment and characterization of recombinant Mur29 
The three known congeners of the muraymycin D series, which differ only at the 2′′ 
substituent of the ADR-GlyU disaccharide core (Figure 4.1), were isolated from Streptomyces 
sp. NRRL 30475, a previously reported mutant strain of Streptomyces sp. NRRL 304712. MS 
and NMR spectroscopic data were consistent with their identities as muraymycin D1 (Figures 
S4.2-S4.7), muraymycin D2 (Figures S4.8-S4.12), and muraymycin D3 (Figures S4.13 and 
S4.14). The ADR-GlyU disaccharide, the likely biosynthetic precursor of muraymycin D1 and 
D2 as well as the other members of the peptidyl nucleoside MraY inhibitors (Figure 4.1), was 
prepared using the synthetic methodology developed by Ichikawa with slight modifications16. 
MS and NMR spectroscopic data were comparable to the prior report and likewise consistent 
with the identity of the disaccharide (Figures S4.15-S4.19). 
Mur29 was produced in E. coli BL21(DE3) as a maltose-binding protein (MBP)-fusion 
to obtain soluble protein for in vitro assays. Using HPLC analysis to monitor the reaction, 
incubation of recombinant Mur29 with muraymycin D1 and ATP revealed a new peak eluting 
with a later retention time relative to muraymycin D1 (Figure 4.2A). HR-MS analysis of the 
purified product revealed an (M + H)+ ion at m/z = 1259.5045, consistent with the molecular 
formula of C48H75N16O22P, corresponding to a monoadenylated muraymycin D1 (expected m/z 
= 1259.5052) (Figure S4.20). 1H NMR spectroscopic data (Figures S4.21 and S4.22) were 
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likewise consistent with adenylation of muraymycin D1 (Figure 4.2B), and comparison of the 
substrate and product spectra revealed a clear downfield shift of the 3′′ proton (Figure 4.2C). 
Thus, the results are consistent with Mur29 catalyzing a regioselective adenylation to yield the 
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Figure 4.2 Functional assignment of Mur29 
(A) HPLC analysis after (i) 12 h incubation without Mur29 and (ii) 12 h reaction. Data were 
collected using gradient program 1 (GP1) described in the Supplemental Material. (▼) denotes 
peak corresponding to D1-AMP; A260, absorbance units at 260 nm. (B) Structure of 3′′-
monoadenylated muramycin D1. (C) Comparison of the 1H-NMR spectrum for muraymycin 





To provide insight into the specificity and timing of adenylation during muraymycin 
biosynthesis, the activity of Mur29 was tested with the remaining two D series congeners and 
ADR-GlyU disaccharide. In contrast to the disaccharide, which was not a substrate for Mur29, 
both muraymycin D2 and muraymycin D3 yielded products with an (M + H)+ ion at m/z = 
1246.2 and 1229.2, respectively, consistent with monoadenylated products (expected m/z = 
1245.5 for D2-AMP and 1229.5 for D3-AMP) (Figures S4.23 and S4.24). The lack of activity 
with ADR-GlyU disaccharide is consistent with the Mur29 reaction occurring after the addition 
of the aminopropyl linker. Single-substrate kinetic analysis with variable muraymycins D1, D2, 
and D3 revealed non-Michaelis Menten kinetics with modest substrate-inhibition for all three 
substrates (Figures 4.3A-C). Comparison of the second order rate constants from the extracted 
kinetic parameters did not reveal a clear substrate preference (Table 4.1). 
Specificity toward the nucleoside triphosphate co-substrate was also examined using 
muraymycin D1 as an acceptor. HPLC and LC-MS analysis revealed that the other canonical 
ribonucleotide triphosphates could substitute for ATP to generate the corresponding 
mononucleotide muraymycin D1 (Figures S4.25-S4.27). 2′-deoxy-ATP and 2′-deoxy-TTP were 
also used by Mur29 as nucleotidyl donors (Figures S4.28 and S4.29). The highest specific 
activity, however, was realized with ATP (Figure 4.3D). Finally, the addition of magnesium to 
the reaction was essential for activity. The addition of 20 mM EDTA abolished the reaction. 





































































































Figure 4.3 Biochemical characterization of Mur29. 
Single-substrate kinetic analysis using near saturating ATP and variable (A) muraymycin D1, 
(B) muraymycin D2, and (C) muraymycin D3. (D) Relative activity of Mur29 with muraymycin 
D1 and different nucleotide donors. 
4.3.3 In vitro functional assignment and characterization of Mur28  
His6-Mur28 was initially produced in Streptomyces lividans TK24 to obtain soluble 
protein for in vitro assays. In contrast to Mur29, incubation of recombinant Mur28 with 
muraymycin D1 and ATP did not reveal any new peaks. However, HPLC analysis of an 
overnight reaction of Mur28 with ATP and muraymycin D2, which is the likely direct 
biosynthetic precursor of muraymycin D1, revealed the appearance of a new peak eluting after 
muraymycin D2 (Figure 4.4A). The new peak was collected by semipreparative HPLC, and 
HR-MS analysis of the purified product revealed an (M + H)+ ion at m/z = 996.4050, consistent 
with the molecular formula of C37H62N11O19P, corresponding to a monophosphorylated 
muraymycin D2 (expected m/z = 996.4034) (Figure S4.30). 1H NMR spectroscopic data 
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(Figures S4.31 and S4.32) were likewise consistent with phosphorylation of muraymycin D2 
(Figure 4.4B), and similarly to the Mur29-catalyzed adenylation of muraymycin D1, 
comparison of the substrate and product spectra revealed a clear downfield shift of the 3′′ proton 
(Figure 4.4C). To provide further evidence for a classical kinase activity, the Mur28-catalyzed 
reaction was performed with [γ-P18O4]ATP. LC-MS analysis of the monophosphorylated 
product revealed a shift of + 6.0 amu, consistent with the incorporation of the γ-phosphate of 
ATP into muraymycin D2 (Figure S4.33). Finally, Mur28 was produced as a MBP-fusion 
protein from E. coli BL21(DE3), and comparable results were obtained. Thus, the data are 
consistent with Mur28 catalyzing a regioselective phosphorylation to yield the product, 3′′-
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Figure 4.4 Functional assignment of Mur28. 
(A) HPLC analysis after (i) 12 h incubation without Mur28 and (ii) 12 h reaction. Data were 
collected using GP1. (▼) denotes peak corresponding to D2-PHOS; (*) denotes unidentified 
peak; A260, absorbance units at 260 nm. (B) Structure of 3′′-phospho-muramycin D2. (C) 




The specificity and timing of phosphorylation during muraymycin biosynthesis was 
subsequently investigated. LC-MS analysis of Mur28 reactions with hypothetical substrates 
muraymycin D3 or the ADR-GlyU disaccharide yielded new peaks with (M + H)+ ions at m/z 
= 980.1 and 527.0, respectively, consistent with the formation of a monophosphorylated product 
(expected m/z = 980.4 for D3-PHOS and 527.1 for ADR-GlyU-PHOS) (Figures S4.34 and 
S4.35). Single-substrate kinetic analysis with variable muraymycin D2 and D3 revealed non-
Michaelis-Menten kinetics with modest substrate-inhibition, while analysis with the ADR-
GlyU disaccharide revealed typical Michaelis-Menten kinetics (Figures 4.5A-C). Second order 
rate constants from the extracted kinetic parameters revealed >60-fold higher catalytic 
efficiency with ADR-GlyU relative to muraymycin D2, consistent with phosphorylation 
occurring prior to the attachment of the aminopropyl-linked peptide.  
LC-MS analysis of reactions using muraymycin D2 as the acceptor revealed Mur28 
uses alternative phosphate donors, results that were similar to Mur29 (Figure S4.36). The 
highest activity was achieved with ATP, although good conversion was realized with dATP, 
dTTP, and the remaining ribonucleoside triphosphates (Figure 4.5D). Unexpectedly, ADP was 
also utilized as a co-substrate, although D2-PHOS was only detected in trace amounts 
suggesting that this activity is insignificant in vivo. Finally, similar to Mur29, the inclusion of 
magnesium was essential for activity. In total the data are consistent with the functional 
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Figure 4.5 Biochemical characterization of Mur28. 
Single-substrate kinetic analysis using near saturating ATP and variable (A) muraymycin D2, 
(B) muraymycin D3, and (C) ADR-GlyU. (D) Relative activity of Mur28 with muraymycin 




Table 4.1 Kinetic parameters for Mur29 and Mur28 
 




Mur29 Muraymycin D1 14 ± 2  (4.6 ± 1.4) x 103 1.4 ± 0.1 1.7 x 103 100 
Muraymycin D2 41 ± 8 (4.9 ± 1.1) x 102 4.0 ± 0.4 1.6 x 103 94 
Muraymycin D3 39 ± 10 (2.6 ± 0.8) x 102 2.4 ± 0.4 1.0 x 103 59 
ADR-GlyU NA NA NA NA NA 
Mur28 Muraymycin D1 NA  NA NA NA NA 
 Muraymycin D2 (1.7 ± 0.4) x 102 (5.6 ± 1.0) x 102 5.2 ± 0.7 5.1 x 102 1.5 
 Muraymycin D3 ND ND ND ND ND 
 ADR-GlyU 38 ± 4  NA 75 ± 2 3.3 x 104 100 




4.3.4 Insight into the Function of Mur28-homologs BsTmrB  
BsTmrB, which has never been functionally assigned in vitro except for its ability to 
bind ATP74, 76 and tunicamycin75, was initially targeted to serve as a control due to its modest 
sequence similarity to Mur28. Soluble His6-TmrB and MBP-TmrB fusion protein were 
obtained using E. coli BL21(DE3) as an expression host. Using HPLC to monitor the reaction, 
recombinant TmrB did not have any phosphotransferase activity when incubated with ATP and 
commercial tunicamycin. Unexpectedly, however, LC-MS analysis revealed TmrB was able to 
phosphorylate muraymycin D2 and ADR-GlyU using ATP as the phosphate donor (Figure 
S4.37). The conversion of both was comparable to the Mur28-catalyzed reaction. Likewise, a 
trace amount of D2-PHOS was detected with ADP as the phosphate donor. In contrast to Mur28, 
however, no other nucleotide triphosphates were substrates for BsTmrB. 
4.3.5 Potential role of Mur29 and Mur28 in self-resistance 
The possibility that Mur29 and/or Mur28 play a role in self-resistance to muraymycins 
was explored using three approaches. We first examined the antibacterial activity of 
muraymycin D1 and D2 against E. coli BL21(DE3) harboring the mur29, mur28, or tmrB 
expression plasmids (Table 4.2). E. coli BL21(DE3) harboring an expression plasmid for mur20, 
encoding a putative aminotransferase likely involved in ADR biosynthesis, was used as control. 
Both muraymycin D1 and D2 have low antibacterial activity against plasmid-free E. coli 
BL21(DE3) or strains expressing mur20, with MICs determined in the range of 16-32 μg/mL.  
A similar MIC for muraymycin D1 (32 μg/mL) was obtained against E. coli BL21(DE3) 
expressing mur28 or tmrB. However, E. coli BL21(DE3) expressing mur29 was resistant to 
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muraymycin D1 (MIC > 256 μg/mL). E. coli BL21(DE3) cells expressing mur29, mur28, or 
tmrB were likewise all resistant to muraymycin D2 (MIC > 256 μg/mL). These results were 
consistent with the substrate selectivity of each enzyme that was revealed through in vitro 
assays.  
The purified Mur29 and Mur28 products (D1-AMP and D2-PHOS) were next screened 
against Mycobacterium smegmatis and E. coli DH5α/tolC (Table 2). Both strains are more 
sensitive compared to E. coli BL21(DE3) with MIC = 4 μg/mL (muraymycin D1 or D2) and 1 
μg/mL (muraymycin D1 or D2), respectively. In contrast to the unmodified muraymycins, D1-
AMP and D2-PHOS were inactive against M. smegmatis (MIC > 256 μg/mL) while both had 
reduced activity against E. coli DH5α/tolC (MIC = 16 μg/mL).  The results are consistent 
with the conferred resistance upon heterologous expression of mur29 and mur28 in E. coli 
BL21(DE3). 
The third and final approach to examine a potential role in self-resistance was to screen 
D1-AMP and D2-PHOS for inhibitory activity against recombinant Staphylococcus aureus 
MraY (SaMraY) in vitro. In contrast to muraymycin D1 and D2, which were determined to be 
sub-nanomolar inhibitors of SaMraY with IC50 = 0.48 ± 0.13 and 0.39 ± 0.11 nM, respectively, 
D1-AMP and D2-PHOS were significantly less potent with IC50 = 82 ± 32 nM and 20 ± 5 nM, 
respectively. Therefore, the direct inhibition of the translocase I target is positively correlated 


























































D1 0.48±0.13 4 
 
1 32 32 >256 32 32 
muraymycin 
D2 0.39±0.11 4 
 
1 32 >256 >256 >256 16 
muraymycin 
D1-AMP 82±32 >256 
 
16 >256 na na na na 
muraymycin 
D2-Phos 20±5 >256 
 
16 >256 na na na na 
 
4.4 Discussion 
4.4.1 Why We Choose Muraymycin D Series to Test the Activity 
We have provided evidence to support the functional assignment of two enzymes that 
covalently modify known muraymycins or a hypothetical biosynthetic precursor. Twenty-two 
muraymycin congeners, categorized structurally into four series (A-D), were initially 
discovered using an enzyme activity-based screen to identify inhibitors of MraY and/or MurG, 
which catalyze sequential reactions to generate Lipid II intermediate in peptidoglycan cell wall 
biosynthesis. The D series of congeners were targeted here as representative muraymycins in 
part due to (i) the relatively decent titres in our hands, (ii) they are structurally the simplest of 
the independent series, and (iii) this was the only series within which we could isolate the three 
congeners with variations in the ADR (namely, D1, D2, and D3). Unfortunately, this series also 
represents the weakest inhibitors of the four, but nevertheless remain potent inhibitors of the 
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MraY-catalyzed reaction8, 77 and are modestly active against a few bacterial pathogens. In our 
in vitro screen, muraymycin D1 and D2 were very potent inhibitors of recombinant 
Staphylococcus aureus MraY with IC50 of 0.48 and 0.39 nM, respectively. The details of this 
assay and the variability with respect to the literature is reported elsewhere. Given the moderate 
sequence identity (~ 40%) and conservation of key motifs of SaMraY and MraY from different 
Streptomyces including the muraymycin D2 binding site, we predict that the producing strain’s 
MraY is equally inhibited.  
4.4.2 Distinct Temporal Order for Mur29 and Mur28 Catalysis 
The ADR-GlyU disaccharide core of muraymycin is technically an aminoglycoside, 
and thus it seemed plausible that our results are consistent with the functional assignment of 
Mur29 as an ATP-dependent muraymycin adenylyltransferase and Mur28 as an ATP-dependent 
ADR-GlyU phosphotransferase. NMR spectroscopic analyses of each enzyme-catalyzed 
product revealed a downfield shift with respect to the C-3″ proton, the magnitude of which is 
consistent with other enzymes that adenylate or phosphorylate sugars such as the numerous 
aminoglycoside resistance enzymes.78 Interestingly both Mur29 and Mur28 covalently modify 
the ADR with the identical regioselectivity, yet Mur29 did not have any activity with ADR-
GlyU while Mur28 kinetically preferred this muraymycin precursor. The realization of the 
substrate preferences suggests that ADR is phosphorylated at an earlier stage in the biosynthetic 
pathway, and is potentially utilized as a transient resistance mechanism. The biochemical 
data—along with consideration of MraY inhibition—lead us to conclude that ADR-GlyU is the 
authentic in vivo substrate of Mur28, as the kinetic parameters are in line with other 
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phosphotransferases and the attachment of the aminopropyl group leads to the first active 
antibiotic scaffold, FR-900493. Thus, we propose that transient phosphorylation occurs inside 
the cell and protects the producing strain from MraY self-inhibition during antibiotic maturation. 
Following phosphorylation, muraymycin biosynthesis is completed by downstream, as-of-yet 
uncharacterized enzymes, transported outside the cell, and dephosphorylated by an unknown 
enzyme. In contrast to Mur28, the biochemical data support that Mur29 functions later in the 
biosynthetic pathway. Therefore, as opposed to a preventive resistance mechanism that is 
proposed via Mur28-catalyzed phosphorylation, we hypothesize that Mur29-catalyzed 
adenylation provides a protective resistance mechanism in the case of intracellular 
accumulation of muraymycin.  
4.4.3 Predicted Phosphorylation Position of Tunicamycin by TmrB 
Noda et al79 discovered that BsTmrB, responsible for tunicamycin resistance of B. 
subtillis, confers resisitance to tunicamycin on E. coli. The same team also showed that TmrB 
is an ATP-binding membrane protein74, and suggested that it could act to lower the intracellular 
concentration of tunicamycin. Kapp reported the crtystal structure of TmrD (a homolog of 
TmrB) and suggested that either of the three hydroxyls in ribose moiety of tunicamycin could 
be the target by structural alignment and modelling with chloramphenicol phosphotransferase.76 
In our experiment, although TmrB did not show any phosphotransferase activity with a 
commercial mix of tunicamycin congeners, TmrB was able to phosphorylate muraymycin D2 
and ADR-GlyU using ATP as the phosphate donor. Recently, MraY tunicamycin complex 
structure was reported. 80 Based on the comparison of tunicamycin and muraymycin D2 binding 
117 
 
with MraY, ADR-Gly moiety of muraymycin showed similar binding pattern of uridyl moiety 
of tunicamycin to MraY. The 5′ hydroxyl group of tunicamycin located in the similar position 
of aminoribose moiety of muraymycin D2, which lead us to propose that TmrB might transfer 
phosphate from ATP to 5′ hydroxyl group in the ongoing studies. 
4.5 Conclusion 
In conclusion, we have provided evidence to support the functional assignment of 
Mur29 as a Mg·ATP-dependent 3′′-O-muraymycin adenylyltransferase and Mur28 as a 
Mg·ATP-dependent ADR-GlyU 3′′-phosphotransferase. The biochemical data—along with 
consideration of MraY inhibition—lead us to conclude that ADR-GlyU is the authentic in vivo 
substrate of Mur28, as the kinetic parameters are in line with other phosphotransferases and the 
attachment of the aminopropyl group leads to the first active antibiotic scaffold, FR-900493. 
Thus, we propose that transient phosphorylation occurs inside the cell and protects the 
producing strain from MraY self-inhibition during antibiotic maturation. Following 
phosphorylation, muraymycin biosynthesis is completed by downstream, as-of-yet 
uncharacterized enzymes, transported outside the cell, and dephosphorylated by an unknown 
enzyme. In contrast to Mur28, the biochemical data support that Mur29 functions later in the 
biosynthetic pathway. Therefore, as opposed to a preventive resistance mechanism that is 
proposed via Mur28-catalyzed phosphorylation, we hypothesize that Mur29-catalyzed 
adenylation provides a protective resistance mechanism in the case of intracellular 




4.6 Supporting Information 
Table S 4.1 Sequence identity for pairwise sequence alignment with Mur28. 
 
Proteina,b Identity (%) Protein Identity (%) 
BsTmrB 34   
LipX 36 LipI 23 
Cpz27 38 Cpz12 26 
LpmY 38 LpmJ 23 
Mra06 38 Mra16 22 
aAccession numbers for proteins are as follows: BsTmrB, WP_042977443; LipX, BAJ05900; LipI, 
BAJ05885; Cpz27, ACQ63635; Cpz12, ACQ63620; LpmY, ADC96673; LpmJ, ADC96658; Mra06, 
BAM98967; Mra16, BAM98977 
bProtein annotations are Lip, A-90289 from Streptomyces sp. SANK 60405; Cpz, caprazamycin 
from Streptomyces sp. MK730-62F2; Lpm, liposidomycin from Streptomyces sp. SN-1061M; and 





Table S 4.2 Primers used in this study. 
3 
Primer Sequence Note 











































































Table S4.3 Gradient used for muraymycins separation.  
Semipreparative HPLC separation of muraymycin D1, muraymycin D2, muraymycin D3, 
muraymycin D1-AMP and muraymycin D2-Phosphate with an analytical Apollo C18 column 
(250 × 10 mm, 5 µm). 
Solvent A= ddH2O with 0.025% trifluroacetic acid; Solvent B= acetonitrile; A260 
 
Time (min) % Solvent B Flow Rate (mL/min) 
0 10 3.5 
25 22 3.5 
26 100 3.5 
31 100 3.5 
32 10 3.5 
36 10 3.5 
 
Table S4.4 Gradient program 1 (GP1) used for HPLC or LC-MS analysis of reactions with an 
analytical Apollo C18 column (250 mm x 4.6 mm, 5 µm).  
Solvent A= ddH2O with 0.1% formic acid; Solvent B= acetonitrile with 0.1% formic acid; A260 
 
Time (min) % Solvent B Flow Rate (mL/min) 
0 1 0.5 
16 20 0.5 
28 100 0.5 
37 100 0.5 
38 1 0.5 
41 1 0.5 
 
Table S4.5 Gradient program 2 (GP2) used for LC-MS analysis of AQC modified reactions 
with an analytical Apollo C18 column (250 mm x 4.6 mm, 5 µm). 
Solvent A= ddH2O with 0.1% formic acid; Solvent B= acetonitrile with 0.1% formic acid; A260 
 
Time (min) % Solvent B Flow Rate (mL/min) 
0 10 0.4 
25 60 0.4 
26 100 0.4 
36 100 0.4 
37 10 0.4 





Table S4.6 Gradient program 3 (GP3) used for HPLC analysis of reactions with an analytical 
Apollo C18 column (250 mm x 4.6 mm, 5 µm). 
Solvent A = 40 mM acetic acid-triethylamine pH 6.5; Solvent B = 40 mM acetic acid-
triethylamine, 20% methanol, pH 6.5; A260 
 
Time (min) % Solvent B Flow Rate (mL/min) 
0 0 1.0 
8 100 1.0 
18 60 1.0 
19 60 1.0 
20 0 1.0 
22 0 1.0 
 
Table S4.7 Gradient program 4 (GP4) used for HPLC analysis of reactions with an analytical 
Apollo C18 column (250 mm x 4.6 mm, 5 µm). 
Solvent A = 40 mM acetic acid-triethylamine pH 6.5; Solvent B = 40 mM acetic acid-
triethylamine, 20% methanol, pH 6.5; A260 
 
Time (min) % Solvent B Flow Rate (mL/min) 
0 1 0.5 
16 100 0.5 
20 100 0.5 
21 1 0.5 




Figure S4.1 SDS-PAGE analysis of purified Mur28, Mur29, TmrB, LipI and LipX. 
A, His6-Mur28; B, His6-MBP-Mur28; C, His6-MBP-Mur29; D, His6-TmrB; E, His6-MBP-
TmrB; F, His6-LipI; G, His6-MBP-LipX   
 
         
 
Protein Size (aa) Size (kD) 
Mur28 184 20.8 
Mur29 277 30.5 
TmrB 197 22.7 
LipI 189 21.2 
LipX 188 21.3 





















Figure S4.2 (+)-HR-ESI-MS (positive mode) of muraymycin D1  
(calcd for C38H63N11O16 expected (M+H)+ ion at m/z = 930.4527, found 930.4575). 
 
 





Figure S4.4 13C NMR spectrum (D2O, 100 MHz) of muraymycin D1. 
 
 




Figure S4.6 1H−1H COSY spectrum (D2O, 400 MHz) of muraymycin D1. 
 
 





Figure S4.8 (+)-HR-ESI-MS (positive mode) of muraymycin D2  

















Figure S4.12 1H-1H COSY spectrum (D2O, 400 MHz) of muraymycin D2. 
 
Figure S4.13 (+)-HR-ESI-MS (positive mode) of muraymycin D3. (calcd for C37H61N11O15, 
expected (M+H)+ ion at m/z = 900.4421, found 900.4307; expected (M+2H)2+ ion at m/z = 




Figure S4.14 1H NMR spectrum (D2O, 400 MHz) of muraymycin D3. 
 
Figure S4.15 (+)-HR-ESI-MS (positive mode) of compound ADR-GlyU  





Figure S4.16 1H NMR spectrum (D2O, 100 MHz) of compound ADR-GlyU. 
 
 





Figure S4.18 HSQC spectrum (D2O, 400 MHz) of compound ADR-GlyU. 
 





Figure S 4.20 (+)-HR-ESI-MS (positive mode) of compound D1-AMP. 
 (calcd for C48H75N16O22P, expected (M+H)+ ion at m/z =1259.5052, found: 1259.5045). 
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Figure S4.23 Reaction catalyzed by Mur29 with muraymycin D2 and ATP.  
(A) LC-MS analysis after (i) 12 h incubation without Mur29 and (ii) 12 h reaction. Data were 
collected using GP1. (▼) denotes peak corresponding to D2-AMP; (*) denotes unidentified 
peak; A260, absorbance units at 260 nm. (B) Mass spectrum for the peak eluting at t = 26.0 min 
(D2-AMP, C47H73N16O22P, expected (M+H)
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Figure S4.24 Reaction catalyzed by Mur29 with muraymycin D3 and ATP. 
(A) LC-MS analysis after (i) 12 h incubation without Mur29 and (ii) 12 h reaction. Data were 
collected using GP1. (▼) denotes peak corresponding to D3-AMP; A260, absorbance units at 
260 nm.  (B) Mass spectrum for the peak eluting at t = 25.9 min (D3-AMP, C47H73N16O21P, 
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Figure S4.25 Reaction catalyzed by Mur29 with muraymycin D1 and GTP. 
A, LC-MS analysis using muraymycin D1 and GTP after (I) 12 h reaction without Mur29, (II) 
12 h reaction. B, mass spectrum for the ion peak eluting at time t = 26.926 min of Mur29 
reaction with muraymycin D1. (D1-GMP, C48H75N16O23P, , expected (M+2H)2+ ion at m/z 
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Figure S4.26 Reaction catalyzed by Mur29 with muraymycin D1 and CTP.  
A, LC-MS analysis using muraymycin D1 and CTP after (I) 12 h reaction without Mur29, (II) 
12 h reaction. B, mass spectrum for the ion peak eluting at time t = 15.363 min of Mur29 
reaction with muraymycin D1. (D1-CMP, C47H75N14O23P, expected (M+2H)2+ ion at m/z = 
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Figure S4.27 Reaction catalyzed by Mur29 with muraymycin D1 and dATP.  
A, LC-MS analysis using muraymycin D1 and dATP after (I) 12 h reaction without Mur29, (II) 
12 h reaction. B, mass spectrum for the ion peak eluting at time t = 26.633 min of Mur29 
reaction with muraymycin D1. (D1-dAMP, C48H75N16O21P, expected (M+2H)2+ ion at m/z = 






2 4 6 8 1 0 1 2 1 4 1 6 1 8 2 0 2 2 2 4











Figure S4.28 Reaction catalyzed by Mur29 with muraymycin D1 and dTTP. 
A, LC-MS analysis using muraymycin D1 and dTTP after (I) 12 h reaction without Mur29, (II) 
12 h reaction. B, mass spectrum for the ion peak eluting at time t = 17.347 min of Mur29 
reaction with muraymycin D1. (D1-dTMP, C48H76N13O23P, expected (M+H)+ ion at m/z = 
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Figure S4.29 Reaction catalyzed by Mur29 with muraymycin D1 and UTP. 
A, LC-MS analysis using muraymycin D1 and UTP after (I) 12 h reaction without Mur29, (II) 
12 h reaction. B, mass spectrum for the ion peak eluting at time t = 26.986 min of Mur29 
reaction with muraymycin D1. (D1-UMP, C47H74N13O24P, expected (M+H)+ ion at m/z = 






Figure S 4.30 (+)-HR-ESI-MS (positive mode) of compound D2-PHOS 













Figure S4.33 Reaction catalyzed by Mur28 with D2 and [γ-P18O4]ATP. 
A, mass spectrum for the ion peak eluting at time t = 27.167 min of Mur28 reaction with 
muraymycin D2 and ATP. B, mass spectrum for the ion peak eluting at time t = 27.116 min of 
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Figure S4.34 Reaction catalyzed by Mur28 with muraymycin D3 and ATP. 
(A) LC-MS analysis using muraymycin D3 and ATP after (i) 12 h incubation without Mur29 
and (ii) 12 h reaction. Data were collected using GP1. Adenosine was only observed when 
reactions were performed with excess enzyme and prolonged incubation, suggesting the 
formation is due to a contaminating phosphatase. (▼) denotes peak corresponding to D3-
PHOS; A260, absorbance units at 260 nm. (B) Mass spectrum of the D3-PHOS peak generated 
with natural-isotope abundance ATP. (C) Mass spectrum of the D3-PHOS peak generated with 
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Figure S4.35 Reaction catalyzed by Mur28 with ADR-GlyU and ATP 
(A) LC-MS analysis using ADR-GlyU and ATP after (i) 12 h incubation without Mur29 and 
(ii) 12 h reaction. Data were collected using GP3. (▼) denotes peak corresponding to ADR-
GlyU-PHOS; (*) denotes unidentified peak; A260, absorbance units at 260 nm. (B) (+)-HR-
ESI-MS of compound ADR-GlyU-PHOS (calcd for C16H25N4O14P, expected (M+H)
+ ion at 
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Figure S4.36 Reaction catalyzed by Mur28 with muraymycin D2 and different phosphate 
donors.  
LC-MS analysis after 12 h reactions including (i) all nucleotides and without Mur28, (ii) CTP, 
(iii) GTP, (iv) TTP, (v) UTP, (vi) ATP, (vii) dATP. Data were collected using GP2. (▼) denotes 
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Figure S4.37 Reaction catalyzed by TmrB. 
(A) LC-MS analysis using muraymycin D2 and ATP after (i) 12 h incubation without enzyme; 
(ii) 12 h reaction with Mur28; and (iii) 12 h reaction with TmrB. Data were collected using 
GP1. (▼) denotes peak corresponding to D2 -PHOS; (*) denotes unidentified peak; A260, 
absorbance units at 260 nm. (B) LC-MS analysis using ADR-GlyU and ATP with (i) ADR-
GlyU control and after (ii) 12 h incubation without enzyme, (iii) 12 h reaction with TmrB, and 
(iv) 12 h reaction with Mur28. Data were collected using GP4. (▼) denotes peak 
corresponding to ADR-GlyU-PHOS; A260, absorbance units at 260 nm. (C) LC-MS analysis 
using muraymycin D2 and ADP after (i) 12 h incubation without enzyme, (ii) 12 h reaction 
with TmrB, and (iii) 12 h reaction with Mur28. Data were collected using GP1. (▼) denotes 
peak corresponding to D2 -PHOS; (*) denotes unidentified peak; A260, absorbance units at 260 




Chapter 5 : A PLP and AdoMet Dependent Strategy for Aminopropyl Group 
Incorporation in Nuceloside Antibiotics Biosynthesis 
 
5.1 Introduction 
Several nucleoside antibiotics represented by muraymycins from Streptomyces sp. 
NRRL3047122, A-90289A from Streptomyces sp. SANK6040581, Spharimicins from 
Sphaerisporangium sp. SANK6091161 and FR-900493 from Bacillus cereus No204582 are 
structurally characterized with a high-carbon glycosylated aminopropyl uronic acid (Figure 5.1), 
which undergoes different modifications to form the final nucleoside antibiotic. SAR studies 
have shown that the 3-amino-3-carboxypropyl group is essential for the antibacterial activity 
of muraymycins.21 Here we present the functional assignment of a butyric acid 
ribofuranosylated 5′-C-glycyluridine synthase and a PLP-dependent butyric acid decarboxylase. 





Figure 5.1 Structure of representative nucleoside antibiotics containing an aminopropyl moiety 




5.2 Materials and Methods 
5.2.1 Synthesis 
5.2.1.1 Materials and Methods 
Hydrogen chloride solution (4.0 M in dioxane), Boc-L-vinylglycine and solvents were 
purchased from Sigma-Aldrich (St. Louis, MO), and used without further purification. 
Compound 7 was kindly provided by Prof. Christian Ducho (Department of Pharmacy, Saarland 
University, Germany). All NMR data was recorded at 400 MHz for 1H and 100 MHz for 13C 
with a Varian Inova NMR spectrometer (Agilent, Santa Clara, CA). LC-MS was conducted 
with an Agilent 6120 Quadrupole MSD mass spectrometer (Agilent Technologies, Santa Clara, 
CA) equipped with an Agilent 1200 Series Quaternary LC system and an Eclipse XDB-C18 
column (150 × 4.6 mm, 5 µm). HR-ESI-MS spectra were acquired with an AB SCIEX Triple 
TOF 5600 System (AB Sciex, Framingham, MA, USA). HPLC analysis was performed on an 
Agilent 1200 system equipped with a photodiode array (PDA) detector and an analytical ZIC®-
HILIC column (250 mm x 4.6 mm, 5 µm). 
5.2.1.2 Disaccharide Phosphate, 8 
 
The reaction mixture consisted of 25 mM potassium phosphate (pH 8.5), 500 μM 7, 2 
mM MgCl2, 2 mM ATP and 200 nM Mur28 was incubated at 30 °C. The reaction was terminated 
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by ultrafiltration using a Microcon YM-3. 8 was purified by HPLC with HILIC column. The 
separation gradient is shown in Table S5.2. The peak corresponding to the product 8 was 
collected and freeze-dried as white solid prior to analysis. 
5.2.1.3 L- Vinylglycine 
 
An aliquot (500 μL) of hydrogen chloride solution (4.0 M in dioxane) was added to 
Boc-L-vinylglycine (10 mg), and the mixture was stirred at room temperature for 30 min. Upon 
completion of the reaction the volatiles were evaporated and the resulting mixture was 
dissolved in DI water. The aqueous solution was freeze-dried twice from water as an off-white 
solid prior to analysis. 
5.2.2 Isotopic Enrichment 
5.2.2.1 Fermentation, Extraction, Isolation, and Purification of Muraymycin D1 
Streptomyces sp. NRRL30475 was cultivated in 250 mL Erlenmeyer flasks containing 
50 mL TSBG (Tryptic soy broth (Difco) supplemented with 20 g/L glucose) at 30 °C on a rotary 
shaker (250 rpm) for 72 h. The seed culture was used to inoculate flasks (250 mL) containing 
50 mL PM-1 medium83. PM-1 was composed of glucose 2%, soluble starch 1%, pressed yeast 
0.9%, peptone (Bacto) 0.5%, meat extract (Fluka) 0.5%, NaCl 0.5%, CaCO3 0.3% and CB-442 
(NOF Co., Ltd.) 0.01% (pH 7.4, before sterilization). The fermentation was continued for 7 
days at 23 °C on a rotary shaker (210 rpm). 
All culture flasks were combined and centrifuged at 5000 rpm for 15 min to separate 
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the mycelium and water phase. The mycelial-cake portion was extracted with MeOH by 
sonication, and the organic phase was evaporated to obtain a brown crude extract. 
Amberlite XAD-16 (4%) resin was added to the water phase and stirred for 12 h. The 
resin was washed with water until the effluent became colorless, and then eluted with methanol. 
The MeOH extract was concentrated under reduced pressure to obtain a crude extract.  
Components of the mycelium crude extract and water phase crude extract were 
subjected to Sephadex LH-20 (25-100 μm GE Healthcare) column, and MeOH was used to 
elute compounds at a flow rate at 2 mL/min. The major fraction was further purified by using 
semipreparative HPLC. The separation gradient used for semipreparative analysis is shown in 
Table S5.3. 
5.2.2.2 Isotopic Enrichment 
Fermentation media and growth conditions for Streptomyces sp. NRRL30475 are 
described above. A seed culture was incubated at 30 °C for 72 h, when 2 ml was used to 
inoculate 50 mL fresh medium. After fermentation for 65 h, 25 mg of filter-sterilized L- 
[13C5,15N]Met or L- [13C4,15N]Asp (Cambridge Isotope Laboratories, Inc) was added to each 
flask (50 mL of liquid medium in a 250 mL flask). Fermentation was continued an additional 
72 h. Muraymycin D1 were extracted and purified as described in section 5.2.2.1. Purified 
muraymycin D1 was analyzed by NMR, and relative peak intensities were assigned based on 
uronic acid C-1 from the natural abundance 13C NMR spectra.  
5.2.3 Heterologous Protein Expression  
5.2.3.1 Materials and Bacterial Strains 
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Synthetic oligonucleotides were purchased from Integrated DNA Technologies 
(Coralville, IA). Phusion DNA polymerase, restriction enzymes and T4 DNA ligase were 
obtained from New England Biolabs Inc (Ipswich, MA) and used according to the 
manufacturer’s instructions. LA-Taq polymerase were obtained from Takara Bio Inc. (Shiga, 
Japan). Routine DNA sequencing was carried out at ACGT Inc. Competent E. coli NEB® 5-
alpha and BL21(DE3) from New England Biolabs (Ipswich, MA) and S. lividans TK24 were 
used for routine cloning and protein expression. 
5.2.3.2 Protein Expression Constructs 
5.2.3.2.1 Cloning Genes of mur23, mur24 and lipJ 
The gene for mur23 and mur24 was amplified from genomic DNA extracted from 
Streptomyces sp. NRRL30473 by PCR using Phusion DNA polymerase (primers listed in Table 
S5.1). Genomic DNA of Streptomyces sp. NRRL30473 was extracted using UltraClean 
Microbial DNA Isolation Kit (MoBio laboratories, Inc) following manufacturer’s protocol. 
DNA quality and concentration were confirmed using Nanodrop 2000c spectrophotometer 
(Thermo Scientific) and gel electrophoresis. The gel-purified PCR product was digested with 
NdeI-BamHI and ligated to the identical sites of pXY200 to yield pXY200-mur23 and 
pXY200-mur24 following the standard protocol and confirmed by DNA sequencing.  
5.2.3.2.2 Site-directed Mutagenesis 
A K70A point mutation of Mur23, K234A of Mur24 and F201Y of Mur24 was 
generated by PCR amplification with Q5 hot start high-fidelity DNA polymerase using pET30-
mur23 or pET30-mur24 as a template, respectively. The template, pET30-mur23 and pET30-
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mur24, was obtained using ligation-independent cloning with pET-30 Xa/LIC vector following 
the provided protocol. The template DNA after the PCR amplification was digested with 10 
units of DpnI for 2 h at 37 °C and transformed into E. coli NEB5α competent cells. The 
sequence of the entire gene with the introduction of the correct point mutation were confirmed 
by DNA sequencing to yield pET30-mur23 (K70A), pET30-mur24 (K234A) and pET30-mur24 
(F201Y), all of which were digested with NdeI-BamHI and the DNA fragment of the expected 
size was purified and ligated to the identical sites of pXY200 to yield pXY200-mur23 (K70A), 
pXY200-mur24 (K234A) and pXY200-mur24 (F201Y) were yielded following the same 
procedure as described above. 
5.2.3.3 Heterologous Protein Expression 
Plasmids pXY200-mur23, pXY200-mur24, pXY200-mur23 (K70A), pXY200-mur24 
(K234A) and pXY200-mur24 (F201Y) were transformed into S. lividans TK24 using PEG-
mediated protoplast transformation and plated on R2YE supplemented with 50 μg/mL 
apramycin. After 6 days at 28 °C, positive transformants were confirmed by colony PCR using 
InstaGene Matrix from Bio-Rad (Hercules, CA) and LA-Taq polymerase with GC buffer I. 
The recombinant strain was utilized to inoculate 50 mL R2YE containing 50 
μg/mL apramycin, grown for 3 days at 28 °C at 250 rpm, and 2 mL transferred to fresh 
100 mL containing 50 μg/mL apramycin. Following growth for 3 days at 28 °C at 250 
rpm, protein expression was induced by addition of thiostrepton (5 μg/mL) and the 
culture was incubated for another 24 h before harvesting. The cells from 400 mL of 
culture were collected by centrifugation. The pellet was thoroughly resuspended in ice-
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cold Buffer A supplemented with 4 mg/mL of lysozyme was subsequently added to the 
suspension. After incubation at 30 °C for 30 min, the cell suspension was mixed by 
pipetting and lysed using a Qsonica sonicator (Qsonica LLC, Newtown, CT) for 
sonication for a total of 10 min at 40% amplitude with 30 s pulses separated by 30 s 
rest periods. Cells were harvested after an overnight incubation at 18 °C and lysed in Buffer 
A (100 mM KH2PO4, 300 mM NaCl, 10 mM imidazole, pH 8.3) using a Qsonica sonicator 
(Qsonica LLC, Newtown, CT) for sonication for a total of 6 min at 40% amplitude with 30 s 
pulses separated by 30 s rest periods. Following centrifugation the protein was purified using 
affinity chromatography with HisPurTM Ni-NTA agarose (Thermo Scientific, Rockford, IL), 
and proteins were eluted with increasing concentrations of imidazole in Buffer A. Purified 
proteins were concentrated and buffer exchanged into Buffer B (25 mM KH2PO4, 100 mM 
NaCl, pH 8.3) using Amicon Ultra 10000 MWCO centrifugal filter (Millipore) and stored as 
glycerol stocks (40%) at -20 °C. Protein purity was assessed as by 12% acrylamide SDS-PAGE; 
His6-tagged proteins were utilized without further modifications. Protein concentration was 
determined using UV/Vis spectroscopy, and the extension coefficients were calculated using 
the ProtParam tool available from ExPASY (Mur23 ɛ280 = 44522 M
-1cm-1; Mur24 ɛ280 = 53922 
M-1cm-1. 
5.2.4 Enzyme Assays 
5.2.4.1 Materials and Methods 
S-(5-Adenosyl)-L-methionine chloride dihydrochloride (AdoMet), 1-
aminocyclopropanecarboxylic acid (ACC), 3-methyl-2-benzothiazolinone hydrazine 
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hydrochloride (MBTH), PLP and ATP were purchased from Sigma-Aldrich (St. Louis, MO), 
[(3S)-3-amino-3-carboxypropyl] (dimethyl)-sulfonium iodide (SMM) was obtained from VWR 
(Radnor, PA), 6-aminoquinolyl-N-hydroxysuccinimidyl carbamate (AQC) was purchased from 
Apollo Scientific (Denton, Manchester) and used without further purification. All NMR data 
were recorded at 400 MHz for 1H and 100 MHz for 13C with a Varian Inova NMR spectrometer 
(Agilent, Santa Clara, CA). LC-MS was conducted with an Agilent 6120 Quadrupole MSD 
mass spectrometer (Agilent Technologies, Santa Clara, CA) equipped with an Agilent 1200 
Series Quaternary LC system. HR-ESI-MS spectra were acquired with an AB SCIEX Triple 
TOF 5600 System (AB Sciex, Framingham, MA, USA). HPLC analysis was performed on an 
Agilent 1200 system equipped with a photodiode array (PDA) detector and an analytical ZIC®-
HILIC column (250 mm x 4.6 mm, 5 µm) and an analytical Apollo C18 column (250 mm x 4.6 
mm, 5 µm). 
5.2.4.2 Tandem Enzymatic Reaction with Mur28, Mur24 and Mur23 
The assay mixture for the reaction consisted of 25 mM potassium phosphate (pH 8.3), 
500 μM 7, 500 μM AdoMet, 1 mM ATP, 1 mM MgCl2, 100 μM PLP, and 200 nM Mur28, 
Mur24 and Mur23 at 30 °C, and the reaction was subsequently quenched by adding two 
volumes of acetonitrile followed by centrifugation (14000 rpm, 30 min) to remove the 
precipitated protein. The reaction components were analyzed by HPLC using C-18 reverse-
phase column with gradient shown in Table S5.4 or monitored by HPLC using ZIC®-HILIC 
column with the gradient shown in Table S5.2 with detection at 260 nm. 6-aminoquinolyl-N-
hydroxysuccinimidyl carbamate (AQC), a derivatizing reagent for amines, was used for pre-
column derivation. The reaction 20 μL was mixed with 60 μL of 0.2M sodium borate buffer 
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(pH = 8.8) and 20 μL 3 mg/ mL AQC acetonitrile solution. The mixtures were incubated at 
55 °C for 10 min and then allowed to cool to room temperature. The AQC-derivatized samples 
(50 μL) were applied to LC-MS using C-18 reverse-phase column with detection at 260 nm 
with gradient shown in Table S5.5.  
5.2.4.3 Butyric Acid Incorporation Activity of Mur24  
Reactions consisted of 25 mM potassium phosphate (pH 8.3), 500 μM 8, 500 μM 
potential aminopropyl donor (AdoMet, SMM, L-VG or ACC), 100 μM PLP and 200 nM 
enzyme (Mur24, Mur24 (K234A), Mur24 (F201Y) at 30 °C and the reaction was terminated by 
adding two volumes of acetonitrile followed by centrifugation (14000 rpm, 30 min) to remove 
the precipitated protein. The reaction was monitored by LC-MS using ZIC®-HILIC column 
with gradient shown in Table S5.2 with detection at 260 nm. Large scale production of the 
Mur24 product 9 was identical to the reactions described above and isolated by HPLC using 
ZIC®-HILIC column. 
5.2.4.4 Deaminase Activity of Mur24 or LipJ 
Reactions for identification of α-ketobutyrate consisted of 50 mM potassium phosphate 
(pH 8.3), 500 μM potential aminopropyl donor, 100 μM PLP and 400 nM or 4 μM enzyme at 
30 °C and the reaction was terminated by ultrafiltration using a Microcon YM-3.  Reaction 
mixtures were treated with MBTH as follows according to the method described by Tanaka54. 
50 μL reaction mixtures were mixed with 50 μL of 1 M sodium acetate (pH 5.0) and 50 μL of 
8 mM MBTH aqueous solution. The mixtures were then incubated at 50 °C for 30 min and then 
analyzed by LC-MS with the gradient shown in Table S5.6 with detection at 325 nm. 
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5.2.4.5 Activity of Mur23 
Reactions consisted of 25 mM potassium phosphate (pH 8.3), 500 μM 9, 100 μM PLP 
and 200 nM Mur23 or Mur23 (K70A) at 30 °C and the reaction was terminated by adding two 
volumes of acetonitrile followed by centrifugation (14000 rpm, 30 min) to remove the 
precipitated protein. The reaction was monitored by LC-MS using ZIC®-HILIC column with 
the gradient shown in Table S5.2 with detection at 260 nm. Large scale production of the Mur23 
product 10 was identical to the reactions described above and was isolated by HPLC using 
ZIC®-HILIC column. 
5.2.4.6 Kinetics of Mur24 
Assays consisted of 25 mM potassium phosphate (pH 8.3), 100 μM PLP, near saturating 
AdoMet (2 mM) with variable 8 (5 μM–500 μM). The reaction was performed at 30 °C with 
200 nM Mur24 for 3 h and analyzed under initial velocity conditions. Product formation was 
determined using HPLC with gradient shown in Table S5.2. Each data point represents a 
minimum of three replicate end point assays; kinetic constants were obtained by nonlinear 
regression analysis using GraphPad Prism (GraphPad Software, La Jolla, CA). 
5.2.4.7 Kinetics of Mur23 
Assays consisted of 25 mM potassium phosphate (pH 8.3), 100 μM PLP with variable 
8 (5 μM–1000 μM). The reaction was performed at 30 °C with 50 nM Mur23 for 1 h and 
analyzed under initial velocity conditions. Product formation was determined using HPLC with 
gradient shown in Table S5.2. Each data point represents a minimum of three replicate end point 
assays; kinetic constants were obtained by nonlinear regression analysis using GraphPad Prism 
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(GraphPad Software, La Jolla, CA). 
5.3 Results and Discussion 
5.3.1 Bioinformatic Analysis of Mur23 and Mur24 
Blast analysis revealed that Mur24 belonged to pyridoxal-5’-phosphate (PLP) 
dependent aspartate aminotransferase family (type I), members of which have a diverse set of 
functions including transamination, racemization, decarboxylation, and various side-chain 
reactions. However, sequence analysis of Mur24 didn’t show modest sequence identity (>30%) 
to any characterized enzyme. Two clues shed light on our proposed function of Mur24, 
especially after comparison of the biosynthetic gene clusters among other nucleoside antibiotics.  
One is that Mur24 has 45% sequence identity (Cover 95%) to DNA binding transcription 
regulator (SCL26195.1) that belongs to MocR family, the mechanism of which hasn’t been well 
understood yet. This similarity, however, suggested that Mur24 potentially uses a nucleoside as 
a substrate. Another is that Mur24 has 27% sequence identity (Cover 41%) to ACC synthase-
like protein (XP0213717 68.1). Mur23 has modest sequence identity to several proteins 
annotated as PLP dependent diaminopimelate decarboxylase.  
Comparison among A-90289, caprazamycin and spharimicin biosynthetic gene cluster 
revealed that Mur24 homolog is shared by the four gene clusters, while only sphaerimicin gene 
cluster has Mur23 homolog. Structure comparison of the four nucleoside antibiotics revealed 
that the four nucleoside antibiotics share the similar aminopropyl group (Figure 5.1 highlighted 
in red), and both A-90289 and caprazamycin retain the carboxylate group (Figure 5.1 
highlighted in blue) while both muraymycin and spharimicin do not. The bioinformatics 
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analysis above led us to propose the pathway that Mur24 catalyzes the aminobutyric acid 
incorporation, followed with decarboxylation reaction catalyzed by Mur23. 
5.3.2 Feeding Experiments: the Source of the Aminopropyl Group  
Two potential pathways for incorporation of aminopropyl group were proposed, 
inspired by the characterized polyamine84 and staphylopine85 biosynthetic pathways. From 
analysis of these two pathways, S-adenosylmethionine or aspartate β-semialdehyde serve as 
aminopropyl group donors prior to further downstream modification by distinct enzymes. 
In order to determine which precursor is the authentic donor of the aminopropyl group 
in muraymycins, universal labeled L-methionine (L-Met) or L-aspartic acid (L-Asp) was fed to 
the muraymycin D1 producer Streptomyces sp. NRRL30475 at the onset of production.  
Analysis by 13C NMR spectroscopy revealed enriched resonances (average enrichment = 12%) 
with fermentation fed with L-Met (Figure 5.2). The 13C-NMR resonances showed four carbon 
resonances at δ25.0 (t), 35.8 (dd), 45.5 (d) and 57.9 (s) with increased abundance flanking the 
other natural singlets, indicating that methionine is the origin of C1-C3 of aminopropane moiety 
and 2′-O-methyl group of the aminoribose moiety of muraymycin. In contrast no significant 
enrichment was observed with L-Asp. Mass analysis and extraction of the NMR coupling 






    
Figure 5.2 13C NMR spectrum of isotope labelled muraymycin D1.  
(A) Chemical shift assignment for muraymycin D1. (B) 13C NMR spectra of muraymycin D1 
fed with L-Methionine (13C5, 99%; 15N, 98%) and L-Aspartic acid (13C4, 99%; 15N, 99%), 









5.3.3 Six-enzyme Biosynthesis of Amino Disaccharide, compound 7: the Aminopropyl Group 
Acceptor 
Since muraymycin has a similar disaccharide moiety of A-90289, we compared the 
biosynthetic gene cluster of muraymycin with that of A-90289. Six genes (mur16, mur17, 
mur18, mur19, mur20, and mur26) have modest similarity to genes in A-90289 that are 
responsible for the biosynthesis of the disaccharide moiety.47, 49, 55 However, the 
glycosyltransferase (LipN) in A-90289 biosynthetic pathway was only confirmed to utilize 
uridine as a surrogate aminoribose acceptor. The functions of the six enzymes were confirmed 
individually upon in vitro characterization (Figure 5.3) (details shown in chapter 3), and Mur19 
was shown to utilize GlyU as an acceptor to produce 7 with in situ generated activated amino 
ribose 6. Notably, aminopropyl GlyU cannot be utilized by Mur19 to produce 7, which suggests 
that aminopropyl group was added after the formation of 7. 
 
Figure 5.3 Biosynthesis of the amino disaccharide moiety of muraymycins. 
5.3.4 Function Assignment of Mur23 and Mur24 
To interrogate the mechanism of aminopropane incorporation, Mur23 and Mur24 were 
expressed in E. coli; however, the recombinant protein was completely insoluble under a variety 
of expression conditions. In contrast, expression in S. lividans TK24 yielded soluble proteins 
(Mur23, 5.8 mg/L, Mur24, 5.1 mg/L) (Figure S5.1A). Mur23 was yellowish and shown to co-
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purify with PLP cofactor by UV/vis spectroscopy (Figure S5.1B), while Mur24 was purified 
with bound PLP only when purification buffers were supplemented with PLP.  
Based on the confirmed biosynthetic pathway of 7, we initially proposed 7 as the 
aminopropyl group acceptor (Figure 5.4A), and incubated Mur24 and Mur23 with 7 and L-Met 
derived aminopropyl group donors including L-Met, AdoMet and SMM, but observed no 
reaction by both HPLC and LC-MS after pre-column primary amine derivation with 6-
aminoquinolyl-N-hydroxysuccinimidyl carbamate (AQC).  
Since the initially proposed product 7 only lacks N-methylation compared to 
nucleoside antibiotic FR-900493, we suspected that 7 might also have inhibitory effect to 
bacteria and therefore a self-resistance modification of the acceptor might be required before 
the incorporation of the aminopropyl group. Careful analysis of the gene cluster of muraymycin, 
two ORFs (mur28 and mur29) have sequence similarity to proteins predicted to belong to 
aminoglycoside resistance enzymes. In chapter 4, we reported the respective activity of Mur28 
and Mur29. To our surprise, by single substrate kinetics we found that Mur28, which was a 
kinase, preferred utilizing the precursor of muraymycin, 7, as its substrate; while a series of 
muraymycin congeners showed inhibition to Mur28 at high concentration. However, Mur29, a 
nucleotidyltransferase, can only catalyze muraymycins rather than its precursor (details shown 
in chapter 4). This discovery led to another proposal that the incorporation of the aminopropyl 





Figure 5.4 Two proposed biosynthetic pathway of the incorporation of aminopropyl moiety of 
muraymycins. 
 
LC-MS analysis of enzyme coupled reaction by incubating Mur28, Mur24 and Mur23 
with 7 after pre-column derivation by AQC yielded an (M+2H)2+ ion at m/z = 463.7, consistent 
with the molecular formula C39H46N9O16P of an AQC-modified 10 (10’), (expected m/z = 463.6) 
(Figure S5.7). Since a C18 column did not give good separation for the reaction even under ion 
pairing condition (Figure S5.4) due to the high polarity of the substrate and product, the tandem 
reactions were analyzed with HILIC column without pre-column derivation (Figure 5.5).  In 
situ generated disaccharide phosphate by Mur28 was clearly processed by Mur24 and a new 
peak was formed, which was identified as butyric acid disaccharide 9 by HR-ESI-MS with 
(M+H)+ ion at m/z =630.1643, consistent with the molecular formula C20H33N5O16P of 9 
(expected (M + H)+ ion at m/z = 630.1654) (Figure S5.11). Decarboxylation of in situ generated 
9 was also observed when incubating with Mur23. HR-ESI-MS of the purified new peak 
yielded an (M + H)+ ion at m/z = 586.1735, consistent with the molecular formula C19H33N5O14P 
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Figure 5.5 HPLC analysis of tandem enzymatic reaction with Mur23, Mur24 and Mur28.  
I, control reaction with ATP and 7; II, 6 h reaction with Mur28; III, 6 h reaction with ATP, 7, 
AdoMet and Mur28; IV, 6 h reaction with Mur24 and Mur28; V, 6 h reaction with Mur23, 
Mur24 and Mur28.  
Purified 8 was used as substrate to directly test Mur24-catalyzed reaction with AdoMet 
(Figure 5.6A) to confirm that 8 is the genuine aminopropyl group acceptor. The structure of the 
product 9 was elucidated by NMR spectroscopy (Figure 5.7, S5.8-S5.10, S5.12-S5.15, S5.17-
S5.18). As expected, the connection between the butyric acid group and 8 in 9 was confirmed 
by 1H-13C HMBC from the proton signal at δH 3.79 (H-10) to the carbon signal at δC 45.6 (C-
17) (Figure S5.15). Accordingly, purified 9 was used as substrate to test the activity of Mur23 
(Figure 5.6B). NMR analysis of purified product 10 revealed the decarboxylation at C-19 
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Figure 5.6 Characterization of Mur24 and Mur23. 
(A) LC-MS analysis of Mur24 reaction using 8 as substrate. I, control reaction with AdoMet no 
Mur24; II, 6 h reaction with AdoMet and Mur24; III, 6 h reaction with AdoMet and Mur24 
(K234A); IV, 6 h reaction with L-Met and Mur24; V, 6 h reaction with SMM and Mur24. (B) 
LC-MS analysis of Mur23 reaction using 9 as substrates. I, control reaction without Mur23; II, 












Figure 5.7 Chemical shift assignment for compound 7, 8, 9 and 10. 
5.3.5 Kinetic and Mutational Analysis of Mur24 and Mur23 
Single-substrate kinetic analysis of Mur24 revealed typical Michaelis−Menten kinetics 
with respect to varied 8, yielding kinetic constants of Km = 92.3 ± 7.3 μM and kcat = 2.67 ± 0.08 
min−1 (Figure 5.8A). A Mur24 (K234A) mutant was generated by site-directed mutagenesis 
with the expectation that the point mutation would make the enzyme unable to form an internal 
aldimine with PLP which is a prerequisite for the catalytic activity, and as expected, incubation 
of 8 with AdoMet and Mur24 (K234A) revealed no detectable conversion to 9 (Figure 5.6A). 
Also, absence of adding PLP in the reaction with Mur24 greatly reduced the yield of the product 
9 (Figure S5.21), which suggested that Mur24 catalyzed an unusual PLP-dependent reaction to 
modify the high carbon nucleoside scaffold.  Kinetic analysis of Mur23 with respect to 9 also 
revealed Michaelis-Menten kinetics yielding a Km = 701.8 ± 9.2 μM and kcat = 144.8 ± 1.1 min
−1 
(Figure 5.8B). Mur23 (K70A) mutant was still yellowish and had a similar UV/Vis profile to 
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wild-type Mur23 (Figure S5.1). The activity of Mur23 (K70A) was significantly reduced when 
incubating 9, suggesting an important—although not essential—role for this Lys residue in the 
Mur23 reaction. 



















0 1 0 0 2 0 0 3 0 0 4 0 0 5 0 0 6 0 0 7 0 0 8 0 0 9 0 0 1 0 0 0
0
1 0 0 0
2 0 0 0
3 0 0 0
4 0 0 0
5 0 0 0














Figure 5.8 Kinetic analysis of Mur24 and Mur23. 
(A) Single-substrate kinetic analysis of Mur24 with 2 mM AdoMet and variable 8. (B) Single-
substrate kinetic analysis of Mur23 with variable 9. 
 
5.3.6 Mechanism Study of Mur24 
Formation of 9 can involve in one of a few possible mechanisms (Figure 5.9). The 
proposed ‘addition’ pathway involves an L-VG intermediate as an active vinyl ketamine. 
Alternatively, in the ‘cyclization’ pathway, 1-aminocyclopropanecarboxylic acid (ACC) 
involves as an intermediate to form the active aldimine. Moreover, the regular SN2 mechanism 
for the aminopropane incorporation is also possible. To distinguish among the proposed 
mechanisms, L-VG, ACC and SMM were tested as alternative aminopropane donor in the 
reaction with 8 and Mur24. However, activity was only detected when incubating with SMM, 
which, although suggested that the adenosyl group is not required for its activity, did not provide 
further insight into the mechanism. However, Mur24 did have deaminase activity when 8 was 
absent in the reaction, generating α-ketobutyrate (α-KB) (identified by treating with reagent 3-




Surprisingly, the formation of α-KB was also observed when incubating L-VG with 10 times 
more Mur24, but was not observed in reaction with ACC. Mur24 (K234A) revealed no 
detectable conversion to α-KB with AdoMet and SMM (Figure 5.10, S5.22). The inhibition 
effect of L-VG to Mur24 was observed when testing its deaminase activity. Although neither 
L-VG nor ACC can be aminopropyl donor of Mur24, the deaminase activity of Mur24 with L-
VG rather than with ACC possibly supported the proposed ‘addition’ mechanism with L-VG 
as intermediate for the aminopropyl moiety incorporation reaction. However, since L-VG 
cannot act as aminopropane donor in this reaction, the regular SN2 mechanism is still possible 
for the reaction. 
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Figure 5.10 LC-MS analysis of MBTH modified Mur24 catalyzed reactions. 
(A) α-keto-butyrate reacts with MBTH. (B) LC traces of MBTH modified Mur24 reaction with 
AdoMet. I, control reaction without enzyme; II, MBTH modified 6 h reaction with Mur24 
(K234A); III, MBTH modified 6 h reaction with Mur24. (C) LC traces of MBTH modified 
Mur24 reaction with SMM. I, control reaction without enzyme; II, MBTH modified 6 h reaction 
with Mur24 (K234A); III, MBTH modified 6 h reaction with Mur24. (D) LC traces of MBTH 
modified Mur24 reaction with L-VG. I, control reaction without enzyme; II, MBTH modified 








5.4.1 Similarity between ACC Synthase and Mur24 
ACC synthase is a PLP dependent enzyme that catalyzes the formation of ACC from 
AdoMet (Figure 5.11).86 ACC synthases have only been found in higher plants and fungus. It 
catalyzes α, γ-elimination from SAM to produce ACC and MTA; it also catalyzes β, γ-
elimination to yield L-VG in 1 of 30,000 catalytic cycle.87 Like Mur24, ACC belongs to α 
family of PLP-dependent enzymes. It can also transaminate L-VG and SMM to α-ketobutyrate 
and ammonia.88-89 Although the aminotransferase activity of ACC synthase is similar to Mur24, 
ACC synthase can only catalyze AdoMet to form ACC, and SMM cannot be utilized to form 
ACC. However, Mur24 can utilize both AdoMet and SMM for the butyric acid encorporation. 
 
Figure 5.11 The biosynthesis of ethylene. 
5.4.2 Relationship of Mur24 and MocR Transcription Regulator 
Mur24 has modest sequence identity to PLP dependent MocR/GabR DNA binding 
transcription regulator, the molecular mechanism of which remains to be elucidated. 
MocR/GabR DNA binding transcription regulators also have PLP dependent Class I 
aminotransferase domain but lack the aminotransferase acitivity. Okuda etal90 reported the 
spectroscopic studies of the aminotransferase domain of GabR, a PLP dependent transcriptional 
regulator and revealed that GABA forms an external aldimine with the PLP in the 
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aminotransferase domain of GabR. It’s possible to speculate that Mur24 may also regulate the 
transcription of its downstream genes. 
5.4.3 Phosphorylation Modification is Also Required in Caprazamycin Biosynthetic Pathway 
LipJ, from biosynthetic gene cluster of caprazamycin A-90289 (Figure 5.1), shared 35% 
sequence identity to Mur24. Activity tests revealed that, like Mur24, LipJ catalyzes the 
incorporation of butyric acid to phosphorylated disaccharide, and also showed deaminase 
activity with AdoMet. Recently, Shiraishi etal62 reported the identification of caprazol-3″-
phosphate (Figure 5.12) in cpz23(acyltransferase)-deleted caprazamycin producing strain 
mutants. This discovery indicated that the phosphorylation at the 3″ position will also exist in 
the following biosynthetic steps. 
 
Figure 5.12 Structures of caprazol-3’’-phosphate. 
5.5 Conclusion 
In this chapter, Mur23 and Mur24 were assigned as two enzymes that modify the 
cryptic phosphorylated intermediate by attachment of an aminopropyl group. Structures of the 
products were elucidated by the cumulative analysis of NMR spectroscopy and HR-ESI-MS. 
Three possible catalytic mechanism was proposed. Mur24 catalyzes an unusual β, γ elimination 
of AdoMet to form a vinylglycine-bound intermediate that serves as the Michael-type acceptor 
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of the phosphorylated-disaccharide, or the phosphorylated-disaccharide attacks γ carbon of 
AdoMet-bound PLP aldimine via SN2 to incorporate the butyric acid. Following the butyric 





5.6 Supporting Information 
Table S5.1 Primers used in this study. 
Primer Sequence Note 
mur23_NdeI 5′-GATAGGCATATG AGCAGGCACGCACACAC-3′ mur23 
expression  mur23_BamHI 5′-CGAGTTGGATCC TCACCGCGCTCCGTCCG-3′ 
mur24_NdeI 5′-GATAGGCATATG AGCGTCGTCGACAACG-3′ mur24 
expression  mur24_BamHI 5′-CGAGTTGGATCCTCACGGCAGTAGTGACTCCAG-
3′ 




















pTipA 5′-GAG AAG GGA GCG GAC ATA C-3′ pXY200 
sequencing 
primer 




Table S5.2 Gradient used for HPLC or LC-MS analysis of Mur28, Mur24, or Mur23 product 
with an analytical ZIC®-HILIC column (250 mm x 4.6 mm, 5 µm). 
Solvent A= ddH2O with 0.1% formic acid; Solvent B= acetonitrile with 0.1% formic acid; A260 
 
Time (min) % Solvent B Flow Rate (mL/min) 
0 80 0.4 
12 50 0.4 
26 50 0.4 
27 80 0.4 
35 80 0.4 
 
Table S5.3 Gradient used for semipreparative HPLC isolation of muraymycin D1 with an 
Apollo C-18 column (250 mm x 10 mm, 5 μm). 
Solvent A= ddH2O with 0.025% trifluoroacetic acid; Solvent B= acetonitrile; A260 
 
Time (min) % Solvent B Flow Rate (mL/min) 
0 10 3.5 
25 22 3.5 
26 100 3.5 
31 100 3.5 
32 10 3.5 
36 10 3.5 
 
Table S5.4 Gradient used for HPLC analysis of Mur28, Mur24 and Mur23 tandem reactions 
with an analytical Apollo C18 column (250 mm x 4.6 mm, 5 µm). 
Solvent A= 40 mM acetic acid-triethylamine pH 6.5; Solvent B= 40 mM acetic acid-
triethylamine, 20% methanol, pH 6.5; A260 
 
Time (min) % Solvent B Flow Rate (mL/min) 
0 1 0.5 
16 100 0.5 
20 100 0.5 
21 1 0.5 





Table S5.5 Gradient used for LC-MS analysis of AQC modified Mur28, Mur24 and Mur23 
tandem reactions with an analytical AcclaimTM 120 C18 column (100 mm x 4.6 mm, 5 µm) 




% Solvent B Flow Rate (mL/min) 
0 1 0.4 
40 20 0.4 
41 100 0.4 
44 100 0.4 
45 1 0.4 
47 1 0.4 
 
Table S5.6 Gradient used for LC-MS analysis of MBTH modified α-KB production by Mur24 
or LipJ with an analytical AcclaimTM 120 C18 column (100 mm x 4.6 mm, 5 µm) 
Solvent A= ddH2O with 0.1% formic acid; Solvent B= acetonitrile with 0.1% formic acid; A325 
Time (min) % Solvent B Flow Rate (mL/min) 
0 10 0.4 
10 40 0.4 
20 100 0.4 
27 100 0.4 
28 10 0.4 









No. 7 8 9 10 
1 7.60, d (7.7) 7.55, d (8.0) 7.57, d (7.8) 7.53, d (8.2) 
2 5.71, d (7.7) 5.78, d (8.0) 5.80, d (7.8) 5.75, d (8.1) 
5 5.66, br s 5.65, br s 5.66, br s 5.62, br s 
6 4.18, m 4.16, m 4.29, m 4.22, m 
7 4.07, m 4.11, m 4.17, m 4.11, m 
8 4.06, m 4.05, m 4.14, m 4.14, m 
9 4.35, br s 4.44, br s 4.42, br s 4.55, brs 
10 3.73, br s 3.86, br s 3.79, br s 3.56, br s 
12 5.02, br s 5.02, br s 5.07, br s 5.04, br s 
13 3.98, m 4.10, m 4.13, m 4.07, m 
14 3.99, m 4.24, m 4.30, m 4.25, m 
15 3.96, m 4.03, m 4.09, m 4.00, m 
16a 2.95, t (9.9, 
12.2)  
3.03, m 3.11, m 3.08, m 
16b 3.15, d (11.4) 3.20, m 3.23, m 3.17, m 
17     3.17, m 2.90, t (7.4) 
18     2.09, m 1.83, m  






   
















M u r2 3
M u r2 3  1 m in  w / 9
M u r2 3  w / 9
M u r2 3 (K 7 0 A )
M u r2 3 (K 7 0 A ) 1 m in  w / 9
 
Protein Size (aa) Size(kD) 
Mur23 388 42 
Mur24 433 48 
 
Figure S5.1 SDS-PAGE analysis of purified protein and UV/Vis spectrum of Mur23. 
(A) SDS-PAGE analysis of purified His6-Mur23 (lane 1), His6-Mur23 (K70A) (lane 2), His6-
Mur24 (lane 3), His6-Mur24 (234A) (lane 4), His6-Mur24 (F201Y) (lane 5). (B) UV/Vis 









Figure S5.2 (+)-HR-ESI-MS (positive mode) of L-[13C5,15N] Met enriched muraymycin D1.  
 
 
Figure S5.3 1H NMR spectrum (D2O, 100 MHz) of isotope enriched (L-[
13C5, 15N] Met or L-
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Figure S5.4 Analysis of tandem enzymatic reaction with Mur23, Mur24 and Mur28  
(A) HPLC analysis of tandem enzymatic reaction with Mur23, Mur24 and Mur28 using ion 
pairing condition with C18 column. I, 6 h reaction with 7 and Mur28; II, 6 h reaction with 7, 
Mur24 and Mur28; III, 6 h reaction with 7, Mur23, Mur24 and Mur28. (B) LC-MS analysis of 
AQC modified tandem enzymatic reaction with Mur23, Mur24 and Mur28. I, 6 h reaction with 
7 and Mur28; II, 6 h reaction with 7, Mur24 and Mur28; III, 6 h reaction with 7, Mur23, Mur24 












Figure S5.5 ESI-MS spectrum of 7’ eluted at 23.325 min 
(calcd for C36H37N8O16P, expected (M+H)
 + ion at m/z = 869.21, found 869.1). 
 
 
Figure S5.6 ESI-MS of 10’ eluted at 24.157min 
(calcd for C39H45N9O16P, expected (M+2H)









Figure S5.7 (+)-HR-ESI-MS (positive mode) of compound 8 
(calcd for C16H25N4O14P, expected (M+H)








Figure S5.9 HSQC spectrum (D2O, 400 MHz) of compound 8. 
 
 




Figure S5.11 (+)-HR-ESI-MS (positive mode) of compound 9 
(calcd for C20H32N5O16P, expected (M+H)
+ ion at m/z = 630.1654, found: 630.1643). 
 
 





Figure S5.13 HSQC spectrum (D2O, 400 MHz) of compound 9. 
 










Figure S5.16 (+)-HR-ESI-MS (positive mode) of compound 10 
(calcd for C19H32N5O14P, expected (M+H)
+ ion at m/z = 586.1756, found: 586.1735). 
 





Figure S5.18 1H-1H COSY spectrum (D2O, 400 MHz) of compound 10. 
 
 
Figure S5.19 (+)-HR-ESI-MS (positive mode) of 5’-deoxy-5’-(methylthio) adenosine 
(calcd for C11H15N5O3S, expected (M+H)





Figure S5.20 1H NMR spectrum (D2O, 400 MHz) of L-VG. 
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Figure S5.21 HPLC analysis of Mur24 reaction with or without PLP using 8 as substrates. 








    
 
Figure S5.22 LC-MS analysis of MBTH modified Mur24 catalyzed reactions. 
(A) Mass spectrum for the ion peak eluting at time t = 21.210 min of MBTH modified Mur24 
reaction (MBTH modified α-keto-butyrate expected (M+H)+ ion at m/z = 264.08, found: 264.1). 
(B) Mass spectrum for the ion peak eluting at time t = 22.413 min of MBTH modified Mur24 










The cupin superfamily, which was named on the basis of a conserved β barrel fold of 
the proteins, is one of the most functionally diverse protein superfamily. The largest subset of 
this family is the non-heme Fe(II), α-ketoglutarate dependent dioxygenases. In this chapter in 
vitro data are provided to support the functional assignment of Mur15, an enzyme that belongs 
to cupin superfamily, from the muraymycin gene cluster, as a non-heme, Fe(II)-dependent α-
KG: muraymycin dioxygenase that catalyzes the β-hydroxylation of leucine moiety in 
muraymycin D1 to form muraymycin C1. It can also hydroxylate the γ-position of leucine 
moiety to muraymycins with fatty acid chain in β-position. To our knowledge, this is the first 





6.2 Materials and Methods 
6.2.1 Cloning, Overexpression and Purification of Proteins 
The gene for mur15 was amplified from genomic DNA extracted from Streptomyces 
sp. NRRL30473 by PCR using Phusion DNA polymerase with primer pairs:  
mur15 (forward) 5′-GGTATTGAGGGTCGCGTGAGGAGCCCTCC-3′/ 
 (reverse) 5′-AGAGGAGAGTTAGAGCCTCAGCCGTCCGCGC-3′. 
Genomic DNA of Streptomyces sp. NRRL30473 was extracted using UltraClean 
Microbial DNA Isolation Kit (MoBio laboratories, Inc) following manufacturer’s protocol. 
DNA quality and concentration were confirmed using Nanodrop 2000c spectrophotometer 
(Thermo Scientific) and gel electrophoresis. The gel-purified PCR product of mur15 was 
inserted into pET30 Xa/LIC using ligation-independent cloning as described in the provided 
protocol to yield pET30-mur15 and confirmed by DNA sequencing. The procedure of protein 
overexpression and purification from E. coli BL21 (DE3) was stated in section 3.2.1. 
6.2.2 Fermentation, Extraction, Isolation, and Purification of Muraymycins 
Muraymycin producer strains Streptomyces sp. NRRL30473, 30475 and 30477 were 
cultured for the production of muraymycin A1, B2, B6, C1, D1and D2 following the method 
stated in section 4.2.3. 
6.2.3 Activity Assay of Mur15 
Reactions consisted of 50 mM HEPES (pH 7.5), 2.5 mM α-KG, 500 μM ascorbic acid, 
500 μM FeCl2, 1 mM muraymycin congeners, L-Arg, L-Leu or dipeptide and 1 μM Mur15 at 
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30 °C. The reaction was terminated by adding twice volume of methanol followed by 
centrifugation (14000 rpm, 30 min) to remove the precipitated protein. Following 
centrifugation to remove protein, the reaction was analyzed by HPLC or LC-MS with gradient 
shown in Table S4.3 or Table S4.4 with detection at 260 nm. 
6.2.4 Activity Optimization 
Optimal ascorbic acid concentration for activity was determined with assays containing 
50 mM HEPES (pH 7.5), 2.5 mM α-KG, 0.25 mM muraymycin D1, 200 μM FeCl2 and 0-2000 
μM ascorbic acid and 200 nM Mur15. After identifying the optimal ascorbic acid concentration, 
the optimal iron concentration was determined with reactions containing 50 mM HEPES (pH 
7.5), 2.5 mM α-KG, 0.25 mM muraymycin D1, 500 μM ascorbic acid and 0-1000 μM FeCl2 
and 200 nM Mur15. All reactions were carried out at 30 °C, and product formation was analyzed 
by HPLC with gradient shown in Table S4.3 or Table S4.4 under initial velocity conditions. 
6.2.5 Kinetics of Mur15 
Assays consisted of 50 mM Hepes (pH 7.5), 500 μM ascorbic acid, 500 μM FeCl2, near 
saturating muraymycin D1 (0.25 mM) with variable α-KG (5 μM–200μM), or near saturating 
α-KG (2.5 mM) with variable muraymycin D1 (5 μM–1000μM), or near saturating α-KG (2.5 
mM) with variable muraymycin B2 (5 μM–1000 μM). The reaction was performed at 30 °C 
with 200 nM Mur15 for 2 h and analyzed under initial velocity conditions. Product formation 
was determined using HPLC with gradient shown in Table S4.3. Each data point represents a 
minimum of three replicate end point assays; kinetic constants were obtained by nonlinear 
regression analysis using GraphPad Prism (GraphPad Software, La Jolla, CA). 
193 
 
6.2.6 Antimicrobial Bioactivities   
The protocol used for the determination of the minimum inhibitory concentration (MIC) 
was as described in section 4.2.8.  
6.2.7 MraY Inhibition 
The assay was carried out by Prof. Christian Ducho’s lab in Department of Pharmacy, 
Pharmaceutical and Medicinal Chemistry, Saarland University. Details are described in section 
2.2.5. 
6.3 Results and Discussion 
6.3.1 Bioinformatic Analysis of Mur15 
BLASTP analysis showed that Mur15 belongs to cupin superfamily but has no 
significant sequence homology to any characterized protein. Proteins in cupin superfamily, 
which is named after the conserved barrel domain, has diverse functions.91 Therefore, structural 
homology search using HHpred was carried out.92 Mur15 showed structural homology to α-
ketoglutarate dependent ribosomal oxygenases YcfD in E. coli and nucleolar protein 66 (NO66) 
in human. YcfD catalyzes arginine hydroxylation in ribosomal protein L16 while NO66 
catalyzes histidine hydroxylation in ribosomal protein RPL8.93 Thus, we proposed that Mur15 
may similarly function as an Fe(II) and α-KG dependent dioxygenase to catalyze the 
hydroxylation of the peptide moiety of muraymycin. 
6.3.2 Functional Assignment and Activity Test 
Mur15 was cloned as an N-terminal His6-tagged protein using the genome of 
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Streptomyces sp. NRRL30473 as template, expressed and purified from E. coli BL21(DE3) 
with a yield of 6.3 mg/L (Figure S6.1). As no hydroxylation of free L-leucine catalyzed by 
Mur15 could be detected by LC-MS, five muraymycin congeners, muraymycin D1, D2 (from 
Streptomyces sp. NRRL30475), muraymycin A1, B2, B6, C1 (from Streptomyces sp. 
NRRL30473) were isolated from culture medium of Streptomyces sp. for activity tests. When 
Mur15 was incubated with muraymycin D1 and α-KG, HPLC analysis revealed a new peak 
with concomitant loss of the peak corresponding to D1 (Figure 6.1B). The new peak was 
confirmed as muraymycin C1 by LC-MS, coinjections with authentic muraymycin C1 and 
proton NMR comparison (Figure S6.2). No activity was observed when α-KG was omitted in 
the reaction. Activity of Mur15 was also observed when it was incubated with muraymycin D2 
to generate muraymycin C2 (Figure 6.1C). Therefore, Mur15 is preliminarily assigned as an α-
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Figure 6.1 Characterization of Mur15 with muraymycin D1 (1).  
(A) Reaction catalyzed by Mur15 with 1 or 3. (B) LC-MS analysis using 1 (Ο) after 6 h without 
Mur15 (I), 6 h reaction (II). (C) LC-MS analysis using 3 (Ο) after 6 h without Mur15 (I), 6 h 
reaction (II). 
No activity was detected by HPLC when Mur15 was incubated with C1 and α-KG. 
However, to our surprise, when Mur15 incubated with muraymycin congeners with fatty acid 
chain (muraymycin A1, B2 and B6) in β-position, HPLC and LC-MS traces revealed a new 
peak with 16 amu greater than the substrate (Figure 6.2), indicating that Mur15 also catalyzed 
the hydroxylation reaction of muraymycins with fatty acid chain. Following large scale 
purification of the hydroxyl B2 generated by Mur15, 1HNMR revealed absent signal of proton 
on C4 and downfield shifts of protons on C5 and C6 of leucine moiety, indicating that the 
hydroxylation occurred at the γ position of leucine moiety (Figure 6.3). To our knowledge, this 
is the first discovered natural enzyme that catalyzes the γ-hydroxylation of leucine.94 However, 
the mass of hydroxyl muraymycin A or B congeners were not found in the reported metabolites 
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Figure 6.2 Characterization of Mur15 with muraymycin B2 (5), B6 (7) and A1 (9). 
(A) Reaction catalyzed by Mur15 with 5 or 7 or 9. (B) LC-MS analysis using 5 (Ο) after 6-hr 
without Mur15 (I), 6 h reaction (II). (C) LC-MS analysis using 7 (Ο) after 6 h without Mur15 













Figure 6.3 Comparison of 1H NMR (DMSO-d6, 400 MHz) between muraymycin B2, 5 and 





Discovery of the activity promiscuity of Mur15 led us to test the activity of Mur15 with 
L-Arg and L-Arg-Leu dipepetide as we proposed that hydroxyl arginine possibly is the 
precursor for the biosynthesis of L-epicapreomycidine moiety of muraymycin. No 
hydroxylation activity was detected by LC-MS with free L-Arg. However, Mur15 showed 
hydrolase activity when incubated with Arg-Leu dipeptide and generated free arginine and 
leucine (Figure 6.4). The result didn’t exclude the possibility that Mur15 can catalyze the 
hydroxylation of nonribosomal peptide synthetase (NRPS) tethered arginine, which is still in 
the ongoing NRPS activity study. 
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Figure 6.4 Characterization of Mur15 with L-Arg-Leu dipeptide, 11. 
(A) Reaction catalyzed by Mur15 with 11. (B) LC-MS analysis using 11 (Ο) after 6 h without 





6.3.3 Activity Optimization and Kinetics Analysis 
α-KG and O2 was found to be necessary for the activity of Mur15 while ascorbate or 
Fe (II) was not essential for the reaction. Optimal activity of Mur15 was achieved in the range 
of 10-1000 μM FeCl2. With 500 μM FeCl2, Mur15 was found to have optimal activity in the 
range of 10-1000 μM ascorbate (Figures 6.5 A-B).  
Kinetics analysis of Mur15 with muraymycin D1 revealed Michaelis-Menten kinetics 
yielding a Km = 11±1μM and kcat = 2±0.1 min
-1 with respect to α-KG and Km= 0.6±0.1 mM and 
kcat = 10±1 min
-1 with respect to muraymycin D1. Kinetics analysis of Mur15 with muraymycin 
B2 revealed Michaelis-Menten kinetics yielding a Km = 0.6±0.2 mM and kcat = 6 ± 0.2 min
-1 
with respect to muraymycin B2 (Figures 6.5 C-E). The catalytic efficiency kcat/Km with respect 
to muraymycin D1 is 2.4 times more than that of muraymycin B2, which to some extent 
predicted that the amount of hydroxyl muraymycin A or B congeners should be relatively low 
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Figure 6.5 Activity optimization and kinetic analysis of Mur15. 
(A) Optimal activity of Mur15 with respect to varied ascorbic acid in reactions containing 200 
μM FeCl2 and 200 nM Mur15. (B) Optimal activity of Mur15 with respect to varied FeCl2 in 
reactions containing of 500 μM ascorbic acid and 200 nM Mur15. (C) Single-substrate kinetic 
analysis using variable α-KG (5 μ-200 μM), near saturating muraymycin D1(250 μM) and 200 
nM Mur15. (D) Single-substrate kinetic analysis using variable muraymycin D1 (5 μ-1000 μM), 
near saturating α-KG (2.5 mM) and 200 nM Mur15. (E) Single-substrate kinetic analysis using 
variable muraymycin B2 (5 μ-1000 μM), near saturating α-KG (2.5 mM) and 200 nM Mur15. 







6.3.4 Bioactivity of the Mur15 Products 
The isolated Mur15 products, muraymcyin C1 and muraymycin B2-OH were tested for 
enzyme inhibitory activity against MraY from S. aureus, and antimicrobial activity against 
Gram-positive as well as Gram-negative strains (Table 6.1). To our surprise, muraymycin C1 
showed 32 times decrease in IC50 against muraymycin D1, suggesting that hydroxylation at β 
position of muraymycin D1 greatly increased the inhibitory activity against MraY. Enzyme 
inhibitory activity against MraY S. aureus showed comparable IC50 of B2 and B2-OH, 
indicating that the hydroxylation at γ position didn’t interfere with its binding to the target 
protein MraY. Muraymcyin C1 showed comparable antimicrobial activity to muraymycin D1 
against M. smegmatis and E. coli, which indicates that the β hydroxylation didn’t affect its 
antibacterial activity. Considering that muraymycin C1 showed 32 times increased efficacy 
against the target, hydroxylation at β position of muraymycin D1 possibly interfere its cellular 
penetration. Importantly, B2-OH didn’t show growth inhibitory against M. smegmatis ATCC 
14468 and E. coli BL21(DE3). However, B2-OH showed similar antibacterial activity to B2 
against E. coli ∆tolC mutant, which further indicated that the hydroxylation possibly interfered 
with the cellular uptake. 
Table 6.1 Bacterial MraY assays and antimicrobial activities of the substrate and product of 
Mur15. 
 S. aureus MraY M. smegmatis E. coli ∆tolC mutant E. coli BL21(DE3) 
 inhibition 
growth 
inhibition growth inhibition growth inhibition 
compound IC50 (pM) MIC (μg/mL) MIC (μg/mL) MIC (μg/mL) 
muraymycin B2 10±2 8 1 32 
muraymycin B2-
OH 16±3 >256 1 >256 
muraymycin D1 (4.8 ± 1.3)×102 4 1 16 




6.4.1 Timing of Hydroxylation in Muraymycin Biosynthetic Pathway 
The discovery of muraymycin D and muraymycin C congeners indicates that the 
hydroxylation reaction occurred in the biosynthetic pathway. There are three possibilities of 
when the hydroxylation of the leucine moiety occurs in the biosynthetic pathway of 
muraymycin. I, hydroxylation of free leucine before the peptide assembles. Hydroxylation of 
free amino acid is well known in many biosynthetic pathways of nature products.95-98 L-leucine 
was tested with Mur15 at first. However, Mur15 not reacting with free L-leucine exclude this 
possibility. II, late stage modification of muraymycin D congeners. The discovery of 
muraymycin D and C congeners also suggests that the hydroxylation may happen after the 
formation of muraymycin D. Activity assay and kinetic study of Mur15 with muraymycin D 
congeners both supported this hypothesis. Actually, late stage hydroxylation is also observed in 
many biosynthetic pathways.99-100 III, hydroxylation of nonribosomal peptide synthetases 
(NRPS) tethered leucine moiety. Hydroxylation of NRPS peptidyl carrier protein (PCP)-bound 
amino acid is also found in many biosynthetic pathways.101-103 There are several NRPSs in the 
biosynthetic assembly line of muraymycin, which are proposed to be responsible for the 
biosynthesis of peptide side chain of muraymycin. Whether or not Mur15 can catalyze the 
hydroxylation of NRPS tethered amino acid will be explored in the ongoing NRPS activity 
assays. 
6.4.2 Repeated Hydroxylation by Multifunctional Enzyme 
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Dioxygenase Mur15 showed unusual substrate promiscuity. It catalyzed the 
hydroxylation of muraymycin D congeners, which are further utilized by acyltransferase to 
produce different fatty acid chain appended muraymycins (muraymycin A or B congeners). 
Different lipo-muraymycins can be further oxidized by the same enzyme Mur15 (Figure 6.6). 
Although oxygenase usually has strong substrate specificity, recently an emerging group of 
multifunctional dioxygenase have been studied. These enzymes usually catalyze two or more 
reactions in a very ordered behavior and goes through conformational change to catalyze 
different reactions.104 Structure study of Mur15 bound with different muraymycin congeners 
will offer more information for further study of this unusual repeated hydroxylation reaction. 
 
Figure 6.6 Repeated hydroxylation catalyzed by Mur15. 
6.5 Conclusion 
Enzyme Mur15, which belongs to cupin family and involves in muraymycin late stage 
modification, is functionally assigned as a non-heme, Fe (II)-dependent α-ketoglutarate 
dioxygenase that catalyzes the β hydroxylation of leucine moiety in muraymycin D1 to form 
muraymycin C1. Mur15 can also hydroxylate the γ position of leucine moiety to muraymycins 
with fatty acid chain in β position. Moreover, Mur15 showed lyase activity to hydrolyze 




6.6 Supporting Information 
 
  
Figure S6.1 SDS-PAGE analysis of purified His6-Mur15 
(expected MW of 39 kD). 
 
 
   
Figure S6.2 Identification of the Mur15 product with 1. 
(A) Mass spectrum for the peak at elution time t = 21.893 min corresponding to 1. (B) Mass 


















   
Figure S6.3 Identification of the Mur15 product with 3. 
(A) Mass spectrum for the peak at elution time t = 22.410 min corresponding to 3. (B) Mass 
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Figure S6.4 Identification of the Mur15 product with 1. 
(A) HPLC analysis using 1 (Ο) after 6 h without Mur15 (I), 6 h reaction (II), 6 h reaction co-










   
Figure S6.5 Identification of the Mur15 product with 5. 
(A) Mass spectrum for the peak at elution time t = 25.786 min corresponding to 5. (B) (+)-HR-
ESI-MS (positive mode) of 5 (expected (M+H)+ ion at m/z = 1100.5834, found: 1100.5833). (C) 
Mass spectrum for the peak at elution time t = 25.081 min corresponding to Mur15 product 6. 












Figure S6.6 1H NMR spectrum (DMSO-d6, 400 MHz) of muraymycin B2 (5). 
 
 




Figure S6.8 HSQC spectrum (DMSO-d6, 400 MHz) of muraymycin B2 (5). 
 
 










   
 
   
Figure S6.11 Identification of the Mur15 product with 7. 
(A) Mass spectrum for the peak at elution time t = 24.039 min corresponding to 7. (B) (+)-HR-
ESI-MS (positive mode) of 7(expected (M+H)+ ion at m/z = 1072.5521, found: 1072.5553). (C) 
Mass spectrum for the peak at elution time t = 22.283 min corresponding to Mur15 product 8. 















Figure S6.12 1H NMR spectrum (DMSO-d6, 400 MHz) of muraymycin B6 (7). 
 
 




Figure S6.14 HSQC spectrum (DMSO-d6, 400 MHz) of muraymycin B6 (7). 
 











   
Figure S6.17 Identification of the Mur15 product with 9. 
(A) Mass spectrum for the peak at elution time t = 17.466 min corresponding to 9 (expected 
(M+H)+ ion at m/z = 608.33, found: 608.6). (B) Mass spectrum for the peak at elution time t = 




   
Figure S6.18 Identification of the Mur15 product with 11. 
(A) Mass spectrum for the peak at elution time t = 17.466 min corresponding to 11(Calc: 288.20, 
found: 288.2). (B) Mass spectrum for the peak at elution time t = 19.222 min corresponding to 













Chapter 7 : Ongoing Studies and Future Directions 
7.1 Biosynthetic Mechanism of the NRPS Assembly Line 
We have presented the delineation of the biosynthetic pathway for the alkyl 
aminoribosyl-glycyluridine moiety upon in vitro characterization of nine enzymes (Mur16-20, 
Mur23, 24,26) (Figure 7.1). Next we are going to study the assembly line of the peptidyl moiety 
of muraymycin, which contains basic amino acid-epicapreomycidine-urea-valine moiety with 
interesting amino acid-urea-amino acid motif effectively inverting the direction of the peptide 
chain. Seven enzymes that are proposed to be involved in the NRPS assembly line have been 
expressed. Isotopic enrichment experiment feeding with leucine, arginine, valine and sodium 
bicarbonate is carried out. ATP-PPi exchange assay will be performed to test adenylation 
domains activity. Covalent loading of the amino acid will be characterized by SDS-gel and 
HRMS. The condensation of the assembled peptide with the alkyl aminoribosyl-glycyluridine 
will also be studied. 
 
Figure 7.1 Biosynthetic pathway towards alkyl aminoribosyl-glycyluridine moiety of 
muraymycin. 
7.2 Biosynthetic Mechanism of the Formation of the N-methyldiazepanone Moiety of 
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Caparazamycin Like A-90289 
LipJ, from biosynthetic gene cluster of caprazamycin A-90289 (Figure 5.1), shared 35% 
sequence identity to Mur24. Activity tests revealed that, like Mur24, LipJ catalyzes the 
incorporation of butyric acid to phosphorylated disaccharide. Proposed biosynthetic pathway 
of the formation of N-methyldiazepanone moiety of A-90289 by BLAST analysis is shown in 
Figure 7.2. LipG, LipH, LipI and LipQ were expressed in E. coli BL21(DE3). Activity tests 
will be performed accordingly. 
 
Figure 7.2 Proposed biosynthetic pathway towards N-methyldiazepanone moiety of A-90289.  
7.3 Acyltransferase for the Fatty Acid Chain Appendage of Muraymycin 
All of muraymycins have a common peptide appended aminoribosyl uronic acid core 
structure. Members of this family are mainly different in the fatty acid chain. Muraymycin A1, 
the one with the longest charged fatty acid chain, is the most active one. In chapter 2, we also 
presented that the structure of the fatty acid chain has great impact on activity of muraymycin. 
As in chapter 6 we characterized the function of dioxygenase Mur15, which catalyzes the β 
hydroxylation of muraymycin D1 to form muraymycin C1 (Figure 6.6), we proposed that 
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acyltransferase will be required to form muraymycins with different fatty acid chain. Therefore, 
the acyltransferase that is responsible for the fatty acid chain appendage of muraymycin will be 
characterized. Muraymycins with different fatty acid chains will be made with the 
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